Erbb2 inhibitors

HK40137442APending Publication Date: 2026-09-11COGENT BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125823
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-11
Filing Date
2026-07-07
Publication Date
2026-09-11
Patent Text Reader

Abstract

A compound having the structure of the following formula (I): (I) or a stereoisomer, pharmaceutically acceptable salt or tautomer of the compound, wherein E, L, R3a, R3b, R3c, R3d, R5b, R8, Y1, Y2, Y3, Y4, Y5, Y6, X1, X2, Z1 and Z2 are as defined herein. Pharmaceutical compositions comprising the compounds and their use in methods of treating disease are also described.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Publication Number (43) Publication Date (21) Application Number 202480038693.5 (22) Application Date 2024.04.10 (30) Priority Data 63 / 495,543 2023.04.11 US (85) PCT International Application Entering National Phase Date 2025.12.10 (86) PCT International Application Application Data PCT / US2024 / 023942 2024.04.10 (87) PCT International Application Publication Data WO2024 / 215809 EN 2024.10.17 (71) Applicant: Kogan Biosciences Inc. Address: USA (72) Inventors: L.J. Salitulo, J. Fulton, R.K. Jaluri, L.E. Vane, T. Bertendorf, J. Fisher, J.B. Fair, M.J. Chicarelli, P. Chatterjee, C.A. Malenki (74) Patent Agency: China Council for the Promotion of International Trade Patent & Trademark Office Co., Ltd. 11038 Patent Attorney: Wang Guijie (51) Int.Cl. C07D 487 / 04 (2006.01) C07D 401 / 14 (2006.01) A61K 31 / 519 (2006.01) A61K 45 / 06 (2006.01) A61P 35 / 00 (2006.01) (54) Invention Title: ERBB2 Inhibitor (57) Abstract: A compound having the structure of the following formula (I): (I) or stereoisomers of the compound, pharmaceutically acceptable salts thereof, or tautomers thereof, wherein E, L, R3a, R3b, R3c, R3d, R5b, R8, Y1, Y2, Y3, Y4, Y5, Y6, X1, X2, Z1, and Z2 are as defined herein. Pharmaceutical compositions comprising the compound and their use in methods of treating diseases are also described. Claims 63 pages, Description 189 pages, CN 121311486 A 2026.01.09 CN 1 21 31 14 86 A 1. A compound having the structure of the following formula (I): (I) or a stereoisomer of said compound, a tautomer of said compound, or a pharmaceutically acceptable salt thereof, wherein: X1 is CR1 or N; X2 is CR2 or N; Y1 is CR4 or N; Y2 is CR5a or N; Y3 is C or N; Y4 is CR6 or NR6; Y5 is CR7, O or NR7; Y6 is C or N; R1, R2, R3a, R3b, R3c, R3d, R4, R5a, R5b and R7 are each independently H, halo, C1-C3 alkyl, C1-C3 haloalkyl or C1-C3 heteroalkyl;R6 is H, C1-C3 alkyl, C1-C3 deuterated alkyl, or C1-C3 haloalkyl; R8 and R9 are each independently H or C1-C3 alkyl; Z1 is -NR9-, -O-, -S-, or a direct bond; Z2 is -NR9-, or a direct bond; L is C1-C4 alkyl, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, fused heterobicyclic, bridged heterobicyclic, heterospirocyclic, or a direct bond; E is α,β-unsaturated carbonyl or C2-C4 alkyne conjugated carbonyl; and each is independently a single or double bond, provided the valence allows. 2. The compound of claim 1, wherein the compound has one of the following structures (IA)-(ID): (IA) (IB) (IC) (IC) (IA) (IB) ... 6. The compound of claim 5, wherein the compound has a structure of the following formula (IA-2)-(IB-2): (IA-2), (IB-2), or a stereoisomer of the compound, a tautomer of the compound, or a pharmaceutically acceptable salt thereof. 7. The compound of any one of claims 1-6, wherein R6 is a C1-C3 haloalkyl group. 8. The compound of any one of claims 1-7, wherein R6 is a C1 haloalkyl group. 9. The compound of any one of claims 1-8, wherein R6 is CHF2 or CF3. 10. The compound of any one of claims 1-9, wherein Z1 and Z2 are each direct bonds. 11. The compound of any one of claims 1-10, wherein Z1 is -NR9-, -O-, or -S-, and Z2 is a direct bond. 12. The compound of any one of claims 1-11, wherein Z1 is a direct bond, and Z2 is -NR9-. 13. The compound of any one of claims 1-12, wherein Z1 and Z2 are each -NR9-. 14. The compound of any one of claims 1-13, wherein R9 is H or CH3.15. The compound of any one of claims 1-14, wherein R1, R2, R3a, R3b, R3c, R3d, R4, R5a, R5b and R7 are each independently H, halo, C1 alkyl, C1-C2 haloalkyl or C1-C3 heteroalkyl. 16. The compound of any one of claims 1-15, wherein R1, R2, R3a, R3b, R3c, R3d, R4, R5a, R5b and R7 are each independently H, F, Cl, CH3, CH2CF3, CF3, CHF2, CH2OCH3, CD3, OCHF2, OCF3 or OCH3. 17. The compound of any one of claims 1-16, wherein R1 and R2 are each independently H, F, CH3 or OCH3. 18. The compound of any one of claims 1-17, wherein R3a, R3b, R3c and R3d are each independently H, CH3, OCH3, CH2OCH3, OCHF2, OCF3, F or Cl. 19. The compound of any one of claims 1-18, wherein R4 is H, F, CH3, CH2OCH3 or CH2CF3. 20. The compound of any one of claims 1-19, wherein R5a and R5b are each independently H, CH3, F or OCH3. 21. The compound of any one of claims 1-20, wherein R7 is H or CH3. 22. The compound of any one of claims 1-21, wherein R8 is H or CH3. 23. The compound of any one of claims 1-22, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicycle, the bridged heterobicycle, and the heterospirocycle of L have 1-3 nitrogen atoms. 24. The compound of any one of claims 1-23, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L have 1-2 nitrogen atoms. 25. The compound of any one of claims 1-24, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L are unsaturated heterocycles. 26. The compound of any one of claims 1-25, wherein the C3-C8 heterocyclic alkyl group of L is an aziridine, pyrrolidine, imidazoline, pyrazolidine, piperidine, 1,2-diazine, 1,3-diazine, 1,4-diazine, aziridine-heptane, diaziridine-heptane, or aziridine-octane. 27. The compound according to any one of claims 1-26, wherein the fused heterobicycle of L is 3-azabicyclo[3.1.0]heptane, 2,5-diazabicyclo[4.2.0]octane, octahydropyrrolo[3.4.c]pyrrole, or octahydropyrrolo[3.4.b]Pyrrole, octahydro-1H-pyrrolo[3.4.c]pyridine, decahydro-2,6-naphthidine, 2,5-diazabicyclo[4.1.0]heptane, 3,6-diazabicyclo[3.2.0]heptane or 3,6-diazabicyclo[3.1.0]hexane. 28. The compound according to any one of claims 1-27, wherein the bridged heterobicycle of L is 3,8-diazabicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, 8-azabicyclo[3.2.1]octane, 3-azabicyclo[3.2.1]octane, 3,6-diazabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, 3-oxa-9-azabicyclo[3.3.1]nonane, 3-oxa-9-azabicyclo[3.3.1]non-6-ene, 9-azabicyclo[3.3.1]non-2-ene, 8-azabicyclo[3.2.1]oct-2-ene, or 3,6-diazabicyclo[3.1.1]heptane. 29. The compound according to any one of claims 1-28, wherein the heterospirocycle of L is 2,6-diazaspiro[3.3]heptane, 1,6-diazaspiro[3.3]heptane, 2-diazaspiro[3.3]heptane, 1,6-diazaspiro[3.4]octane, 2,6-diazaspiro[3.4]octane, 2,7-diazaspiro[3.5]nonane, 2,8-diazaspiro[4.5]decane, 3,9-diazaspiro[5.5]undecane, 4,8-diazaspiro[2.5]octane, 5,9-diazaspiro[3.5]nonane, 6,10-diazaspiro[4.5]decane, or 1,5-diazaspiro[5.5]undecane. 30. The compound of any one of claims 1-29, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L are further substituted with deuterium, halogenation, C1-C6 alkyl, or C1-C6 heteroalkyl. 31. The compound of any one of claims 1-30, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L are further substituted with deuterium, halogenation, C1-C3 alkyl, or C1-C3 heteroalkyl. 32. The compound of any one of claims 1-31, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L are further substituted with -D, -F, -CH3, -CF3, -CHF2, -CH2F, -CH2CHF2, -CH2CH3, -CH(CH3)2, -CH2OH, -CH2OCH3, or -CH2CCN. 33. The compound of any one of claims 1-32, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L are substituted with a single, two, three, four, five, or eight.34. The compound of any one of claims 1-33, wherein L is a C2-C4 alkyl or a C4-C5 cycloalkyl. 35. The compound of any one of claims 1-34, wherein the C1-C4 alkyl of L is –(CH2)2- or –CH2C(CH3)2. 36. The compound of any one of claims 1-35, wherein the C3-C8 cycloalkyl of L is […], wherein * indicates the position of the bond with Z2. 37. The compound according to any one of claims 1-36, wherein L has one of the following structures: , ... Claims 6 / 63, page 7, CN 121311486 A 38. The compound of any one of claims 1-37, wherein the α,β-unsaturated carbonyl or C2-C4 alkyne conjugated carbonyl of E is further substituted by a halogen, C1-C3 alkyl, C1-C3 alkyl-halogenated, C1-C6 heteroalkyl, -(CH2)nC3-C7 heterocyclic alkyl, or a combination thereof, wherein n is an integer between 1 and 3. 39. The compound of any one of claims 1-38, wherein the α,β-unsaturated carbonyl of E has one of the following structures: , , , , , , , , , , , , , , , , , , , , or. 40. The compound of any one of claims 1-39, wherein the C2-C4 alkyne conjugated carbonyl is a C2 alkyne conjugated carbonyl or a C3 alkyne conjugated carbonyl. 41. The compound of any one of claims 1-40, wherein the C2-C4 alkyne conjugated carbonyl has the following structure: . 42. The compound of any one of claims 1-41, wherein E has one of the following structures: , , , , , , , , , , , , , , , or. 43. The compound of claim 1, wherein the compound has one of the following structures: ; ...Requesting the following: Page 9 / 63, Item 10: CN 121311486 A; ... ; ; ; ; ; ; 、 Claims 14 / 63 page 15 CN 121311486 A 、 、 、 、 、 、 、 、 Claims 15 / 63 page 16 CN 121311486 A 、 、 、 、 、 、 、 Claims 16 / 63 page 17 CN 121311486 A 、 、 、 、 、 、 、 Claims 17 / 63 page 18 CN 121311486 A 、 、 、 、 、 、 、 Claims 18 / 63 page 19 CN 121311486 A 、 、 、 、 、 、 、 Claims 19 / 63 page 20 CN 121311486 A 、 、 、 、 、 、 、 Claims 20 / 63 page 21 CN 121311486 A, , , , , , , , Claims 21 / 63, page 22 CN 121311486 A, , , , , , , Claims 22 / 63, page 23 CN 121311486 A, , , , , , , , Claims 23 / 63, page 24 CN 121311486 A, , , , , , , Claims 24 / 63, page 25 CN 121311486 A, , , , , , , Claims 25 / 63, page 26 CN 121311486 A, , , , , , , Claims 26 / 63, page 27 CN 121311486 A, , , , , , Claims 27 / 63 Page 28 CN 121311486 A 、 、 、 、 、 、 RightsClaims 28 / 63 pages 29 CN 121311486 A 、 、 、 、 、 、 Claims 29 / 63 pages 30 CN 121311486 A 、 、 、 、 、 、 Claims 30 / 63 pages 31 CN 121311486 A 、 、 、 、 、 、 Claims 31 / 63 pages 32 CN 121311486 A 、 、 、 、 、 、 Claims 32 / 63 pages 33 CN 121311486 A 、 、 、 、 、 、 、 Claims 33 / 63 pages 34 CN 121311486 A 、 、 、 、 、 、 Claims 34 / 63 pages 35 CN 121311486 A 、 、 、 、 、 Claims 35 / 63, page 36, CN 121311486 A; Claims 36 / 63, page 37, CN 121311486 A; Claims 37 / 63, page 38, CN 121311486 A; Claims 38 / 63, page 39, CN 121311486 A; Claims 39 / 63, page 40, CN 121311486 A; Claims 40 / 63, page 41, CN 121311486 A; Claims 41 / 63, page 42, CN 121311486 A. Claims 42 / 63, page 43, CN 121311486 A; Claims 43 / 63, page 44, CN 121311486 A; Claims 44 / 63, page 45, CN 121311486 A; Claims 45 / 63, page 46, CN 121311486 A; Claims 46 / 63, page 47, CN 121311486 A; Claims 47 / 63, page 48, CN 121311486 A; Claims 48 / 63, page 49, CN 121311486 A.Claims 49 / 63, page 50, CN 121311486 A; Claims 50 / 63, page 51, CN 121311486 A; Claims 51 / 63, page 52, CN 121311486 A; Claims 52 / 63, page 53, CN 121311486 A; Claims 53 / 63, page 54, CN 121311486 A; Claims 54 / 63, page 55, CN 121311486 A; Claims 55 / 63, page 56, CN 121311486 A Claims 56 / 63, page 57, CN 121311486 A; Claims 57 / 63, page 58, CN 121311486 A; Claims 58 / 63, page 59, CN 121311486 A; Claims 59 / 63, page 60, CN 121311486 A; Claims 60 / 63, page 61, CN 121311486 A; Claims 61 / 63, page 62, CN 121311486 A; Claims 62 / 63, page 63, CN 121311486 A or. 44. A pharmaceutical composition comprising the compound of claim 1 and an additional therapeutic agent. 45. The compound of any one of claims 1-43 or the pharmaceutical composition of claim 44, for treating a disease associated with a mutation in human epidermal growth factor receptor 2 (ErbB2). 46. A method of treating a disease associated with a mutation in ErbB2, comprising: administering to a subject in need the compound of any one of claims 1-43 or the pharmaceutical composition of claim 45. 47. The method of claim 46, wherein the subject is an animal. 48. The method of any one of claims 46-47, wherein the subject is a human. 49. The method of any one of claims 46-48, wherein the disease associated with a mutation in ErbB2 is cancer.50. The method of any one of claims 46-49, wherein the cancer is lung cancer, glioma, esophageal cancer, liver cancer, gastric cancer, uterine cancer, cervical cancer, biliary tract cancer, skin cancer, head and neck cancer, salivary gland cancer, breast cancer, pancreatic cancer, colorectal cancer, kidney cancer, bladder cancer, or prostate cancer. 51. The method of any one of claims 46-50, wherein the cancer is non-small cell lung cancer. Claims 63 / 63 pages 64 CN 121311486 A ERBB2 Inhibitor Technical Field

[0001] This disclosure relates to substituted pyrimidine-pyrimidine compounds used as inhibitors of human epidermal growth factor receptor 2 (ErbB2). This disclosure also provides compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of said compounds for treating abnormal cell growth (such as cancer) in a subject. Background Art

[0002] Human epidermal growth factor receptor 2 (ErbB2) is a member of the epidermal growth factor receptor family with tyrosine kinase activity. ErbB2 plays a crucial role in the signal transduction cascade of biochemical pathways responsible for cell growth and differentiation. Alterations in ErbB2 (including amplification and mutation) are known to result in unregulated cell proliferation in cancers such as breast cancer, bladder cancer, colorectal cancer, and lung cancer. Existing therapies, including but not limited to monoclonal antibodies, bispecific antibodies, and kinase inhibitors, still suffer from high relapse rates and acquired resistance.

[0003] While current kinase inhibitors are effective in treating cancer, their use may be limited by their poor selectivity for ErbB2 relative to EGFR. EGFR-related toxicities (including GI effects and rash) require modifications to the treatment regimen, such as dosing pauses or dose reductions, resulting in suboptimal target coverage and reduced efficacy.

[0004] Furthermore, ErbB2 exon 20 YVMA insertion is associated with a high incidence of brain metastases in NSCL cancer patients with ErbB2 alterations. Brain-penetrating ErbB2 inhibitors that effectively combat ErbB2 mutations (including YVMA) could be used to treat patients with brain metastases.

[0005] There remains a need to identify potent, brain-penetrating, mutation-resistant, and EGFR-non-interfering ErbB2 inhibitors for the treatment of patients with cancer or other proliferative disorders or conditions driven by ErbB2 alterations. Summary of the Invention

[0006] In short, this disclosure provides compounds that can be used alone or in combination with other therapeutic agents, including their stereoisomers, tautomers, or pharmaceutically acceptable salts.

[0007] In one embodiment, a compound having the structure of formula (I) is provided: (I) or its stereoisomers, tautomers, or pharmaceutically acceptable salts, E, L, R3a, R3b, R3c, R3d, R5b, R8, Specification 1 / 189 pages 65 CN 121311486 AY1, Y2, Y3, Y4, Y5, Y6, X1, X2, Z1, and Z2 are as defined herein.

[0008] Pharmaceutical compositions comprising one or more of the compounds of formula (I) and an additional therapeutic agent are also provided.

[0009] In other embodiments, a method of treating a disease by administering a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I) to a subject in need is provided.

[0010] Aspects and embodiments will now be described more fully below. Such aspects and embodiments may take many different forms, and the exemplary aspects and embodiments disclosed herein should not be construed as limiting; rather, these embodiments are provided so that the contents of this disclosure will be thorough and complete, and its scope will be fully conveyed to those skilled in the art. Detailed Description

[0011] I. Definitions For convenience, certain terms used herein are brought together in this specification, embodiments, and claims. Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0012] Where a range of numerical values ​​is provided, this disclosure is intended to cover each intermediate value between the upper and lower limits of that range, as well as any other specified or intermediate values ​​within that specified range. For example, if a range of 1 mM to 8 mM is specified, it is also intended to explicitly disclose 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, and 7 mM, as well as ranges of non-integer values ​​greater than or equal to 1 mM and ranges of non-integer values ​​less than or equal to 8 mM.

[0013] The singular forms “a” and “the” include plural references unless the context explicitly specifies otherwise. Thus, for example, reference to “polymer” includes a single polymer as well as two or more identical or different polymers, and reference to “excipient” includes a single excipient as well as two or more identical or different excipients, and so on.

[0014] The term “about” is intended, particularly when referring to a given quantity, to cover a deviation of plus or minus five percent.

[0015] The compositions disclosed herein may comprise, consist substantially of, or consist of the disclosed components.

[0016] Unless otherwise stated, all percentages, parts, and ratios are based on the total weight of the composition, and all measurements were performed at about 25°C.

[0017] As used in this specification and the appended claims, unless otherwise stated, the following terms have indicative meanings: “amino” refers to a -NH2, -NHR, or -NR2 group; “cyano” refers to a -CN group; “hydroxyl” refers to a -OH group; “imino” refers to a =NH or =NR substituent; “nitro” refers to a -NO2 group; “oxo” refers to an =O substituent; “thio” refers to a =S substituent; “trifluoromethyl” refers to a -CF3 group."Hydazido" or "hydrazino" refers to an N-N substituent, wherein each R of "amino" or "imino" is a compatible substituent as described in this disclosure, and wherein isomers are considered and included herein in cases where the R group is chiral.

[0018] "Alkyl" refers to a straight-chain saturated acyclic monovalent hydrocarbon group or a branched-chain saturated acyclic monovalent hydrocarbon group having one to twelve carbon atoms, preferably one to eight carbon atoms or one to six carbon atoms, and being connected to the rest of the molecule by a single bond, such as methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (tert-butyl), 3-methylhexyl, 2-methylhexyl, etc. Optionally substituted alkyl groups are alkyl groups that are optionally substituted with one, two, three, four, or five substituents, provided that the valence state allows. The substituents are independently selected from halogenated, cyano, nitro, aryl, cycloalkyl, heterocyclic, heteroaryl, oxo, trimethylsilyl, -OR′, -OC(O)R′, -N(R′)2, C(O)R′′, -C(O)OR′, -C(O)N(R′)2, -N(R′)C(O)OR′′′, N(R′)C(O)R′′′, -N(R′)S(O)tR′′′ (where t is 1 or 2), -S(O)tOR′′′ (where t is 1 or 2), -S(O)pR′′′ (where p is 0, 1, or 2), and -S(O)tN(R′)2 (where t is 1 or 2), wherein each R′ Independently, it is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclic, or heteroaryl; each R′′ is independently hydrogen, cycloalkyl, aryl, heterocyclic, or heteroaryl; and each R′′′ is independently alkyl, haloalkyl, cycloalkyl, aryl, heterocyclic, or heteroaryl.

[0019] "Alkoxy" refers to a group of formula -ORa, wherein Ra is an alkyl group containing one to twelve carbon atoms as defined above. The alkyl portion of an optionally substituted alkoxy group is optionally substituted as defined above for alkyl groups.

[0020] "Alkoxyalkyl" refers to a group of formula -Ra-O-Rb, wherein Ra is an alkylene group, and Rb is an alkyl group as defined above. The alkyl and alkylene portions of an optionally substituted alkoxyalkyl group are optionally substituted as defined above for alkyl and alkylene chains, respectively.

[0021] “Aryl group” refers to a group of the formula -Ra-Rb, wherein Ra is an alkylene group and Rb is an aryl group as described herein. The alkylene and aryl moieties of an optionally substituted aryl group may optionally be substituted as described herein with respect to the alkylene and aryl groups, respectively.

[0022] “Aryl group” refers to an aromatic monocyclic or polycyclic hydrocarbon ring system containing 6 to 18 carbon atoms, wherein a polycyclic aryl group…The ring system is a bicyclic, tricyclic, or tetracyclic ring system. Aryl groups include, but are not limited to, groups such as fluorenyl, phenyl, and naphthyl. The optionally substituted aryl group is an aryl group optionally substituted with one, two, three, four, or five substituents, wherein the substituents are independently selected from alkyl, alkenyl, halogen, haloalkyl, haloalkenyl, cyano, nitro, aryl, heteroaryl, heteroarylalkyl, -R′′-OR′, -R′′-OC(O)-R′, -R′′-N(R′)2, -R′′-C(O)R′, -R′′-C(O)OR′, -R′′-C(O)N(R′)2, -R′′-N(R′)C(O)OR′′′, -R′′-N(R′)C(O)R′′′, -R′′-N(R′)S(O)tR′′′ (where t is 1 or 2), -R′′-S(O)tOR′′′ (where t is 1 or 2), -R′′-S(O)pR′′′ (where p is 0, 1, or 2) and -R′′-S(O)tN(R′)2 (where t is 1 or 2), wherein each R′ is independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclic, or heteroaryl; each R′′ is independently a direct bond or a straight-chain or branched alkylene or alkenyl chain; and each R′′′ is independently alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, or heteroaryl.

[0023] "Arylalkoxy" refers to a group of the formula –O-R, wherein R is an aralkyl group. Optionally substituted arylalkoxy groups are arylalkoxy groups that are optionally substituted as described herein with respect to aralkyl groups. In some embodiments, the arylalkoxy group is a benzyloxy group.

[0024] "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon group having three to fifteen carbon atoms, preferably three to ten carbon atoms, and is either saturated or unsaturated, and is connected to the rest of the molecule by a single bond. Polycyclic hydrocarbon groups are bicyclic, tricyclic, or tetracyclic ring systems. Unsaturated cycloalkyl groups contain one, two, or three carbon-carbon double bonds and / or one carbon-carbon triple bond. Monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl groups include, for example, adamantyl, norbornyl, decahydronaphthyl, etc. Optionally substituted cycloalkyl groups are cycloalkyl groups optionally substituted with one, two, three, four, or five substituents, wherein the substituents are independently selected from alkyl, alkenyl, halogenated, haloalkyl, haloalkenyl, cyano, nitro, oxo, aryl, aralkyl, cycloalkyl, heterocyclic, heteroaryl, -R′′-OR′, -R′′-OC(O)-R′, -R′′-N(R′)2, -R′′-C(O)R′, -R′′-C(O)OR′, -R′′-C(O)N(R′)2, -R′′-N(R′)C(O)OR′′, -R′′-N(R′)C(O)R′′′、-R′′-N(R′)S(O)tR′′′ (where t is 1 or 2), -R′′-S(O)tOR′′′ (where t is 1 or 2), -R′′-S(O)pR′′′ (where p is 0, 1 or 2) and -R′′-S(O)tN(R′)2 (where t is 1 or 2), wherein each R′ is independently hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclic or heteroaryl; each R′′ is independently a direct bond or a straight or branched alkylene or alkenyl chain; and each R′′′ is independently alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclic or heteroaryl.

[0025] A “deuterated compound” is a compound in which one or more hydrogen atoms have been replaced by deuterium atoms. Deuterated drugs can be derivatives of active compounds. Deuterated drugs can be prodrugs. Deuteration can alter the physical properties, metabolic properties, activity, or safety of a drug.

[0026] “Derivative” is a related chemical substance that can be derived from a similar compound via a chemical reaction. They can encompass minor chemical modifications, atomic substitution with deuterated atoms, atomic substitution with stable or radioactive isotopes, or other modifications that impart desired properties to the compound.

[0027] “Fused” means any ring system described herein that is fused with an existing ring structure in the compounds of the present invention. When the fused ring system is a heterocyclic or heteroaryl group, any carbon atom that is part of the fused ring system in the existing ring structure can be replaced by a nitrogen atom.

[0028] “Halogenated” means a halogen substituent: brominated, chlorinated, fluorinated, and iodinated.

[0029] “Halogenated alkyl” means an alkyl group as defined above that is further substituted with one or more halogen substituents. The number of halogenated substituents included in the haloalkyl group ranges from one to a maximum of the total number of hydrogen atoms that can be replaced by the halogenated substituent (e.g., perfluoroalkyl). Non-limiting examples of haloalkyl groups include trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl, 2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl, 2-bromoethyl, etc. For optionally substituted haloalkyl groups, the hydrogen atoms bonded to the carbon atom of the alkyl portion of the haloalkyl group may optionally be replaced by substituents as defined above for optionally substituted alkyl groups.

[0030] "Haloalkenyl" means an alkenyl group as defined above, which is further substituted by one or more halogenated substituents. The number of halogenated substituents included in the haloalkenyl group ranges from one to a maximum of the total number of hydrogen atoms that can be replaced by the halogenated substituent (e.g., perfluoroalkenyl). Non-limiting examples of haloalkenyl groups include 2,2-difluorovinyl, 3-chloropropyl-1-alkenyl, etc. For optionally substituted alkenyl groups, the hydrogen atom bonded to the carbon atom of the alkenyl moiety may optionally be replaced by a substituent as defined above for the optionally substituted alkenyl group.

[0031] "Haloalkynyl" refers to an alkynyl group as defined above, which is further substituted by one or more halosubstituents. The number of halosubstituents included in the haloalkynyl group is from one to a maximum of the total number of hydrogen atoms that can be replaced by the halosubstituents (e.g., perfluoroalkynyl). Non-limiting examples of haloalkynyl groups include 3-chloroprop-1-alkynyl, etc. The alkynyl portion of the haloalkynyl group may also optionally be substituted as defined above for the alkynyl group.

[0032] "Heteroarylalkyl" refers to a group of the formula -Ra-Rb, wherein Ra is an alkylene group and Rb is a heteroaryl group as described herein. The alkylene and heteroaryl portions of the optionally substituted heteroarylalkyl group may optionally be substituted as described herein for the alkylene group and heteroaryl group, respectively.

[0033] "Heterocyclic group" refers to a stable 3- to 18-membered non-aromatic ring system group having two to twelve carbon atoms and containing a total of one to six heteroatoms independently selected from nitrogen, oxygen, phosphorus, and sulfur. Heterocyclic groups are monocyclic, bicyclic, tricyclic, or tetracyclic ring systems. Bicyclic, tricyclic, or tetracyclic heterocyclic groups are fused ring, spirocyclic, and / or bridged ring systems. Heterocyclic groups can be saturated or unsaturated. Unsaturated heterocyclic groups contain one, two, or three carbon-carbon double bonds and / or one carbon-carbon triple bond. The optionally substituted heterocyclic group is any heterocyclic group substituted with one, two, three, four, or five substituents, wherein the substituents are independently selected from alkyl, alkenyl, halogenated, haloalkyl, haloalkenyl, cyano, oxo, thiooxy, nitro, aryl, aralkyl, cycloalkyl, heterocyclic-, heteroaryl, -R′′-OR′, -R′′-OC(O)-R′, -R′′-N(R′)2, -R′′-C(O)R′, -R′′-C(O)OR′, -R′′-C(O)N(R′)2, -R′′-N(R′)C(O)OR′′′, -R′′-N(R′)C(O)R′′′, -R′′-N(R′)S(O)tR′′′ (where t is 1 or 2), -R′′-S(O)tOR′′′ (where t is 1 or 2), -R′′-S(O)pR′′′ (where p is 0, 1 or 2) and -R′′-S(O)tN(R′)2 (where t is 1 or 2), wherein each R′ is independently hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, heterocyclic or heteroaryl; each R′′ is independently a direct bond or a straight or branched alkylene or alkenyl chain; and each R′′′ is independently alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, heterocyclic or heteroaryl. The nitrogen, carbon, or sulfur atom in the heterocyclic group may be optionally oxidized (when the substituent is oxo and is present on the heteroatom); the nitrogen atom may be optionally quaternized (when the substituent is alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclic, heteroaryl, -R′′-OR′, -R′′-OC(O)-R′, -R′′-N(R′)2, -R′′-C(O)R).When R′′, -R′′-C(O)OR′, -R′′-C(O)N(R′)2, -R′′-N(R′)C(O)OR′′′, -R′′-N(R′)C(O)R′′′, -R′′-N(R′)S(O)tR′′′ (where t is 1 or 2), -R′′-S(O)tOR′′′ (where t is 1 or 2), -R′′-S(O)pR′′′ (where p is 0, 1 or 2), and -R′′-S(O)tN(R′)2 (where t is 1 or 2), R′′ is a straight-chain or branched alkylene or alkenylene chain, and R′ and R′′′ are as defined above. Examples of optionally substituted heterocyclic groups include, but are not limited to, azacyclic butyl, dioxolane, thienyl[1,3]dithiaalkyl, decahydroisoquinolinyl, imidazolinyl, imidazoalkyl, isothiazolyl, isoxazolyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopiperidinyl, 2-oxopiperylyl, oxazolyl-, piperidinyl, piperazinyl, 4-piperidinoneyl, pyrrolyl, pyrazolyl, thiazoalkyl, tetrahydrofuranyl, trithiaalkyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxothiomorpholinyl, and 1,1-dioxo-thiomorpholinyl.

[0034] A “subheterocyclic group” refers to a heterocyclic group in which one of its hydrogen atoms is valence-substituted. Optionally substituted subheterocyclic groups are optionally substituted as described herein with respect to heterocyclic groups.

[0035] "Heteroaryl" refers to a 5- to 18-membered ring system containing at least one aromatic ring, one to seventeen carbon atoms, and a total of one to ten heteroatoms independently selected from nitrogen, oxygen, and sulfur. Heteroaryl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system. Bicyclic, tricyclic, or tetracyclic heteroaryl is a fused ring and / or bridged ring system. Optionally substituted heteroaryl groups are heteroaryl groups optionally substituted with one, two, three, four, or five substituents, wherein the substituents are independently selected from alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkenyl, cyano, oxo, thiooxy, nitro, oxo, aryl, aralkyl, cycloalkyl, heterocyclic, heteroaryl, or heteroarylalkyl-, -R′′-OR′, -R′′-OC(O)-R′, -R′′-N(R′)2, -R′′-C(O)R′, -R′′-C(O)OR′, -R′′-C(O)N(R′)2, -R′′-N(R′)C(O)OR′′′, -R′′-N(R′)C(O)R′′′, -R′′-N(R′)S(O)tR′′′ (where t is 1 or 2), -R′′-S(O)tOR′′′ (where t is 1 or 2), -R′′-S(O)tR′′′ (where p is 0, 1 or 2) and -R′′-S(O)tN(R′)2 (where t is 1 or 2), wherein each R′ is independently hydrogen, alkyl, alkenyl, haloalkyl, cycloalkylR′′ is alkyl, aryl, heterocyclic or heteroaryl; each R′′ is independently a direct bond or a straight or branched alkylene or alkenyl chain; and each R′′′ is alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, heterocyclic or heteroaryl. The nitrogen, carbon, or sulfur atom in the heterocyclic group may optionally be oxidized (when the substituent is oxo-substituted and present on the heteroatom), provided that at least one ring in the heteroaryl group retains aromaticity; the nitrogen atom may optionally be quaternized (when the substituent is alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclic, heteroaryl, -R′′-OR′, -R′′-OC(O)-R′, -R′′-N(R′)2, -R′′-C(O)R′, -R′′-C(O)OR′, -R′′-C(O)N(R′)2, -R′′-N(R′)C(O)OR′′′, -R′′-N(R′)C(O)R′′′, -R′′-N(R′)S(O)tR′′′ (where t is 1 or 2), -R′′-S(O)tOR′′′ (where t is 1 or 2), -R′′-S(O)pR′′′ (where p is 0, 1 or 2) and -R′′-S(O)tN(R′)2 (where t is 1 or 2), where R′′ is a straight-chain or branched alkylene or alkenylene chain, and R′ and R′′′ are as defined above), provided that at least one ring in the heteroaryl group retains aromaticity. Examples of optionally substituted heteroaryl groups include, but are not limited to, those described on page 69 of specification 5 / 189, CN 121311486 A: aziridine, acridine, benzimizolyl, benzothiazolyl, benzoindolyl, benzodioxolane, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxazolyl, 1,4-benzodioxane, benzonaphthuronyl, benzooxazolyl, benzodioxolane, benzodioxinyl, benzopyranyl, benzopyranoneyl, benzofuranyl, benzofuranoneyl, benzothiophene (benzobenzenethio), benzotriazolyl, benzo[4,6]imidazo-[1, 2a] Pyridyl, carbazole, cenolinyl, dibenzofuranyl, dibenzophenylthio, furanyl, furanoneyl, isothiazolyl, imidazoyl, indazole, indoleyl, indazole, isoindoleyl, indolelinyl, isoindolelinyl, isoquinolinyl, indoleazinyl, isoxazolyl, naphthyl, naphthidyl, oxadiazolyl-, 2-oxoazapyridine, oxazolyl, ethylene oxide-, 1-phenyl-1H-pyrroleyl, phenazinyl, phenothiazinyl, phenotoxazinyl, phthalazinyl, pteridinyl, purine, pyrroleyl, pyrazolyl, pyridinyl, pyridinyl, pyrazinyl Pyrimidinyl, pyridazinyl, pyrroleyl, quinazolinyl, quinoxalinyl, quinolinyl, quininecycloyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and phenylthio (i.e., thiophene).

[0036] The phrase “pharmaceutically acceptable” as used herein means suitable for use with persons and / or individuals within the limits of reasonable medical judgment.Those compounds, salts, compositions, dosage forms, etc., that are used in tissues of other mammals without excessive toxicity, irritation, allergic reactions or other problems or complications, and whose benefits / risks are commensurate with a reasonable ratio. In some respects, “pharmaceuticalally acceptable” means approved by a federal or state regulatory agency or listed in the United States Pharmacopeia or other recognized pharmacopoeia for use in animals (e.g., mammals), and more specifically for use in humans.

[0037] A “prodrug” is a compound that is metabolized or otherwise chemically converted into its active form after administration. A prodrug may be a derivative of the active compound. A prodrug may be active or inactive before being converted into its active form in the body.

[0038] The term “treatment” is used herein when referring to methods for treating, for example, inflammatory diseases or gastrointestinal disorders, and generally includes the administration of a compound or composition that reduces the frequency of symptoms of a subject’s medical condition (e.g., autoimmune disease, inflammatory condition, gastrointestinal disorder) or delays its onset relative to a subject who has not received the compound or composition. This may include reversing, alleviating, or suppressing symptoms, clinical signs, and underlying pathology of the condition in a manner that improves or stabilizes the condition of the subject (e.g., symptom relief in autoimmune or inflammatory diseases, such as improved MAYO scores in the treatment of ulcerative colitis).

[0039] The embodiments disclosed herein cover all pharmaceutically acceptable compounds that are isotopically labeled (I)-(IL) by replacing one or more atoms with atoms having different atomic masses or mass numbers. Examples of isotopes that may be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 31P, 32P, 35S, 18F, 36Cl, 123I, and 125I, respectively. These radiolabeled compounds can be used to determine or measure the efficacy of the compound by characterizing, for example, the site or mode of action or binding affinity to a pharmacologically important site of action. Certain isotopically labeled (I)-(IL) compounds (e.g., compounds doped with radioactive isotopes) can be used for drug and / or substrate tissue distribution studies. Radioactive isotopes tritium (i.e., 3H) and carbon-14 (i.e., 14C) are particularly suitable for this purpose due to their ease of incorporation and detection.

[0040] Substitution with heavier isotopes (e.g., deuterium, i.e., 2H) can provide certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life or reduced dose requirement, and may therefore be preferred in some cases.

[0041] Substitution with positron emission isotopes (e.g., 11C, 18F, 15O, and 13N) can be useful in positron emission tomography (PET) studies used to examine substrate receptor occupancy. This can generally be achieved using conventional techniques known to those skilled in the art.The isotopically labeled (I)-(IL) compounds are prepared by a method similar to that described in the preparation and examples given below, using an appropriately isotopically labeled reagent instead of the previously used unlabeled reagent.

[0042] The embodiments disclosed herein cover in vivo metabolites of the disclosed compounds. Such products may be generated by oxidation, reduction, hydrolysis, amidation, esterification, etc., of the compounds applied as described on page 6 / 189 of CN 121311486 A, primarily due to enzymatic processes. Therefore, this disclosure includes compounds prepared by a method comprising administering the compound of this disclosure to a mammal for a duration sufficient to produce its metabolites. Such products are typically identified by administering a detectable dose of the radiolabeled compound of this disclosure to an animal (e.g., rat, mouse, guinea pig, monkey) or to a human, allowing sufficient time for metabolism, and separating its metabolites from urine, blood, or other biological samples.

[0043] “Pharmaceutically acceptable salt” includes both acid addition salts and base addition salts.

[0044] A “pharmaceutically acceptable acid addition salt” refers to a salt that retains the bioavailability and properties of a free base, is not biologically or otherwise undesirable, and is formed from an inorganic acid and an organic acid, such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc., and such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetaminobenzoic acid, camphoric acid, camphor-10-sulfonic acid, decanoic acid, hexanoic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclohexane, dodecyl sulfate, ethane-1,2-disulfonic acid, ethanesulfonic acid, etc. 2-Hydroxyethanesulfonic acid, formic acid, fumaric acid, galactosic acid, gentic acid, glucoheponic acid, gluconic acid, glucuronic acid, glutamic acid, glutamate, 2-oxoglutamate, glycerophosphate, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, mesylate, mucoic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, dihydroxynaphthalic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanate, p-toluenesulfonic acid, trifluoroacetic acid (TFA), undecenoic acid, etc.

[0045] A “pharmaceutically acceptable base addition salt” refers to a salt that retains the bioavailability and properties of the free acid and is not biologically or otherwise undesirable. These salts are prepared by the addition of an inorganic or organic base to a free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Preferred inorganic salts are ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, the following:Salts of substances: primary amines, secondary amines and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, tannin, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, heparin, choline, betaine, phenethylbenzylamine, benzoyldiamine, ethylenediamine, glucosamine, methylglucosamine, theobromine, triethanolamine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

[0046] "Pharmaceutical composition" means the compounds of this disclosure and formulations of media generally accepted in the art for delivering bioactive compounds to mammals (e.g., humans). This medium includes all of its pharmaceutically acceptable carriers, diluents, and excipients.

[0047] An “effective amount” or “therapeutic effective amount” means the amount of the compound of this disclosure that is sufficient to achieve a therapeutic effect in a mammal (preferably a human) when administered to the mammal (preferably a human). The amount of the compound constituting the “therapeutic effective amount” will vary depending on the compound, the condition and its severity, the manner of administration, and the age of the mammal to be treated, but can be conventionally determined by those skilled in the art based on their own knowledge and the content of this disclosure.

[0048] A “stereoisomer” means a compound consisting of identical atoms bonded by identical bonds but having different three-dimensional structures that are not interchangeable. This disclosure considers various stereoisomers and mixtures thereof, and includes “enantiomers,” which are two stereoisomers whose molecules are non-overlapping mirror images of each other. This disclosure also considers “diastereomers,” which are non-mirror images of different stereoisomers. Diastereomers are produced when two or more stereoisomers of a compound have different configurations at one or more equivalent stereocenters and are not mirror images of each other.

[0049] “Tautomer” refers to the proton transfer from one atom of a molecule to another atom of the same molecule. This specification, page 7 / 189, CN 121311486 A, includes any tautomer of the said compounds.

[0050] Unless otherwise indicated, “abnormal cell growth” as used herein means cell growth that does not depend on normal regulatory mechanisms (e.g., loss of contact inhibition). Abnormal cell growth can be benign (non-cancerous) or malignant (cancerous).

[0051] By reserving or excluding the rights of any individual member of any such group (including any subrange or combination of subranges within that group), protection may be claimed according to the scope or in any similar manner, and protection may be claimed for any reason less than the full scope of this disclosure. Furthermore, by reserving or excluding any individual substituents, analogues,The rights of any member of a compound, ligand, structure, or group thereof, or any member of the claimed group, may be claimed for any reason less than the full scope of this disclosure.

[0052] Throughout this disclosure, various patents, patent applications, and publications are cited. The disclosures of these patents, patent applications, and publications are incorporated herein by reference in their entirety in order to provide a more comprehensive description of the level of the art as known to those skilled in the art up to the date of this disclosure. In the event of any inconsistency between the cited patents, patent applications, and publications and this disclosure, this disclosure shall prevail.

[0053] II. Compounds The compounds described herein are ErbB2 inhibitors. In one embodiment, a compound having the structure of formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided: (I) wherein X1 is CR1 or N; X2 is CR2 or N; Y1 is CR4 or N; Y2 is CR5a or N; Y3 is C or N; Y4 is CR6 or NR6; Y5 is CR7, O, or NR7; Y6 is C or N; R1, R2, R3a, R3b, R3c, R3d, R4, R5a, R5b, and R7 are each independently H, halogenated, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 heteroalkyl; R6 is H, C1-C3 alkyl, C1-C3 deuterated, or C1-C3 haloalkyl; R8 and R9 Each is independently H or C1-C3 alkyl; Z1 is -NR9-, -O-, -S- or a direct bond; Z2 is -NR9- or a direct bond; L is C1-C4 alkyl, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, fused heterobicyclic, bridged heterobicyclic, heterospirocyclic or a direct bond; E is α,β-unsaturated carbonyl or C2-C4 alkyne conjugated carbonyl; and each is independently a single or double bond where the valence allows.

[0054] In one embodiment, Y2 is CR5a or N. In some embodiments, Y2 is CR5a. In some embodiments, Y2 is N.

[0055] In one embodiment, Y4 is CR6 or NR6. In some embodiments, Y4 is CR6. In some embodiments, Y4 is NR6.

[0056] In one embodiment, Y6 is C or N. In some embodiments, Y6 is C. In some embodiments, Y6 is N.

[0057] In one embodiment, Y2 is CR5a, Y4 is NR6, and Y6 is C. In one embodiment, Y2 is N, Y4 is NR6 (page 8 / 189 of specification CN 121311486 A), and Y6 is C. In one embodiment, Y2 is CR5a, Y4 is CR6, and Y6 is C. In one embodiment, Y2 is N, Y4 is CR6, and Y6 is C.

[0058] In one embodiment, the compound has one of the following structures (IA)-(ID): (IA) (IB) (IC) Specification 9 / 189 page 73 CN 121311486 A, (ID) or a stereoisomer of the compound, a tautomer of the compound, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of formula (IA): .

[0059] (IA) In some embodiments, the compound has the structure of formula (IB): .

[0060] (IB) In some embodiments, the compound has the structure of formula (IC): Specification 10 / 189 page 74 CN 121311486 A .

[0061] (IC) In some embodiments, the compound has the structure of formula (ID): .

[0062] (ID) In ​​one embodiment, Y5 is CR7, O, or NR7. In some embodiments, Y5 is CR7. In some embodiments, Y5 is O. Y5 is NR7.

[0063] In one embodiment, Y3 is C or N. In some embodiments, Y3 is C. In some embodiments, Y3 is N.

[0064] In one embodiment, Y5 is N and Y3 is C.

[0065] In one embodiment, the compound has one of the structures of formula (IA-1)-(IB-1): (IA-1) specification 11 / 189 page 75 CN 121311486 A, (IB-1) or a stereoisomer of the compound, a tautomer of the compound, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of formula (IA-1): .

[0066] (IA-1) In some embodiments, the compound has the structure of formula (IB-1): .

[0067] (IB-1) In one embodiment, Y5 is CR7, and Y3 is C, and R7 is H.

[0068] In one embodiment, the compound has one of the structures of formula (IA-2)-(IB-2): (IA-2), (IB-2), or a stereoisomer of the compound, a tautomer of the compound, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound has the structure of formula (IA-2):

[0069] (IA-2) In some embodiments, the compound has the structure of formula (IB-2):

[0070] (IB-2)In one embodiment, R6 is H, a C1-C3 alkyl, a C1-C3 deuterated alkyl, or a C1-C3 haloalkyl. In some embodiments, R6 is H. In some embodiments, R6 is a C1-C3 alkyl. In some embodiments, R6 is a C1-C3 deuterated alkyl. In some embodiments, R6 is a C1-C3 haloalkyl. In some particular embodiments, R6 is a C1 haloalkyl. In some more particular embodiments, R6 is CHF2 or CF3. In some embodiments, R6 is CHF2. In some embodiments, R6 is CF3.

[0071] In one embodiment, R6 of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) is a C1-C3 haloalkyl. In some embodiments, R6 of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) is a C1 haloalkyl. In some specific embodiments, the R6 of the structures (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) is CHF2 or CF3. In some specific embodiments, the R6 of the structures (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) is CHF2. In some specific embodiments, the R6 of the structures (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) is CF3.

[0072] In one embodiment, the R6 of the structures (IA-1), (IA-2), or (IB-2) is a C1-C3 haloalkyl. In some embodiments, the R6 of the structures (IA-1), (IA-2), or (IB-2) is a C1 haloalkyl. In some specific embodiments, the R6 of the structures (IA-1), (IA-2), or (IB-2) is CHF2 or CF3. In some specific embodiments, R6 of the structure (IA-1), (IA-2), or (IB-2) is CHF2. In some specific embodiments, R6 of the structure (IA-1), (IA-2), or (IB-2) is CF3.

[0073] In one embodiment, Z1 is -NR9-, -O-, -S-, or a direct bond. In some embodiments, Z1 is -NR9-. In some embodiments, Z1 is -O-. In some embodiments, Z1 is -S-. In some embodiments, Z1 is a direct bond.

[0074] In one embodiment, Z2 is -NR9- or a direct bond. In some embodiments, Z2 is -NR9-. In some embodiments, Z2 is a direct bond.

[0075] In one embodiment, Z1 and Z2 are each a direct bond. In this respect, the compound has the following structure: whereinRepresents a connection with the remainder of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). Specification 14 / 189 pages 78 CN 121311486 A

[0076] In one embodiment, Z1 is -NR9-, -O-, or -S-, and Z2 is a direct bond. In this respect, the compound has the following structure: wherein represents a connection with the remainder of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2).

[0077] In one embodiment, Z1 is a direct bond, and Z2 is -NR9-. In this respect, the compound has the following structure: wherein represents a connection with the remainder of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2).

[0078] In one embodiment, Z1 and Z2 are each -NR9-. In this respect, the compound has the following structure: where represents the connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2).

[0079] In one embodiment, R8 and R9 are each independently H or C1-C3 alkyl. In one embodiment, R8 is H or C1-C3 alkyl. In some embodiments, R8 is H. In some embodiments, R8 is C1-C3 alkyl. In one embodiment, R9 is H or C1-C3 alkyl. In some embodiments, R9 is H. In some embodiments, R9 is C1-C3 alkyl. In some embodiments, R9 is H or C1 alkyl. In some specific embodiments, R9 is H or CH3. In some embodiments, R9 is H. In some embodiments, R9 is CH3.

[0080] In one embodiment, R1, R2, R3a, R3b, R3c, R3d, R4, R5a, R5b, and R7 are each independently H, halo, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 heteroalkyl. In some embodiments, R1, R2, R3a, R3b, R3c, R3d, R4, R5a, R5b, and R7 are each independently H, halo, C1 alkyl, C1-C2 haloalkyl, or C1-C3 heteroalkyl. In some embodiments, R1, R2, R3a, R3b, R3c, R3d, R4, R5a, R5b, and R7 are each independently H, F, Cl, CH3, CH2CF3, CF3, CHF2, CH2OCH3, CD3, OCHF2, OCF3, or OCH3.

[0081] In one embodiment, R1 and R2 are each independently H, F, CH3, or OCH3. In some embodiments, R1 is...H, F, CH3, or OCH3. In some embodiments, R1 is H. In some embodiments, R1 is F. In some embodiments, R1 is CH3. In some embodiments, R1 is OCH3. In some embodiments, R2 is H, F, CH3, or OCH3. In some embodiments, R2 is H. In some embodiments, R2 is F. In some embodiments, R2 is CH3. In some embodiments, R2 is OCH3.

[0082] In one embodiment, R3a, R3b, R3c, and R3d are each independently H, CH3, OCH3, CH2OCH3, OCHF2, OCF3, F, or Cl. In some embodiments, R3a is H, CH3, OCH3, CH2OCH3, OCHF2, OCF3, F, or Cl. In some embodiments, R3a is H. In some embodiments, R3a is CH3. In some embodiments, R3a is OCH3. In some embodiments, R3a is CH2OCH3. In some embodiments, R3a is OCHF2. In some embodiments, R3a is OCF3. In some embodiments, R3a is F. In some embodiments, R3a is Cl. In some embodiments, R3b is H. In some embodiments, R3b is CH3. In some embodiments, R3b is OCH3. In some embodiments, R3b is CH2OCH3. In some embodiments, R3b is OCHF2. In some embodiments, R3b is OCF3. In some embodiments, R3b is F. In some embodiments, R3b is Cl. In some embodiments, R3c is H. In some embodiments, R3c is CH3. In some embodiments, R3c is OCH3. In some embodiments, R3c is CH2OCH3. In some embodiments, R3c is OCHF2. In some embodiments, R3c is OCF3. In some embodiments, R3c is F. In some embodiments, R3c is Cl. In some embodiments, R3d is H. In some embodiments, R3d is CH3. In some embodiments, R3d is OCH3. In some embodiments, R3d is CH2OCH3. In some embodiments, R3d is OCHF2. In some embodiments, R3d is OCF3. In some embodiments, R3d is F. In some embodiments, R3d is Cl.

[0083] In one embodiment, R4 is H, F, CH3, CH2OCH3, or CH2CF3. In some embodiments, R4 is H. In some embodiments, R4 is F. In some embodiments, R4 is CH3. In some embodiments, R4 is CH2OCH3. In oneIn some embodiments, R4 is CH2CF3.

[0084] In one embodiment, R5a and R5b are each independently H, CH3, F, or OCH3. In some embodiments, R5a is H, CH3, F, or OCH3. In some embodiments, R5a is H. In some embodiments, R5a is CH3. In some embodiments, R5a is F. In some embodiments, R5a is OCH3. In some embodiments, R5b is H, CH3, F, or OCH3. In some embodiments, R5b is H. In some embodiments, R5b is CH3. In some embodiments, R5b is F. In some embodiments, R5b is OCH3.

[0085] In one embodiment, R7 is H or a C1 alkyl group. In some embodiments, R7 is H. In some embodiments, R7 is a C1 alkyl group. In some embodiments, R7 is H or CH3. In some embodiments, R7 is CH3.

[0086] In one embodiment, R8 is H or C1 alkyl. In some embodiments, R8 is H. In some embodiments, R8 is C1 alkyl. In some embodiments, R8 is H or CH3. In some embodiments, R8 is CH3.

[0087] In one embodiment, the compound has one of the following structures: , , , , , , , , Specification 16 / 189 pages 80 CN 121311486 A , , , , , , , , , , , , , , , or, wherein represents a connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1) or (IB-2). In some embodiments, the compound has, wherein represents a connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1) or (IB-2). In some embodiments, the compound has a structure representing a connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has a structure representing a connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has a structure representing a connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has a structure representing a connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2).The connection of the remaining portion. In some embodiments, the compound has, wherein, represents a connection with the remaining portion of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has, wherein, represents a connection with the remaining portion of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has, wherein, represents a connection with the remaining portion of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). Specification 17 / 189 pages 81 CN 121311486 A In some embodiments, the compound has, wherein, represents a connection with the remaining portion of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has a connection representing the remaining portion of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has a connection representing the remaining portion of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has a connection representing the remaining portion of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has a connection representing the remaining portion of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has a connection representing the remaining portion of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has [a structure representing a connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has [a structure representing a connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has [a structure representing a connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has [a structure representing a connection with the remainder of the structure (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2)]., wherein represents the connection with the remainder of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). Specification 18 / 189 pages 82 CN 121311486 A In some embodiments, the compound has , wherein represents the connection with the remainder of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In some embodiments, the compound has , wherein represents the connection with the remainder of the structure of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2).

[0088] In one embodiment, L is a C1-C4 alkyl, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, fused heterobicyclic, bridged heterobicyclic, heterospirocyclic, or direct bond. In some embodiments, L is a C1-C4 alkyl. In some embodiments, L is a C3-C8 cycloalkyl. In some embodiments, L is a C3-C8 heterocyclic alkyl group. In some embodiments, L is a fused heterobicyclic ring. In some embodiments, L is a bridged heterobicyclic ring. In some embodiments, L is a heterospirocyclic ring. In some embodiments, L is a direct bond.

[0089] In one embodiment, the C3-C8 heterocyclic alkyl group, fused heterobicyclic ring, bridged heterobicyclic ring, and heterospirocyclic ring of L have 1-3 nitrogen atoms. In some embodiments, the C3-C8 heterocyclic alkyl group of L has 1-3 nitrogen atoms. In some embodiments, the fused heterobicyclic ring of L has 1-3 nitrogen atoms. In some embodiments, the bridged heterobicyclic ring of L has 1-3 nitrogen atoms. In some embodiments, the heterospirocyclic ring of L has 1-3 nitrogen atoms.

[0090] In one embodiment, the C3-C8 heterocyclic alkyl group, fused heterobicyclic ring, bridged heterobicyclic ring, and heterospirocyclic ring of L have 1-2 nitrogen atoms. In some embodiments, the C3-C8 heterocyclic alkyl group of L has 1-2 nitrogen atoms. In some embodiments, the fused heterobicyclic ring of L has 1-2 nitrogen atoms. In some embodiments, the bridged heterobicyclic ring of L has 1-2 nitrogen atoms. In some embodiments, the heterospirocyclic ring of L has 1-2 nitrogen atoms.

[0091] In one embodiment, the C3-C8 heterocyclic alkyl, fused heterobicyclic, bridged heterobicyclic, and heterospirocyclic ring of L are unsaturated heterocycles. In some embodiments, the C3-C8 heterocyclic alkyl of L is an unsaturated heterocycle. In some embodiments, the fused heterobicyclic ring of L is an unsaturated heterocycle. In some embodiments, the bridged heterobicyclic ring of L is an unsaturated heterocycle. In some embodiments, the heterospirocyclic ring of L is an unsaturated heterocycle.

[0092] In one embodiment, the C3-C8 heterocyclic alkyl of L is a nitrogen-containing heterocyclic butane, pyrrolidine, imidazoline, pyrazolidine, piperazine, etc.The compounds are pyridine, 1,2-diazine, 1,3-diazine, 1,4-diazine, aziridine, diaziridine, or aziridine. In some embodiments, the C3-C8 heterocyclic alkyl group of L is aziridine. In some embodiments, the C3-C8 heterocyclic alkyl group of L is pyrrolidine. In some embodiments, the C3-C8 heterocyclic alkyl group of L is imidazoline. In some embodiments, the C3-C8 heterocyclic alkyl group of L is pyrazolidine. In some embodiments, the C3-C8 heterocyclic alkyl group of L is piperidine. In some embodiments, the C3-C8 heterocyclic alkyl group of L is 1,2-diazine. In some embodiments, the C3-C8 heterocyclic alkyl group of L is 1,3-diazine. In some embodiments, the C3-C8 heterocyclic alkyl group of L is 1,4-diazine. In some embodiments, the C3-C8 heterocyclic alkyl group of L is aziridine. In some embodiments, the C3-C8 heterocyclic alkyl group of L is diazabicycloheptane. In some embodiments, the C3-C8 heterocyclic alkyl group of L is azabicyclooctane.

[0093] In one embodiment, the fused heterobicyclo group of L is 3-azabicyclo[3.1.0]heptane, 2,5-diazabicyclo[4.2.0]octane, octahydropyrrolo[3.4.c]pyrrole, octahydropyrrolo[3.4.b]pyrrole, octahydro-1H-pyrrolo[3.4.c]pyridine, decahydro-2,6-naphthidine, 2,5-diazabicyclo[4.1.0]heptane, 3,6-diazabicyclo[3.2.0]heptane, or 3,6-diazabicyclo[3.1.0]hexane. In some embodiments, the fused heterobicyclo group of L is 3-azabicyclo[3.1.0]heptane. In some embodiments, the fused heterobicyclic ring of L is 2,5-diazabicyclo[4.2.0]octane. In some embodiments, the fused heterobicyclic ring of L (see page 83 of CN 121311486 A, specification 19 / 189) is octahydropyrrolo[3.4.c]pyrrole. In some embodiments, the fused heterobicyclic ring of L is octahydro-1H-pyrrolo[3.4.c]pyridine. In some embodiments, the fused heterobicyclic ring of L is decahydro-2,6-naphthidine. In some embodiments, the fused heterobicyclic ring of L is 2,5-diazabicyclo[4.1.0]heptane. In some embodiments, the fused heterobicyclic ring of L is 3,6-diazabicyclo[3.2.0]heptane. In some embodiments, the fused heterobicyclic ring of L is 3,6-diazabicyclo[3.1.0]hexane. In some embodiments, the fused heterobicyclic ring of L is octahydropyrrolo[3.4.b]pyrrole.

[0094] In one embodiment, the bridged heterobicyclic ring of L is 3,8-diazabicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, 8-diazabicyclo[3.2.1]octane, 3-diazabicyclo[3.2.1]octane, or 3,6-diazabicyclo[3.2.1]octane.[3.2.1]Octane, 9-azabicyclo[3.3.1]nonane, 3-oxa-9-azabicyclo[3.3.1]nonane, 3-oxa-9-azabicyclo[3.3.1]non-6-ene, 9-azabicyclo[3.3.1]non-2-ene, 8-azabicyclo[3.2.1]oct-2-ene, or 3,6-diazabicyclo[3.1.1]heptane. In some embodiments, the bridged heterobicyclo of L is 3,8-diazabicyclo[3.2.1]octane. In some embodiments, the bridged heterobicyclo of L is 2,5-diazabicyclo[2.2.2]octane. In some embodiments, the bridged heterobicyclo of L is 8-azabicyclo[3.2.1]octane. In some embodiments, the bridged heterobicyclic ring of L is 3-azabicyclo[3.2.1]octane. In some embodiments, the bridged heterobicyclic ring of L is 3,6-diazabicyclo[3.2.1]octane. In some embodiments, the bridged heterobicyclic ring of L is 9-azabicyclo[3.3.1]nonane. In some embodiments, the bridged heterobicyclic ring of L is 3-oxa-9-azabicyclo[3.3.1]nonane. In some embodiments, the bridged heterobicyclic ring of L is 3-oxa-9-azabicyclo[3.3.1]non-6-ene. In some embodiments, the bridged heterobicyclic ring of L is 9-azabicyclo[3.3.1]non-2-ene. In some embodiments, the bridged heterobicyclic ring of L is 8-azabicyclo[3.2.1]oct-2-ene. In some embodiments, the bridged heterobicyclic ring of L is 3,6-diazabicyclo[3.1.1]heptane.

[0095] In one embodiment, the heterospirocyclic ring of L is 2,6-diazaspiro[3.3]heptane, 1,6-diazaspiro[3.3]heptane, 2-diazaspiro[3.3]heptane, 1,6-diazaspiro[3.4]octane, 2,6-diazaspiro[3.4]octane, 2,7-diazaspiro[3.5]nonane, 2,8-diazaspiro[4.5]decane, 3,9-diazaspiro[5.5]undecane, 4,8-diazaspiro[2.5]octane, 5,9-diazaspiro[3.5]nonane, 6,10-diazaspiro[4.5]decane, or 1,5-diazaspiro[5.5]undecane. In some embodiments, the heterospirocycle of L is 2,6-diazaspiro[3.3]heptane. In some embodiments, the heterospirocycle of L is 1,6-diazaspiro[3.3]heptane. In some embodiments, the heterospirocycle of L is 2-diazaspiro[3.3]heptane. In some embodiments, the heterospirocycle of L is 1,6-diazaspiro[3.4]octane. In some embodiments, the heterospirocycle of L is 2,6-diazaspiro[3.4]octane. In some embodiments, the heterospirocycle of L is 2,7-diazaspiro[3.5]nonane. In some embodiments, the heterospirocycle of L is 2,8-diazaspiro[4.5]decane. In some embodiments, the heterospirocycle of L is 3,9-diazaspiro[3.5]decane.Spiro[5.5]undecane. In some embodiments, the heterospirocycle of L is 4,8-diazaspiro[2.5]octane. In some embodiments, the heterospirocycle of L is 5,9-diazaspiro[3.5]nonane. In some embodiments, the heterospirocycle of L is 6,10-diazaspiro[4.5]decane. In some embodiments, the heterospirocycle of L is 1,5-diazaspiro[5.5]undecane.

[0096] In one embodiment, the C3-C8 heterocyclic alkyl, fused heterobicyclic, bridged heterobicyclic and heterospirocycle of L are further substituted with deuterium, halogenated, C1-C6 alkyl or C1-C6 heteroalkyl. In some embodiments, the C3-C8 heterocyclic alkyl, fused heterobicyclic, bridged heterobicyclic and heterospirocycle of L are further substituted with deuterium, halogenated, C1-C3 alkyl or C1-C3 heteroalkyl. In some embodiments, the C3-C8 heterocyclic alkyl group, fused heterobicyclic ring, bridged heterobicyclic ring, and heterospirocyclic ring of L are further substituted with -D, -F, -CH3, -CF3, -CHF2, -CH2F, -CH2CHF2, -CH2CH3, -CH(CH3)2, -CH2OH, -CH2OCH3, or -CH2CCN.

[0097] In one embodiment, the C3-C8 heterocyclic alkyl group is further substituted with -D, -F, -CH3, -CF3, -CHF2, -CH2F, -CH2CHF2, -CH2CH3, -CH(CH3)2, -CH2OH, -CH2OCH3, or -CH2CCN. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -D. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -F (see specification 20 / 189, page 84, CN 121311486 A). In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -CH3. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -CF3. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -CHF2. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -CH2F. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -CH2CHF2. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -CH2CH3. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -CH(CH3)2. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -CH2OH. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -CH2OCH3. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted. In some embodiments, the C3-C8 heterocyclic alkyl group is further substituted with -CH2CCN.

[0098] In one embodiment, the fused heterobicyclic ring is further substituted with -D, -F, -CH3, -CF3, -CHF2, -CH2F, -CH2CHF2, -CH2CH3, -CH(CH3)2, -CH2OH, -CH2OCH3, or -CH2CCN. In some embodiments, the fused heterobicyclic ring is further substituted with -D. In some embodiments, the fused heterobicyclic ring is further substituted with -F. In some embodiments, the fused heterobicyclic ring is further substituted with -CH3. In some embodiments, the fused heterobicyclic ring is further substituted with -CF3. In some embodiments, the fused heterobicyclic ring is further substituted with -CHF2. In some embodiments, the fused heterobicyclic ring is further substituted with -CH2F. In some embodiments, the fused heterobicyclic ring is further substituted with -CH2CHF2. In some embodiments, the fused heterobicyclic ring is further substituted with -CH2CH3. In some embodiments, the fused heterobicyclic ring is further substituted with -CH(CH3)2. In some embodiments, the fused heterobicyclic ring is further substituted with -CH2OH. In some embodiments, the fused heterobicyclic ring is further substituted with -CH2OCH3. In some embodiments, the fused heterobicyclic ring is further substituted. In some embodiments, the fused heterobicyclic ring is further substituted with -CH2CCN.

[0099] In one embodiment, the bridging heterobicyclic ring is further substituted with -D, -F, -CH3, -CF3, -CHF2, -CH2F, -CH2CHF2, -CH2CH3, -CH(CH3)2, -CH2OH, -CH2OCH3, or -CH2CCN. In some embodiments, the bridging heterobicyclic ring is further substituted with -D. In some embodiments, the bridging heterobicyclic ring is further substituted with -F. In some embodiments, the bridging heterobicyclic ring is further substituted with -CH3. In some embodiments, the bridging heterobicyclic ring is further substituted with -CF3. In some embodiments, the bridging heterobicyclic ring is further substituted with -CHF2. In some embodiments, the bridging heterobicyclic ring is further substituted with -CH2F. In some embodiments, the bridging heterobicyclic ring is further substituted with -CH2CHF2. In some embodiments, the bridging heterobicyclic ring is further substituted with -CH2CH3. In some embodiments, the bridging heterobicyclic ring is further substituted with -CH(CH3)2. In some embodiments, the bridging heterobicyclic ring is further substituted with -CH2OH. In some embodiments, the bridging heterobicyclic ring is further substituted with -CH2OCH3. In some embodiments, the bridging heterobicyclic ring is further substituted. In some embodiments, the bridging heterobicyclic ring is further substituted with -CH2CCN.

[0100] In one embodiment, the heterospirocyclic ring is further substituted with -D, -F, -CH3, -CF3, -CHF2, -CH2F, -CH2CHF2, -CH2CH3, -CH(CH3)2, -CH2OH, -CH2OCH3, or -CH2CCN. In some embodiments, the heterospirocyclic ring is further substituted with -D. In some embodiments, the heterospirocyclic ring is further substituted with -F. In some embodiments, the heterospirocyclic ring is further substituted with -CH3. In some embodiments, the heterospirocyclic ring is further substituted with -CF3. In some embodiments, the heterospirocyclic ring is further substituted with -CHF2. In some embodiments, the heterospirocyclic ring is further substituted with -CH2F. In some embodiments, the heterospirocyclic ring is further substituted with -CH2CHF2. In some embodiments, the heterospirocyclic ring is further substituted with -CH2CH3. In some embodiments, the heterospirocyclic ring is further substituted with -CH(CH3)2. In some embodiments, the heterospirocycle is further substituted with -CH2OH. In some embodiments, the heterospirocycle is further substituted with -CH2OCH3. In some embodiments, the heterospirocycle is further substituted. In some embodiments, the heterospirocycle is further substituted with -CH2CCN.

[0101] In one embodiment, the C3-C8 heterocyclic alkyl, fused heterobicyclic, bridged heterobicyclic, and heterospirocycle of L are mono-, di-, tri-, tetra-, penta-, or octa-substituted. In some embodiments, the C3-C8 heterocyclic alkyl of L is mono-, di-, tri-, tetra-, penta-, or octa-substituted. In some embodiments, the fused heterobicyclic of L is mono-, di-, tri-, tetra-, penta-, or octa-substituted. In some embodiments, the bridged heterobicyclic of L is mono-, di-, tri-, tetra-, penta-, or octa-substituted. In some embodiments, the heterospirocycle of L is mono-, di-, tri-, tetra-, penta-, or octa-substituted.

[0102] In one embodiment, L is a C2-C4 alkyl or a C4-C5 cycloalkyl. In some embodiments, L is a C2-C4 alkyl group. In some embodiments, L is a C4-C5 cycloalkyl group. In some embodiments, the C1-C4 alkyl group of L is –(CH2)2- or –CH2C(CH3)2. In some embodiments, the C1-C4 alkyl group of L is –(CH2)2-. In some embodiments, the C1-C4 alkyl group of L is –CH2C(CH3)2.

[0103] In one embodiment, the C3-C8 cycloalkyl group of L is , where * indicates the position of the bond with Z2.

[0104] In one embodiment, L has one of the following structures: , ...、 ... In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is. In some implementations, L is.In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is specification 24 / 189 page 88 CN 121311486 A. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is. In some embodiments, L is.

[0106] In one embodiment, E is an α,β-unsaturated carbonyl or a C2-C4 yne conjugated carbonyl. In some embodiments, E is an α,β-unsaturated carbonyl. In some embodiments, E is a C2-C4 yne conjugated carbonyl. In some embodiments, the α,β-unsaturated carbonyl or C2-C4 yne conjugated carbonyl of E is further substituted by a halogen, a C1-C3 alkyl, a C1-C3 alkyl halide, a C1-C6 heteroalkyl, a -(CH2)nC3-C7 heterocyclic alkyl, or a combination thereof, wherein n is an integer between 1 and 3.

[0107] In one embodiment, the α,β-unsaturated carbonyl of E has one of the following structures: , , , , , , , , , , , , , , or specification 25 / 189 page 89 CN 121311486 A. In some embodiments, the α,β-unsaturated carbonyl of E is. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information]. In some embodiments, the α,β-unsaturated carbonyl group of E is [missing information].,β-unsaturated carbonyl is. In some embodiments, the α,β-unsaturated carbonyl of E is.

[0108] In one embodiment, the C2-C4 yne conjugated carbonyl is a C2 yne conjugated carbonyl or a C3 yne conjugated carbonyl. In some embodiments, the C2-C4 yne conjugated carbonyl is a C2 yne conjugated carbonyl. In some embodiments, the C2-C4 yne conjugated carbonyl is a C3 yne conjugated carbonyl. In some specific embodiments, the C2-C4 yne conjugated carbonyl has the following structure: . In some embodiments, the C2-C4 yne conjugated carbonyl is.

[0109] In one embodiment, E has one of the following structures: , , , , , , , , , , , , , , , , or. In some embodiments, E is 26 / 189 pages 90 CN 121311486 A. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is. In some embodiments, E is.

[0110] In one embodiment, the compound of formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) has one of the following structures shown in Table 1 below.

[0111] Table 1: List of compounds of (I), (IA)-(ID), (IA-1), (IA-2), (IB-1) or (IB-2) Specification 27 / 189 page 91 CN 121311486 A Specification 28 / 189 page 92 CN 121311486 A Specification 29 / 189 page 93 CN 121311486 A Specification 30 / 189 page 94 CN 121311486 A Specification 31 / 189 page 95 CN 121311486 A Specification 32 / 189 page 96 CN 121311486 A Specification 33 / 189 page 97 CN 121311486 A Specification 34 / 189 page 98 CN 121311486 A Specification 35 / 189 page 99 CN 121311486 A Instruction Manual 36 / 189 pages 100 CN 121311486 A Instruction Manual 37 / 189 pages 101 CN 121311486 A Instruction Manual 38 / 189 pages102 CN 121311486 A Specification 39 / 189 pages 103 CN 121311486 A Specification 40 / 189 pages 104 CN 121311486 A Specification 41 / 189 pages 105 CN 121311486 A Specification 42 / 189 pages 106 CN 121311486 A Specification 43 / 189 pages 107 CN 121311486 A Specification 44 / 189 pages 108 CN 121311486 A It is understood that the compounds described herein are capable of developing new disease therapies without the need for special chemical methods or specialized reagents or manufacturing techniques.

[0112] III. Other embodiments of the pharmaceutical composition relate to pharmaceutical compositions. In some embodiments, the pharmaceutical composition comprises any (or more) of the foregoing compounds and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is formulated for oral administration. In other embodiments, the pharmaceutical composition is formulated for injection. In still more embodiments, the pharmaceutical composition comprises compounds as disclosed herein and additional therapeutic agents (e.g., anticancer agents). Non-limiting examples of such additional therapeutic agents are described below.

[0113] Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, mucosal, transdermal, vaginal, ocular, nasal, and topical administration. Furthermore, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injection, and intrathecal, direct intracardiac, intraperitoneal, intralymphatic, and intranasal injection.

[0114] In some embodiments, compounds as described herein are administered locally rather than systemically, via direct injection into an organ, typically in the form of a reservoir formulation or a sustained-release formulation. In specific embodiments, long-acting formulations are administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. Furthermore, in other embodiments, compounds are delivered in targeted drug delivery systems, such as in liposomes coated with organ-specific antibodies. In such embodiments, liposomes are targeted to organs and selectively absorbed therein. In other embodiments, the compounds described herein are provided as immediate-release, delayed-release, or intermediate-release formulations. In other embodiments, the compounds described herein are applied topically.

[0115] In a treatment method according to an embodiment of the present disclosure, an effective amount of at least one compound of formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) is administered to a subject suffering from or diagnosed with such disease, condition, or medical symptom. The effective amount or dose can be determined by methods such as modeling, dose-escalation studies, or clinical trials, e.g.Such as the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the disease, the severity of the condition or symptom and course of action, the subject's prior or current treatment, the subject's health status and response to the drug, and the judgment of the treating physician.

[0116] The compounds according to this disclosure are effective over a wide dose range. For example, in the treatment of adults, doses of about 0.001 to 0.1 mg, 0.01 to 0.1 mg, 0.5 to 5 mg, 0.5 to 10 mg, 0.01 to 10 mg, 10 to 5000 mg, 100 to 5000 mg, 1000 mg to 4000 mg, or 1000 to 3000 mg daily are examples of doses used in some embodiments. The exact dose will depend on the route of administration, the form in which the compound is administered, the subject to be treated, the weight of the subject to be treated, and the preferences and experience of the attending physician.

[0117] In some embodiments, the compounds of this disclosure are administered in a single dose. In one embodiment, a single dose is administered orally. In another embodiment, a single dose is administered by injection. However, other routes are used where appropriate. In some embodiments, the compounds of this disclosure are administered in multiple doses. In some embodiments, the compound is administered about once, twice, three times, four times, five times, six times, or more than six times daily. In other embodiments, the compound is administered about once a month, once every two weeks, once a week, or once every other day. In another embodiment, the compound of this disclosure is administered together with another agent (e.g., another anticancer agent) about once daily to about six times daily. The administration of the compound and the agent of this disclosure lasts for less than about 7 days. In yet another embodiment, the administration lasts for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous administration is achieved, and continuous administration is maintained as long as necessary.

[0118] The compounds of this disclosure can be administered continuously as long as necessary. In some embodiments, the compound of this disclosure is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, the compounds of this disclosure are administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, the compounds of this disclosure are administered continuously for a prolonged period, for example, to treat chronic effects.

[0119] In some embodiments, the compounds of this disclosure are administered in a single dosage form. It is known in the art that due to differences in the pharmacokinetics of compounds among subjects, dosing regimens need to be personalized in order to optimize the therapy.

[0120] In some embodiments, the compounds described herein are formulated into pharmaceutical compositions. In specific embodiments, the pharmaceutical compositions are formulated in a conventional manner using one or more physiologically acceptable carriers, said physiologically acceptable carriers.The carrier contains excipients and adjuvants that facilitate the processing of the disclosed compound into a pharmaceutically acceptable formulation. Appropriate formulation depends on the chosen route of administration. Suitable pharmaceutical compositions described herein can be formulated using any pharmaceutically acceptable technique, carrier, and excipient: Remington: The Science and Practice of Pharmacy, 19th edition (Easton, PA: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L. (eds.), Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th edition (Lippincott Williams & Wilkins 1999).

[0121] This document provides pharmaceutical compositions comprising one or more compounds of formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) and a pharmaceutically acceptable carrier. This document also provides pharmaceutical compositions comprising one or more compounds selected from formula (I)-(IL) and a pharmaceutically acceptable diluent, excipient, and carrier. In some embodiments, the described compounds are administered as pharmaceutical compositions, wherein, as in combination therapy, one or more compounds selected from formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) are mixed with other active ingredients. This document covers all combinations of active substances listed in the combination therapy section below and throughout this disclosure. In specific embodiments, the pharmaceutical composition comprises one or more compounds of formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). Instructions for Use, 46 / 189 pages, 110 CN 121311486 A

[0122] As used herein, a pharmaceutical composition refers to one or more compounds selected from formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1) or (IB-2) and such as a carrier, stabilizer, diluent, dispersant, suspending agent, thickener.A mixture of other chemical components of the compound and / or excipients. In some embodiments, the pharmaceutical composition facilitates the administration of the compound to an organism. In some embodiments, a therapeutically effective amount of one or more compounds selected from the formulas (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) provided herein is administered to a mammal suffering from a disease, condition, or medical symptom to be treated, in the form of a pharmaceutical composition. In a particular embodiment, the mammal is a human. In some embodiments, the therapeutically effective amount varies depending on the severity of the disease, the age and relative health status of the subject, the potency of the compound used, and other factors. The compounds described herein are used alone or in combination with one or more therapeutic agents as components of a mixture.

[0123] In one embodiment, one or more compounds selected from the formulas (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) are formulated in an aqueous solution. In a particular embodiment, by way of example only, the aqueous solution is selected from physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. In other embodiments, one or more compounds selected from formulas (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) are formulated for transmucosal administration. In specific embodiments, the transmucosal formulation includes a permeabilizer suitable for penetrating the barrier to be penetrated. In other embodiments, where the compounds described herein are formulated for other parenteral injections, suitable formulations include aqueous or non-aqueous solutions. In specific embodiments, such solutions include physiologically compatible buffers and / or excipients.

[0124] In another embodiment, the compounds described herein are formulated for oral administration. The compounds described herein are formulated by combining the active compound with, for example, a pharmaceutically acceptable carrier or excipient. In various embodiments, the compounds described herein are formulated into oral dosage forms, which, by way of example only, include tablets, powders, pills, sugar-coated pills, capsules, liquids, gels, syrups, elixirs, slurries, suspensions, etc.

[0125] In some embodiments, a pharmaceutical formulation for oral use is obtained by mixing one or more solid excipients with one or more compounds described herein, optionally grinding the resulting mixture, and, if necessary, adding suitable adjuvants to process the mixture into granules to obtain a tablet or sugar-coated core. Suitable excipients include fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; and cellulose formulations such as, for example, corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, microcrystalline cellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, etc.Sodium cellulose; or other substances such as polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. In specific embodiments, a disintegrant may optionally be added. By way of example only, disintegrants include croscarmellose sodium, polyvinylpyrrolidone, agar or alginate or a pharmaceutically acceptable salt thereof, such as sodium alginate.

[0126] In one embodiment, an oral dosage form such as a pill, capsule or tablet comprises one or more suitable layers or coatings. In specific embodiments, the dosage form is coated using a concentrated sugar solution. The sugar solution may optionally contain additional components, by way of example only, such as gum arabic, talc, polyvinylpyrrolidone, carbomer gel, polyethylene glycol and / or titanium dioxide, lacquer solution and suitable organic solvents or solvent mixtures. For identification purposes, dyes and / or pigments may optionally be added to the coating. Additionally, dyes and / or pigments may optionally be used to characterize different combinations of active compound dosages.

[0127] In some embodiments, a therapeutically effective amount of at least one of the compounds described herein is formulated into other oral dosage forms. Oral dosage forms include push-in capsules made of gelatin and soft-sealable capsules made of gelatin and plasticizers (such as glycerin or sorbitol). In specific embodiments, push-in capsules contain an active ingredient mixed with one or more fillers. Fillers include, by way of example only, lactose, binders (such as starch) and / or lubricants (such as talc or magnesium stearate) and optionally stabilizers. In other embodiments, soft capsules contain one or more active compounds dissolved or suspended in a suitable liquid. Suitable liquids include, by way of example only, one or more fatty oils, liquid paraffin or liquid polyethylene glycol. Additionally, stabilizers are optionally added.

[0128] In other embodiments, the compounds described herein are formulated for parenteral injection, including formulations suitable for push-in or continuous infusion. In specific embodiments, the formulations for injection are provided in unit dosage forms (e.g., in ampoules) or multi-dose containers. Preservatives are optionally added to the injectable formulations. In other embodiments, the pharmaceutical composition is formulated into a form suitable for parenteral injection, such as a sterile suspension, solution, or emulsion in an oily or aqueous medium. The parenteral injection formulation optionally contains a formulation such as a suspending agent, stabilizer, and / or dispersant. In specific embodiments, the pharmaceutical formulation for parenteral administration comprises an aqueous solution of the active compound in a water-soluble form. In further embodiments, a suspension of one or more compounds selected from formulas (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) is prepared as a suitable oily injection suspension. By way of example only, suitable lipophilic solvents or mediators for the pharmaceutical compositions described herein include fatty oils (such as sesame oil) or synthetic fatty acid esters (such as ethyl oleate or triglycerides) or liposomes.In some specific embodiments, the aqueous injectable suspension contains a substance that increases the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension contains a suitable stabilizer or a reagent that increases the solubility of the compound to allow for the preparation of a highly concentrated solution. Alternatively, in other embodiments, the active ingredient is in powder form for formulation with a suitable medium (e.g., sterile, pyrogen-free water) prior to use.

[0129] The pharmaceutical composition comprises at least one pharmaceutically acceptable carrier, diluent, or excipient, and one or more compounds selected from formulas (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) as the active ingredient. The active ingredient is in the form of a free acid or free base or a pharmaceutically acceptable salt. Furthermore, the methods and pharmaceutical compositions described herein include N-oxides, crystalline forms (also known as polymorphs), and active metabolites having the same type of activity using these compounds. All tautomers of the compounds described herein are included within the scope of the compounds given herein. In addition, the compounds described herein encompass both unsolvable forms and solvated forms with pharmaceutically acceptable solvents (such as water, ethanol, etc.). The solvated forms of the compounds given herein are also considered to be disclosed herein. Furthermore, pharmaceutical compositions optionally include other drugs or agents, carriers, adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, solution promoters, pharmaceutically acceptable salts for regulating osmotic pressure, buffers, and / or other substances of therapeutic value.

[0130] Methods of preparing compositions comprising the compounds described herein include formulating the compounds with one or more inert, pharmaceutically acceptable excipients or carriers to form solid, semi-solid, or liquid compositions. Solid compositions include, but are not limited to, powders, tablets, dispersible granules, capsules, pouches, and suppositories. Liquid compositions include solutions in which the compounds are dissolved, emulsions containing the compounds, or solutions containing liposomes, micelles, or nanoparticles comprising compounds as disclosed herein. Semi-solid compositions include, but are not limited to, gels, ointments, suspensions, and creams. The forms of pharmaceutical compositions described herein include liquid solutions or suspensions, solid forms suitable for dissolving or suspending in a liquid prior to use, or as emulsions. These compositions may also optionally contain small amounts of non-toxic excipients, such as wetting or emulsifying agents, pH buffers, etc.

[0131] In some embodiments, pharmaceutical compositions comprising one or more compounds selected from formulas (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) are exemplary in liquid form, wherein the pharmaceutical agent is present in a solution, a suspension, or both. Typically, when the composition is administered in suspension form, a first portion of the pharmaceutical agent is present in a solution, and a second portion of the pharmaceutical agent is present in particulate form in a suspension in the form of a liquid matrix. In some embodiments, the liquidThe composition includes a gel formulation. In other embodiments, the liquid composition is aqueous.

[0132] In some embodiments, the aqueous suspension contains one or more polymers as suspending agents. Polymers include water-soluble polymers, such as cellulose polymers, for example hydroxypropyl methylcellulose, and water-insoluble polymers, such as cross-linked carboxyl-containing polymers. Some pharmaceutical compositions described herein contain, for example, mucoadhesive polymers selected from carboxymethyl cellulose, carbomer (acrylate polymer, page 48 / 189, CN 121311486 A), poly(methyl methacrylate), polyacrylamide, polycarboxyphene, acrylate / butyl acrylate copolymer, sodium alginate, and dextran.

[0133] The pharmaceutical composition may also optionally include a solubilizer that contributes to the solubility of one or more compounds selected from formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). The term "sorcelain solubilizer" generally includes an agent that results in the formation of a micelle solution or a true solution of the reagent. Certain acceptable nonionic surfactants (e.g., polysorbate 80) can be used as solubilizers, as can ophthalmologically acceptable glycols, polyethylene glycols (e.g., polyethylene glycol 400), and glycol ethers.

[0134] In addition, the pharmaceutical composition optionally includes one or more pH adjusters or buffers, including acids such as acetic acid, boric acid, citric acid, lactic acid, phosphoric acid, and hydrochloric acid; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, and tris(hydroxymethyl)aminomethane; and buffers such as citrate / dextrose, sodium bicarbonate, and ammonium chloride. The amounts of such acids, bases, and buffers included are necessary to maintain the pH of the composition within an acceptable range.

[0135] The composition also optionally includes one or more pharmaceutically acceptable salts in amounts necessary to maintain the osmotic pressure of the composition within an acceptable range. Pharmaceutically acceptable salts of this type include those having sodium, potassium, or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate, or bisulfite anions; suitable pharmaceutically acceptable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite, and ammonium sulfate.

[0136] Other pharmaceutical compositions optionally include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances, such as nitrocresol mercury and thimerosal; stabilized chlorine dioxide; and quaternary ammonium compounds, such as benzalkonium chloride, cetrimonium bromide, and cetylpyridinium chloride.

[0137] The composition may include one or more surfactants to enhance physical stability or for other purposes. Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, such as polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkyl ethers and alkylphenyl ethers, such as octylbenzyl alcohol 10 and octylbenzyl alcohol 40.

[0138] The composition may include one or more antioxidants to enhance chemical stability if desired. Suitable antioxidants, by way of example only, include ascorbic acid and sodium metabisulfite.

[0139] In some embodiments, the aqueous suspension composition is packaged in a single-dose, non-resealed container. Alternatively, a multi-dose, resealed container is used, in which case a preservative is typically included in the composition.

[0140] In alternative embodiments, other delivery systems for hydrophobic pharmaceutical compounds are employed. Liposomes and emulsions are examples of delivery media or carriers useful herein. In some embodiments, organic solvents, such as N-methylpyrrolidone, are also used. In other embodiments, sustained-release systems are used to deliver the compounds described herein, such as using a semi-permeable matrix of a solid hydrophobic polymer containing the therapeutic agent. Various sustained-release substances may be used herein. In some embodiments, sustained-release capsules release the compound for several weeks to over 100 days. Additional protein stabilization strategies are employed depending on the chemical properties and biological stability of the therapeutic agent.

[0141] In some embodiments, the formulations described herein comprise one or more antioxidants, metal chelators, thiol-containing compounds and / or other general stabilizers. Examples of such stabilizers include, but are not limited to: (a) about 0.5% to about 2% w / v glycerol, (b) about 0.1% to about 1% w / v methionine, (c) about 0.1% to about 2% w / v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w / v ascorbic acid, (f) about 0.003% to about 0.02% w / v polysorbate 80, (g) about 0.001% to about 0.05% w / v polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrin, (l) pentosan polysulfates and other heparin-like substances, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.

[0142] In some embodiments, the concentration of one or more compounds selected from formulas (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) provided in the pharmaceutical composition is greater than 90%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25%, 18%, 17.75%, 17.50%, 17.25%, 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25%, 15%, 14.75%, 14.50%, 14.25%.14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25% 6%, 5.75%, 5.50%, 5.25%, 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50% 1.25%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002% or 0.0001% w / w, w / v or v / v. In another embodiment, the amount of a compound selected from formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) in the pharmaceutical composition is between about any two values ​​listed in the preceding sentence, such as between about 2-70 w / w%, 3.5-80 w / w%, and 1-30 w / w%.

[0143] In some embodiments, the concentration of one or more compounds selected from formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) provided in the pharmaceutical compositions of this disclosure is from about 0.0001% to about 50%, from about 0.001% to about 40%, from about 0.01% to about 30%, from about 0.02% to about 29%, from about 0.03% to about 28%, from about 0.04% to about 27%, from about 0.05% to about 26%, from about 0.06% to about 25%, from about 0.07% to about 24%, from about 0.08% to about 23%, from about 0.09% to about 22%, from about 0.1% to about 21%, from about 0.2% to about 20%, from about 0.3% to about 19%, from about 0.4% to about 18%, from about 0.5% to about 17%, and from about 0.6% to about 16%.The range is approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, and approximately 1% to approximately 10% w / w, w / v, or v / v.

[0144] In some embodiments, the amount of one or more compounds selected from formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) provided in the pharmaceutical compositions of this disclosure is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, etc. g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g or 0.0001 g.

[0145] In some embodiments, the amount of one or more compounds selected from formulas (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) provided in the pharmaceutical compositions of this disclosure is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.

[0146] Packaging materials for packaging the pharmaceutical compositions described herein include those found, for example, in U.S. Patent Nos. 5,323,907, 5,052,558, and 5,033,252. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for the selected formulation and intended mode of administration and treatment. For example, the container includes one or more compounds described herein, optionally in the composition, or in combination with those described herein.Another combination of pharmaceutical preparations. Containers optionally have a sterile inlet (e.g., containers are intravenous solution bags or vials with stoppers that can be punctured by a hypodermic needle). Such kits optionally contain compounds with labeling or instructions or instructions regarding their use in the methods described herein.

[0147] For example, kits typically include one or more additional containers, each containing one or more of a variety of substances from the commercial and user-friendly perspectives of which the use of the compounds described herein is desirable (e.g., reagents and / or devices optionally in concentrated form). Non-limiting examples of such substances include, but are not limited to, buffers, diluents, filters, needles, syringes; carriers, packaging, containers, vials and / or tube labels listing the contents and / or instructions for use, and package inserts with instructions for use. A set of instructions is also typically included. Labels are optionally on or associated with the container. For example, when the letters, numbers, or other characters forming the label are affixed, molded, or etched onto the container body, the label is on the container; when the label is present within a receiver or carrier that also holds the container, the label is associated with the container, such as as a packaging insert. Furthermore, the label is used to indicate that the contents are intended for a specific therapeutic application. Additionally, the label indicates instructions for use of the contents, such as those used in the methods described herein. In some embodiments, the pharmaceutical composition is provided in a packaging or dispenser device containing one or more unit dosage forms containing the compounds provided herein. For example, the packaging may contain metal or plastic foil, such as blister packs. Alternatively, the packaging or dispenser device may be accompanied by instructions for use, or the packaging or dispenser may be accompanied by a notification associated with the container, in the form prescribed by a government agency regulating the manufacture, use, or sale of the drug, reflecting that the agency has approved the drug form for human or veterinary use. Such notification is, for example, a prescription drug label or approved product information sheet approved by the U.S. Food and Drug Administration. In some embodiments, a composition containing the compounds provided herein formulated in a compatible drug carrier is prepared, placed in a suitable container, and labeled with the indication of a symptom for therapeutic purposes.

[0148] As described above, the compounds and compositions of this disclosure will be applicable to a wide range of diseases and conditions mediated by protein kinases, including diseases and conditions mediated by kinases. For example, such diseases may include (but are not limited to) cancers such as lung cancer, NSCLC (non-small cell lung cancer), oat cell carcinoma, bone cancer, pancreatic cancer, skin cancer, dermatofibrosarcoma protuberans, head and neck cancer, melanoma of the skin or eye, uterine cancer, ovarian cancer, colorectal cancer, anal cancer, gastric cancer, colon cancer, breast cancer, gynecological tumors (e.g., uterine sarcoma, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, or vulvar cancer), Hodgkin's disease, liver cancer, etc.Cancer cells, esophageal cancer, small bowel cancer, endocrine system cancers (e.g., thyroid cancer, pancreatic cancer, parathyroid cancer, or adrenal cancer), soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer (especially hormone-resistant), chronic or acute leukemia, childhood solid tumors, hypereosinophilia, lymphocytic lymphoma, bladder cancer, kidney cancer, or ureteral cancer (e.g., renal cell carcinoma, renal pelvis cancer), pediatric malignancies, central nervous system tumors (e.g., primary CNS lymphoma, spinal axis tumors, medulloblastoma, brainstem glioma, or pituitary adenoma), Barrett's esophagus (pre-malignant syndrome), neoplastic skin diseases, psoriasis, mycosis fungoides and benign prostatic hyperplasia, diabetes-related diseases such as diabetic retinopathy, retinal ischemia and retinal neovascularization, cirrhosis, angiogenesis, cardiovascular diseases such as atherosclerosis, immune diseases such as autoimmune diseases, and kidney diseases.

[0149] In some embodiments, the pharmaceutical composition has the above-described compounds and a pharmaceutically acceptable carrier, including, for example, any adjuvant, carrier, excipient, gliding agent, sweetener, diluent, preservative, dye / coloring agent, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier that has been approved by the U.S. Food and Drug Administration for use in humans or livestock.

[0150] In one embodiment, a pharmaceutical composition comprising a compound of formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2) and an additional therapeutic agent is disclosed.

[0151] In one embodiment, a pharmaceutical composition is disclosed comprising a compound of formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2), or a compound comprising formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2), and an additional therapeutic agent for treating a disease associated with mutations in human epidermal growth factor receptor 2 (ErbB2).

[0152] In one embodiment, a method of treating a disease associated with mutations in ErbB2 comprises administering to a subject in need a compound of formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2), or a pharmaceutical composition comprising a compound comprising formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1), or (IB-2). In one embodiment, the subject is an animal. In some implementations, the subjects are human. In some implementations, the disease associated with ErbB2 mutations is cancer. For example, cancers associated with ErbB2 mutations include lung cancer, glioma, esophageal cancer, liver cancer, stomach cancer, uterine cancer, etc.Cervical cancer, bile duct cancer, skin cancer, head and neck cancer, salivary gland cancer, breast cancer, pancreatic cancer, colorectal cancer, kidney cancer, bladder cancer, or prostate cancer. In some embodiments, cancer associated with ErbB2 mutations is lung cancer. In some embodiments, cancer associated with ErbB2 mutations is glioma cancer. In some embodiments, cancer associated with ErbB2 mutations is esophageal cancer. In some embodiments, cancer associated with ErbB2 mutations is liver cancer. In some embodiments, cancer associated with ErbB2 mutations is stomach cancer. In some embodiments, cancer associated with ErbB2 mutations is uterine cancer. In some embodiments, cancer associated with ErbB2 mutations is cervical cancer. In some embodiments, cancer associated with ErbB2 mutations is bile duct cancer. In some embodiments, cancer associated with ErbB2 mutations is skin cancer. In some embodiments, cancer associated with ErbB2 mutations is head and neck cancer. In some embodiments, cancer associated with ErbB2 mutations is salivary gland cancer. In some embodiments, the cancer associated with the ErbB2 mutation is breast cancer. In some embodiments, the cancer associated with the ErbB2 mutation is pancreatic cancer. In some embodiments, the cancer associated with the ErbB2 mutation is colorectal cancer. In some embodiments, the cancer associated with the ErbB2 mutation is kidney cancer. In some embodiments, the cancer associated with the ErbB2 mutation is bladder cancer. In some embodiments, the cancer associated with the ErbB2 mutation is prostate cancer. In some specific embodiments, the cancer is non-small cell lung cancer.

[0153] IV. Methods of Preparation The methods for preparing the above-described compounds and compositions are described below and / or are known in the art.

[0154] Those skilled in the art will understand that in the methods described herein, the functional groups of the intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxyl, amino, mercapto, and carboxylic acids. Suitable protecting groups for hydroxyl groups include trialkylsilyl or diarylalkylsilyl (e.g., tert-butyldimethylsilyl, tert-butyldiphenylsilyl, or trimethylsilyl), tetrahydropyranyl, benzyl, etc. Suitable protecting groups for amino, amidine, and guanidine groups include tert-butyloxycarbonyl, benzyloxycarbonyl, etc. Suitable protecting groups for mercapto groups include —C(O)—R″ (where R″ is alkyl, aryl, or arylalkyl), p-methoxybenzyl, triphenylmethyl, etc. Suitable protecting groups for carboxylic acids include alkyl, aryl, or arylalkyl esters. Protecting groups can be added or removed according to standard techniques known to those skilled in the art and as described herein. Green, TW, and PGM Wutz, Protective Groups in Organic Synthesis (1999), p. 3The use of protecting groups is described in detail in the Wiley edition. As those skilled in the art will understand, protecting groups may also be polymer resins, such as Wang resin, Rink resin, or 2-chlorotriphenylmethyl chloride resin.

[0155] Those skilled in the art will also understand that although such protected derivatives of the compounds of the present invention may not be pharmacologically active themselves, they can be administered to mammals and subsequently metabolized in vivo to form pharmacologically active compounds of the present invention. Thus, such derivatives can be described as “prodrugs”. All prodrugs of the compounds of the present invention are included within the scope of the present invention.

[0156] Furthermore, all compounds of the present invention existing in the form of free bases or acids can be converted into their pharmaceutically acceptable salts by methods known to those skilled in the art using suitable inorganic or organic bases or acids. Salts of the compounds of the present invention can be converted into their free base or acid forms using standard techniques.

[0157] Examples The following sections describe the abbreviations used in the examples and include examples of the preparation of intermediate compounds I1-I178 (Examples 1-88) and examples of the preparation of compounds 1-414 (Examples 89-104).

[0158] Abbreviations: Specification 52 / 189 pages 116 CN 121311486 A Sat.: saturated Aq.: aqueous solution TEA: triethylamine DIPEA: N,N-diisopropylethylamine MeCN: acetonitrile TFA: 2,2,2-trifluoroacetic acid FA: formic acid DCM: dichloromethane Pd / C: palladium supported on activated carbon PET: petroleum ether DMF: N,N-dimethylformamide IPA: isopropanol EtOH: ethanol MeOH: methanol n-ButOH: but-1-ol Quant.: quantitative HATU: 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisourea hexafluorophosphate (V) K2CO3: Potassium carbonate; Cs2CO3: Cesium carbonate; Na2SO4: Sodium sulfate; MgSO4: Magnesium sulfate; DMF-DMA: N,N-dimethylformamide dimethyl acetal; Pd2(dba)3: Tris(dibenzylacetone)dipalladium(0); XantPhos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthanyl; MsOH: Methanesulfonic acid; LCMS: Liquid chromatography-mass spectrometry; EtOAc: Ethyl acetate; THF: Tetrahydrofuran; MeI: Iodomethane; KOAc: Potassium acetate; DMSO: Dimethyl sulfoxide; HPLC: High performance liquid chromatography; CuCN: Copper cyanide(I) Synthesis of intermediate compounds Example 1 (I1) 1-Methyl-1H-benzo[d][1,2,3]triazol-5-ol Specification 53 / 189 pages 117 CN 121311486 A Step A.4-Methoxy-N-methyl-2-nitroaniline. Two parallel batches each contained a solution of 1-fluoro-4-methoxy-2-nitrobenzene (45.0 g, 0.26 mol) and methylamine hydrochloride (81.7 g, 1.21 mol) in MeCN (800 mL). DIPEA (229 mL, 1.31 mol) was added, and the reaction mixture was stirred at 80 °C for 12 h. The mixture was concentrated under vacuum, and the resulting residue was diluted with water (1 L) and extracted with EtOAc (1 L x 3). The organic layers were combined, washed with water (3x) and brine, dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The two batches were combined to give 4-methoxy-N-methyl-2-nitroaniline (93.6 g, 98% yield) as a red solid. LCMS (MM-ES+APCI, positive ion mode): m / z 183.3 (M+H).

[0159] Step B. 4-Methoxy-N1-methylbenzene-1,2-diamine. Pd / C (8.76 g, 8.23 ​​mmol, 10 wt%) was added to a solution of 4-methoxy-N-methyl-2-nitroaniline (30.0 g, 165 mmol) in MeOH (400 mL), and the reaction mixture was stirred at 25 °C and H2 (3.4 atm) for 1 h. The mixture was filtered through diatomaceous earth, and the filter cake was washed with MeOH (1 L). The filtrate was concentrated under vacuum, and the residue was purified by silica gel column chromatography (10% to 15% EtOAc / PET) to give 4-methoxy-N1-methylbenzene-1,2-diamine (18.0 g, 72% yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 153.5 (M+H).

[0160] Step C. 5-Methoxy-1-methyl-1H-benzo[d][1,2,3]triazole. Tert-butyl nitrite (15.9 mL, 134 mmol) and MsOH (15.9 mL, 223 mmol) were added dropwise to a solution of 4-methoxy-N1-methyl-phenyl-1,2-diamine (17.0 g, 112 mmol) in EtOH (200 mL) at 0 °C. The mixture was stirred at 25 °C for 1 h and concentrated under vacuum. The resulting residue was quenched by slow addition of a saturated aqueous solution of NaHCO3 (1 L), and the product was extracted with 3% MeOH / DCM (1 L x 5). The combined organic layers were washed with brine (2 x 1 L), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude substance was purified by silica gel column chromatography (10% to 15% EtOAc / PET) to give 5-methoxy-1-methylbenzotriazole (14.9 g, 82% yield) as a brown solid. LCMS(MM-ES+APCI, positive ion mode): m / z 164.5 (M+H).

[0161] Step D. 1-Methyl-1H-benzo[d][1,2,3]triazole-5-ol. BBr3 (13.2 mL, 137 mmol) was added to a solution of 5-methoxy-1-methyl-benzotriazole (14.9 g, 91.3 mmol) in DCM (200 mL) at 0 °C. The mixture was heated to 25 °C, stirred for 2 h, and then quenched with water (200 mL). The mixture was neutralized with NaHCO3 (pH 7) and extracted with DCM (200 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to give 1-methyl-benzotriazole-5-ol (11.9 g, 87% yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 150.1 (M+H).

[0162] Example 2 (I65) 1-Ethyl-1H-benzo[d][1,2,3]triazol-5-ol Specification 54 / 189 pages 118 CN 121311486 A Steps A to D. 1-Ethyl-1H-benzo[d][1,2,3]triazol-5-ol. Prepared according to Example 1 using ethylamine hydrochloride instead of methylamine hydrochloride, 1-ethyl-1H-benzo[d][1,2,3]triazol-5-ol (1.60 g, 57% yield) was obtained as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 164.3 (M+H).

[0163] Example 3 (I2) 7-Fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-ol Step A. 4-Bromo-2-fluoro-N-methyl-6-nitroaniline. NaH (5.11 g, 127 mmol, 60 wt%) was added to a solution of 4-bromo-2-fluoro-6-nitroaniline (25.0 g, 106 mmol) in THF (250 mL) at 0 °C and N2. The mixture was heated to 25 °C and held for 30 min, and MeI (9.93 mL, 160 mmol) was added. The reaction system was stirred at 25 °C for 30 min and then stirred at 60 °C for 5 h. The reaction was quenched with a saturated aqueous solution of NH4Cl (50 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (30 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give 4-bromo-2-fluoro-N-methyl-6-nitroaniline (38.4 g, quantitative yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 249.0 (M+H).

[0164] Step B.4-Bromo-6-fluoro-N-1-methylbenzene-1,2-diamine. NH4Cl (41.2 g, 771 mmol) and iron powder (21.5 g, 385 mmol) were added to a solution of 4-bromo-2-fluoro-N-methyl-6-nitroaniline (38.4 g, 77.1 mmol) in EtOH (200 mL) and H2O (100 mL). The mixture was stirred at 80 °C for 2 h, cooled to 25 °C, and filtered. Water (50 mL) was added to the filtrate, and the product was extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (15% EtOAc / PET) to give 4-bromo-6-fluoro-N1-methyl-phenyl-1,2-diamine (14.0 g, 68% yield) as a brown oil. LCMS (MM-ES+APCI, positive ion mode): m / z 219.0 (M+H).

[0165] Step C. 5-bromo-7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazole. Sodium nitrite (1.13 g, 16.4 mmol) was added to a solution of 4-bromo-6-fluoro-N1-methyl-phenyl-1,2-diamine (3.00 g, 13.7 mmol) in HCl (10 mL, 12 M) and water (5 mL) at 0 °C. The mixture was stirred at 25 °C for 1 h and neutralized with NaHCO3 (pH 7). After dilution with water (50 mL), the product was extracted with EtOAc (50 mL x 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give 5-bromo-7-fluoro-1-methylbenzotriazole (3.11 g, 31% yield) as a brown oil. LCMS (MM-ES+APCI, positive ion mode): m / z 230.0 (M+H).

[0166] Step D. (7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)boronic acid. Add 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1,3,2-dioxoborhexacyclopentane (1.66 g, 6.52 mmol), KOAc (1.28 g, 13.0 mmol), and Pd(dppf)Cl2 (318 mg, 0.44 mmol) to a solution of 5-bromo-7-fluoro-1-methyl-benzotriazole (1.00 g, 4.35 mmol) in 1,4-dioxane (20 mL), KOAc (1.28 g, 13.0 mmol), and Pd(dppf)Cl2 (318 mg, 0.44 mmol) to a solution of 5-bromo-7-fluoro-1-methyl-benzotriazole (1.00 g, 4.35 mmol) in 1,4-dioxane (20 mL). Stir the mixture at 100 °C and N2 for 2 hours.h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a residue, which was purified by preparative HPLC (30% to 35% MeCN / 0.2% FA aqueous solution). After lyophilization, (7-fluoro-1-methyl-benzotriazol-5-yl)boric acid (100 mg, 9% yield) was obtained as a gray solid. LCMS (MM-ES+APCI, positive ion mode): m / z 196.2 (M+H).

[0167] Step E. 7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-ol. H2O2 (148 µL, 1.54 mmol, 30 wt%) was added to a solution of (7-fluoro-1-methyl-benzotriazol-5-yl)boric acid (100 mg, 0.51 mmol) in MeCN (1 mL) at 0 °C, and the mixture was stirred at 25 °C for 2 h. The reaction was quenched with an aqueous sodium sulfite solution (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL x 3), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give gray 7-fluoro-1-methyl-benzotriazole-5-ol (170 mg, quantitative yield). LCMS (MM-ES+APCI, positive ion mode): m / z 167.8 (M+H).

[0168] Example 3 (I66) 1-(methyl-d3)-1H-benzo[d][1,2,3]triazole-5-ol Step A. 4-bromo-N-(methyl-d3)-2-nitroaniline. Methyl-D3-amine hydrochloride (93.8 g, 1.33 mol) was added to a solution of 4-bromo-1-fluoro-2-nitrobenzene (195 g, 0.89 mol) and Cs2CO3 (289 g, 1.77 mol) in DMF (2 L). The reaction system was heated to 80 °C and held for 1 h. The mixture was poured into water (6 L), stirred for 1 h, and filtered. The solid was collected and dried under vacuum to give 4-bromo-N-(methyl-d3)-2-nitrobenzene (203 g, 96% yield) as a red solid.

[0169] Step B. 4-bromo-N1-(methyl-d3)benzene-1,2-diamine. A solution of 4-bromo-N-(methyl-d3)-2-nitroaniline (170 g, 0.73 mol), iron (122 g, 2.18 mol), and NH4Cl (117 g, 2.18 mol) in EtOH (1.7 L) and water (0.34 L) was heated to 80 °C and maintained for 3 h. The reaction mixture was cooled to 30 °C and filtered through diatomaceous earth, then washed with EtOH (0.85 L). After vacuum concentration, the mixture was alkalized with NaOH aqueous solution (2 M) (pH 9) and extracted with EtOAc (2 x 850 mL).Take. The combined organic matter was dried over MgSO4, filtered, and concentrated under vacuum to give 4-bromo-N1-(methyl-d3)benzene-1,2-diamine (146 g, 85% yield).

[0170] Step C. 5-bromo-1-(methyl-d3)-1H-benzo[d][1,2,3]triazole. Concentrated HCl (16 mL, 528 mmol) was added to a solution of 4-bromo-N1-(methyl-d3)benzene-1,2-diamine (23.7 g, 106 mmol) in water (237 mL). The reaction system was cooled to 0 °C, and a solution of NaNO2 (10.9 g, 159 mmol) in water (237 mL) was added. The reaction system was alkalized with an aqueous solution of NaOH (2 M) (pH 9) and extracted with DCM (3 x 75 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated under vacuum. The crude material was purified by silica gel column chromatography (10% to 35% EtOAc / PET) to give 5-bromo-1-(methyl-d3)-1H-benzo[d][1,2,3]triazole (12.7 g, 35% yield) as a brown solid.

[0171] Step D. 1-(methyl-d3)-1H-benzo[d][1,2,3]triazole-5-ol. 5-bromo-1-(methyl-d3)-1H-benzo[d][1,2,3]triazole (2.00 g, 9.30 mmol) was added to a solution of Pd2(dba)3 (0.85 g, 0.93 mmol), tBuXPhos (0.79 g, 1.86 mmol), and KOH (2.97 g, 53.0 mmol) in 1,4-dioxane (40 mL) and water (8 mL). The reaction system was heated to 85°C and held for 2 h, then cooled to ambient temperature. The mixture was acidified with aqueous HCl (pH 5) and extracted with EtOAc (4 x 5 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated under vacuum. The crude material was purified by silica gel column chromatography (10% to 35% EtOAc / PET), followed by further purification via slurry (1:2 EtOAc:heptane) to give 1-(methyl-d3)-1H-benzo[d][1,2,3]triazol-5-ol (200 mg, 12% yield) as a brown solid.

[0172] Example 4 (I67) 7-Methoxy-1-methyl-1H-benzo[d][1,2,3]triazole-5-ol Step A. 5-Bromo-7-methoxy-1-methyl-1H-benzo[d][1,2,3]triazole. To 5-bromo-7-methoxy-1-methyl-1H-benzo[d][1,2,3]triazole (1.00 g, 4.13 g)Pd(dppf)Cl2 (302 mg, 0.41 mmol) was added to a solution of 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1,3,2-dioxoboronyl-2-yl) in 1,4-dioxane (20 mL). The reaction system was purged with N2 and stirred at 100 °C for 2 h. The mixture was filtered through diatomaceous earth and eluted with EtOAc (50 mL). The filtrate was concentrated under vacuum, and the residue was purified by silica gel column chromatography (0% to 100% EtOAc / PET) to give 7-methoxy-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-benzo[d][1,2,3]triazole (1.40 g, quantitative yield) as a grayish-white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 290.2 (M+H).

[0173] Step B. 7-methoxy-1-methyl-1H-benzo[d][1,2,3]triazole-5-ol. To a solution of 7-methoxy-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-benzo[d][1,2,3]triazole (1.30 g, 4.50 mmol) in THF (20 mL) and water (4 mL), NaBO3 hydrate (1.73 mL, 8.99 mmol) was added. The mixture was stirred at 25 °C for 12 h. The suspension was filtered and eluted with MeOH (150 mL). The filtrate was concentrated under vacuum, and the residue was ground in a slurry of EtOAc (15 mL) and water (15 mL) at 25 °C for 0.5 h. After filtration, the filter cake was dried under vacuum to obtain 7-methoxy-1-methyl-1H-benzo[d][1,2,3]triazole-5-ol 3 (1.60 g, quantitative yield), as a grayish-white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 180.1 (M+H).

[0174] Example 5 (I68) 6-fluoro-1-methyl-1H-benzo[d][1,2,3]triazole-5-ol Steps A to C. 5-bromo-6-fluoro-1-methyl-1H-benzo[d][1,2,3]triazole. Replacing 4-bromo-5-fluoro-2-nitroaniline with 4-bromo-2-fluoro-6-nitroaniline, 5-bromo-6-fluoro-1-methyl-1H-benzo[d][1,2,3]triazole (580 mg, 51% yield after 3 steps) was prepared according to Example 3, as a brown solid. LCMS(MM-ES+APCI, positive ion mode): m / z 229.8 (M+H). Specification 57 / 189 pages 121 CN 121311486 A

[0175] Steps D to E. 6-fluoro-1-methyl-1H-benzo[d][1,2,3]triazole-5-ol. Using 5-bromo-6-fluoro-1-methyl-1H-benzo[d][1,2,3]triazole instead of 5-bromo-7-methoxy-1-methyl-1H-benzo[d][1,2,3]triazole, 6-fluoro-1-methyl-1H-benzo[d][1,2,3]triazole was prepared according to steps A to B of Example 4 to obtain 6-fluoro-1-methyl-1H-benzo[d][1,2,3]triazole-5-ol (450 mg, 88% yield after 2 steps), as a gray solid. LCMS (MM-ES+APCI, positive ion mode): m / z 168.1 (M+H).

[0176] Intermediates I68 to I71 in Table 11 were prepared according to steps A to E of Example 5.

[0177] Table 11: List of intermediate compounds I68-I71

[0178] Example 6 (I72) 7-Fluoro-1,6-dimethyl-1H-benzo[d][1,2,3]triazol-5-ol Step A. 2-Fluoro-N,3-dimethyl-6-nitroaniline. K2CO3 (7.98 g, 57.8 mmol) was added to a solution of 2,3-difluoro-1-methyl-4-nitrobenzene (10.0 g, 57.8 mmol) and methylamine hydrochloride (5.85 g, 86.7 mmol) in DMF (130 mL). The mixture was stirred at 25 °C for 2 h. The reaction mixture was poured into water (300 mL), and the resulting precipitate was filtered and washed with water (250 mL). The solid was vacuum dried and milled in 10% EtOAc / PET (110 mL) for 10 minutes. It was filtered and dried to give 2-fluoro-N,3-dimethyl-6-nitroaniline (5.6 g, 52% yield) as a yellow solid. LCMS (MM-ES + APCI, positive ion mode): m / z 185.1 (M+H).

[0179] Step B. 4-Bromo-2-fluoro-N,3-dimethyl-6-nitroaniline. NBS (5.36 g, 30.1 mmol) was added to a solution of 2-fluoro-N,3-dimethyl-6-nitroaniline (5.6 g, 30.1 mmol) in MeCN (50 mL). The mixture was stirred at 25 °C for 2 h. The reaction was quenched with water (30 mL) and the product was extracted with DCM (40 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 4-bromo-2-fluoro-N,3-dimethyl-6-nitroaniline (5.1 g, 64% yield) as a red solid. (LCMS)(MM-ES+APCI, positive ion mode): m / z 263.0, 265.0 (M+H). Specification 58 / 189 pages 122 CN 121311486 A

[0180] Steps C to F. 7-Fluoro-1,6-dimethyl-1H-benzo[d][1,2,3]triazol-5-ol. Using 4-bromo-2-fluoro-N,3-dimethyl-6-nitroaniline instead of 4-bromo-5-fluoro-2-nitroaniline, 7-fluoro-1,6-dimethyl-1H-benzo[d][1,2,3]triazol-5-ol (765 mg, 74% yield) was prepared according to steps B to E of Example 4, as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 182.3 (M+H).

[0181] Example 7 (I73) 6-Fluoro-1,7-dimethyl-1H-benzo[d][1,2,3]triazol-5-ol Steps A to F. 6-Fluoro-1,7-dimethyl-1H-benzo[d][1,2,3]triazol-5-ol. 6-Fluoro-1,7-dimethyl-1H-benzo[d][1,2,3]triazol-5-ol was prepared according to steps A to F of Example 6, replacing 2,3-difluoro-1-methyl-4-nitrobenzene. The result was a brown solid, 6-fluoro-1,7-dimethyl-1H-benzo[d][1,2,3]triazol-5-ol (2.2 g, 52% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 182.0 (M+H).

[0182] Example 8 (I74) 4-((3,5-dimethyl-3H-imidazo[4,5-b]pyridin-6-yl)oxy)-3-methylaniline Step A. 5-bromo-N,6-dimethyl-3-nitropyridine-2-amine. DIPEA (13.6 mL, 77.9 mmol) was added to a solution of 5-bromo-2-chloro-6-methyl-3-nitro-pyridine (4.90 g, 19.5 mmol) and methylamine hydrochloride (2.63 g, 39.0 mmol) in acetonitrile (70 mL). The mixture was stirred at 50 °C for 12 h. The reaction was quenched with water and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 5-bromo-N,6-dimethyl-3-nitropyridine-2-amine (5.37 g, quantitative yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 245.8, 247.8 (M+H).

[0183] Step B. 5-bromo-N,6-dimethylpyridine-2,3-diamine. 5-bromo-N,6-dimethyl-3-nitropyridine-2-amine (5.37 g, 21.8 mmol) was concentrated in EtOH (60 ppm).NH4Cl (11.6 g, 218 mmol) and Fe powder (8.53 g, 153 mmol) were added to a solution of water (20 mL). The mixture was stirred at 80 °C for 2 h. The reaction system was filtered, and the filtrate was concentrated under reduced pressure. The residue was partitioned between saturated NaHCO3 aqueous solution (200 mL) and EtOAc (200 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 5-bromo-N2,6-dimethyl-pyridine-2,3-diamine (4.48 g, 95% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode, page 59 / 189, CN 121311486 A): m / z 216.0, 218.0 (M+H).

[0184] Step C. 6-Bromo-3,5-dimethyl-3H-imidazo[4,5-b]pyridine. A solution of 5-bromo-N2,6-dimethylpyridine-2,3-diamine 3 (4.48 g, 20.7 mmol) in trimethoxymethane (50 mL) was stirred at 110 °C for 1 h. The mixture was concentrated under reduced pressure, and the residue was partitioned between saturated NaHCO3 aqueous solution (100 mL) and EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (0% to 100% EtOAc / PET) to give 6-bromo-3,5-dimethylimidazo[4,5-b]pyridine (3.72 g, 79% yield) as a pink solid. LCMS (MM-ES+APCI, positive ion mode): m / z 226.1 (M+H).

[0185] Steps D to E. 3,5-Dimethyl-3H-imidazo[4,5-b]pyridine-6-ol. 3,5-Dimethyl-3H-imidazo[4,5-b]pyridine was prepared according to steps D to E of Example 4, replacing 5-bromo-6-fluoro-1-methyl-1H-benzo[d][1,2,3]triazole, to obtain 3,5-dimethyl-3H-imidazo[4,5-b]pyridine-6-ol (2.9 g, 72% yield), as a grayish-white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 164.0 (M+H).

[0186] Example 9 (I75) 3-Methyl-3H-[1,2,3]triazolo[4,5-c]pyridine-6-ol Step A. 6-Chloro-N3-methylpyridine-3,4-diamine. To 5-bromo-2-chloro-pyridine-4-amine (2.00 g, 9.64 mmol), methylamine hydrochloride (6.51 g, 96.4 mmol), ...K₂CO₃ (6.66 g, 48.2 mmol) and CuI (0.37 g, 1.93 mmol) were added to a solution of 1-methylpyrrolidone-2-one (30 mL). The reaction mixture was purged with N₂ and heated in a sealed tube at 130 °C for 12 h. The mixture was cooled to ambient temperature, diluted with water (200 mL), and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (200 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (0% to 15% EtOAc / PET) to give 6-chloro-N₃-methylpyridine-3,4-diamine (1.70 g, 38% yield) as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 158.1 (M+H).

[0187] Step B. 6-chloro-3-methyl-3H-[1,2,3]triazolo[4,5-c]pyridine. A flask containing 6-chloro-N3-methyl-pyridine-3,4-diamine (1.70 g, 10.8 mmol) was placed under N2 and cooled to 0°C. A solution of H2SO4 (1.61 mL, 30.2 mmol) in water (30 mL) was added, followed by the addition of NaNO2 (1.49 g, 21.6 mmol) in water (20 mL). The mixture was stirred at 0°C for 1 h. The reaction system was neutralized with a saturated aqueous solution of NH4HCO3 (pH = 7) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude residue was purified by silica gel column chromatography (0% to 50% EtOAc / PET) to give 6-chloro-3-methyl-triazolo[4,5-c]pyridine (530 mg, 27% yield) as a red solid. LCMS (MM-ES+APCI, positive ion mode): m / z 169.2 (M+H).

[0188] Step C. (3-methyl-3H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)boronic acid. KOAc (617) was added to a solution of 6-chloro-3-methyl-triazolo[4,5-c]pyridine 4 (530 mg, 3.14 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1,3,2-dioxoborhexacyclopentanane (2.40 g, 9.43 mmol) in 1,4-dioxane (10 mL). (Instructions for use 60 / 189, page 124, CN 121311486 A)mg, 6.29 mmol), SPhos (258 mg, 0.63 mmol) and Pd2(dba)3 (287 mg, 0.31 mmol). The reaction system was purged with N2 and heated to 100 °C for 12 h. The mixture was concentrated under vacuum to give (3-methyltriazolo[4,5-c]pyridin-6-yl)boronic acid (500 mg, 89% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 178.9 (M+H).

[0189] Step D. 3-methyl-3H-[1,2,3]triazolo[4,5-c]pyridin-6-ol. Sodium borate tetrahydrate (1.08 mL, 5.62 mmol) was added to a solution of (3-methyltriazolo[4,5-c]pyridin-6-yl)boronic acid (500 mg, 2.81 mmol) in THF (10 mL) and water (5 mL). The reaction mixture was stirred at 50 °C for 1 h. The mixture was filtered, and the filtrate was concentrated under vacuum. The residue was purified by preparative HPLC (0.1% NH4OH aqueous solution) and lyophilized to give 3-methyltriazolo[4,5-c]pyridin-6-ol 6 (400 mg, 95% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 152.1 (M+H).

[0190] Example 10 (I3) 4-((7-fluoro-1-methyl-1H-benzo[d]imidazol-5-yl)oxy)-3-methylaniline Step A. 5-bromo-7-fluoro-1-methyl-1H-benzo[d]imidazolium carboxylate. Trimethoxymethane (1.20 mL, 10.9 mmol) was added to a solution of 4-bromo-6-fluoro-N1-methylphenyl-1,2-diamine (2.40 g, 10.9 mmol) in formic acid (20 mL). The mixture was stirred at 100 °C for 1 h and concentrated under vacuum to give 5-bromo-7-fluoro-1-methyl-1H-benzo[d]imidazolium carboxylate (2.00 g, 67%) as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 228.7, 230.7 (M+H-FA).

[0191] Step B. Tert-butyl (4-((7-fluoro-1-methyl-1H-benzo[d]imidazol-5-yl)oxy)-3-methylphenyl)carbamate. CuI (0.67 g, 3.49 mmol) and pyridine-2-carboxylic acid (0.43 g, 3.49 mmol) were added to a solution of 5-bromo-7-fluoro-1-methyl-1H-benzo[d]imidazolium carbamate (2.00 g, 8.73 mmol) and N-(4-hydroxy-3-methyl-phenyl)carbamate (1.95 g, 8.73 mmol) in DMSO (20 mL).mmol) and K2CO3 (3.62 g, 26.2 mmol). The reaction system was stirred at N2 and 100 °C for 12 h. The mixture was filtered, concentrated under reduced pressure, and purified by preparative HPLC (30% to 65% MeCN / 0.05% FA aqueous solution) to give tert-butyl (4-((7-fluoro-1-methyl-1H-benzo[d]imidazol-5-yl)oxy)-3-methylphenyl)carbamate (1.40 g, 40% yield) as a dark brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 372.1 (M+H).

[0192] Step C. 4-((7-fluoro-1-methyl-1H-benzo[d]imidazol-5-yl)oxy)-3-methylaniline hydrochloride. HCl (4M in 1,4-dioxane, 20.3 mL, 81.2 mmol) was added to a solution of (4-((7-fluoro-1-methyl-1H-benzimidazol-5-yl)oxy)-3-methylphenyl)carbamate (1.40 g, 3.77 mmol) in MeOH (5 mL). The mixture was stirred for 2 h and concentrated under vacuum to give 4-(7-fluoro-1-methyl-benzimidazol-5-yl)oxy-3-methylaniline hydrochloride (1.00 g, 86% yield) as a dark brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 272.0 (M+H-HCl).

[0193] Example 11 (I76) Specification 61 / 189 pages 125 CN 121311486 A 7-fluoro-1-methyl-1H-benzo[d]imidazol-5-ol Step A. 7-fluoro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1H-benzo[d]imidazol. 1,4-Dioxane (200 mL) was added to a flask containing 5-bromo-7-fluoro-1-methylbenzimidazole (7.0 g, 29 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1,3,2-dioxoboronyl-2-yl (1.1 g, 1.5 mmol), and Pd(dppf)Cl2 (1.1 g, 1.5 mmol) at 25 °C. The mixture was purged with N2 and heated to 90 °C for 2 h. The reaction was slowly quenched with water (200 mL), and the aqueous layer mixture was extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (0% to 20% EtOAc / PET) to obtain7-Fluoro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)benzimidazole (7.6 g, 74% yield) was a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 276.8 (M+H).

[0194] Step B. 7-Fluoro-1-methyl-1H-benzimidazole-5-ol. Potassium persulfate (6.4 g, 10 mmol) was added to a solution of 7-fluoro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)benzimidazole (7.3 g, 21 mmol) in MeCN (60 mL) and water (60 mL). The mixture was heated to 50 °C and maintained for 3 h. The reaction was slowly quenched with water (200 mL), and the aqueous mixture was extracted with EtOAc (100 mL x 3). The combined organic layers were washed with saturated Na2SO3 aqueous solution (300 mL) and brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give 7-fluoro-1-methyl-benzimidazole-5-ol (3.2 g, 85% yield) as a gray solid. LCMS (MM-ES+APCI, positive ion mode): m / z 167.0 (M+H).

[0195] Example 12 (I4) 1-(difluoromethyl)-1H-benzo[d][1,2,3]triazole-5-ol Step A. 5-methoxy-1H-benzo[d][1,2,3]triazole. 5-Methoxy-1H-benzotriazole (5.03 g, 48% yield) was prepared according to step C of Example 1, replacing 4-methoxy-N1-methyl-phenyl-1,2-diamine, as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 150.3 (M+H).

[0196] Step B. 1-(difluoromethyl)-5-methoxy-1H-benzo[d][1,2,3]triazole. Sodium dichlorofluoroacetate (10.8 g, 70.7 mmol) and Cs2CO3 (23.0 g, 70.7 mmol) were added to a solution of 5-methoxy-1H-benzotriazole (5.27 g, 35.3 mmol) in DMF (50 mL). The reaction mixture was stirred at 80 °C for 1 h, diluted with water (400 mL), and extracted with EtOAc (100 mL x 4). The combined organic layers were washed with brine (200 mL x 2), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give 1-(difluoromethyl)-5-methoxy-benzotriazole (6.49 g, 73% yield).It is a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 200.1 (M+H).

[0197] Step C. 1-(difluoromethyl)-1H-benzo[d][1,2,3]triazole-5-ol. 1-(difluoromethyl)-5-methoxy-benzotriazole was used instead of 5-methoxy-1-methyl-benzotriazole, according to step D of Example 1, to prepare 1-(difluoromethyl)benzotriazole-5-ol (6.12 g, 89% yield), a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 186.2 (M+H).

[0198] Example 13 (I5) 1-(difluoromethyl)-1H-benzo[d]imidazol-5-ol 1-(difluoromethyl)-1H-benzo[d]imidazol-5-ol. 1-(difluoromethyl)-1H-benzo[d]imidazol was prepared according to steps B to C of Example 12, replacing 5-methoxy-1H-benzotriazole (3.00 g, 20.25 mmol), to obtain 1-(difluoromethyl)benzimidazole-5-ol (2.04 g, 81% yield), a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 185.1 (M+H).

[0199] Example 14 (I77) 1-(trifluoromethyl)-1H-benzo[d][1,2,3]triazole-5-ol Step A. 5-methoxy-1-(trifluoromethyl)-1H-benzo[d][1,2,3]triazole. Two parallel batches each contained a solution of 5-methoxy-1H-benzotriazole (250 mg, 1.68 mmol), 3,3-dimethyl-1-(trifluoromethyl)-1,2-benzoiodopyrazine (830 mg, 2.51 mmol), and 1,1,1-trifluoro-N-(trifluoromethylsulfonyl)methanesulfonamide (47.1 mg, 0.17 mmol) in CS2 (10 mL). The mixture was stirred at 60 °C for 1 h and concentrated under vacuum. The two batches were combined and purified by silica gel column chromatography (0% to 20% EtOAc in PET) to give 5-methoxy-1-(trifluoromethyl)benzotriazole (120 mg, 15% yield) as a pale yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 218.0 (M+H).

[0200] Step B. 1-(trifluoromethyl)-1H-benzo[d][1,2,3]triazole-5-ol. 1-(trifluoromethyl)-1H-benzo[d][1,2,3]triazole was used instead of 5-methoxy-1-methyl-benzotriazole and prepared according to step D of Example 1 to give 1-(trifluoromethyl)-1H-benzo[d][1,2,3]triazole.[2,3] Triazole-5-ol (150 mg, 67% yield) was a pale yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 204.0 (M+H).

[0201] Example 15 (I78) 3-(difluoromethyl)-3H-imidazo[4,5-b]pyridine-6-ol Step A. 6-bromo-3-(difluoromethyl)-3H-imidazo[4,5-b]pyridine. Cs2CO3 (72.4 g, 222 mmol) was added to a solution of 6-bromo-3H-imidazo[4,5-b]pyridine (22.0 g, 111 mmol) and sodium 2-chloro-2,2-difluoroacetate (25.4 g, 167 mmol) in DMF (300 mL). The reaction system was stirred at 80 °C for 2 h. The mixture was partitioned between EtOAc (500 mL) and water (500 mL). The aqueous phase was extracted with EtOAc (500 mL x 2), and the combined organic layers were washed with brine (500 mL × 2), dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (0% to specification 63 / 189 pages 127 CN 121311486 A 100% EtOAc / PET) to give 6-bromo-3-(difluoromethyl)-3H-imidazo[4,5-b]pyridine (3.00 g, 11% yield) as a pale yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 247.9 (M+H).

[0202] Steps B to C. 3-(difluoromethyl)-3H-imidazo[4,5-b]pyridine-6-ol. 3-(difluoromethyl)-3H-imidazo[4,5-b]pyridine was prepared according to steps A to B of Example 4, replacing 5-bromo-7-methoxy-1-methyl-1H-benzo[d][1,2,3]triazole, to obtain 3-(difluoromethyl)-3H-imidazo[4,5-b]pyridine-6-ol (1.63 g, 67% yield), a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 186.2 (M+H).

[0203] Example 16 (I79) 2-Methyl-[1,2,4]triazolo[1,5-a]pyridine-7-ol Step A. 2-Imine-4-methoxypyridine-1(2H)-amine. O-(tris(methyltrimethylol)sulfonyl)hydroxylamine trifluoroacetate (8.30 g, 25.2 mmol) was added to a solution of 4-methoxypyridine-2-amine (2.00 g, 16.1 mmol) in DCM (30 mL). The mixture was stirred at 25 °C for 12 h. The reaction mixture was filtered, and the filter cake was dried under vacuum to give 2-imino-4-methoxypyridine-1(2H)-amine (2.00 g, 16.1 mmol).g (89% yield), a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 140.2 (M+H).

[0204] Step B. 7-Methoxy-2-methyl-[1,2,4]triazolo[1,5-a]pyridine. Acetyl chloride (2.04 mL, 28.7 mmol) was added to a solution of 2-imino-4-methoxypyridine-1(2H)-amine (2.00 g, 14.4 mmol) in pyridine (20 mL). The mixture was stirred at 100 °C for 12 h. The reaction system was cooled to ambient temperature, diluted with water (100 mL), and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude residue was purified by silica gel column chromatography (0% to 35% EtOAc / PET) to give 7-methoxy-2-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.73 g, 31% yield) as a pale yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 164.2 (M+H).

[0205] Step C. 2-Methyl-[1,2,4]triazolo[1,5-a]pyridine-7-ol. A sealed tube containing 7-methoxy-2-methyl-[1,2,4]triazolo[1,5-a]pyridine (930 mg, 5.70 mmol) and HBr (33% in AcOH, 10 mL) was stirred at 100 °C for 24 h. The mixture was concentrated under vacuum, and the residue was diluted with saturated NaHCO3 aqueous solution (100 mL). The aqueous mixture was extracted with EtOAc (30 mL x 3), and the aqueous phase was lyophilized to give 2-methyl-[1,2,4]triazolo[1,5-a]pyridine-7-ol (610 mg, 72% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 150.2 (M+H).

[0206] Example 17 (I80) 6-Methyl-[1,2,4]triazolo[1,5-a]pyridine-7-ol Specification 64 / 189 pages 128 CN 121311486 A Step A. 5-Bromo-4-methoxypyridine-2-amine. NBS (21.5 g, 121 mmol) was added to a solution of 4-methoxypyridine-2-amine (15.0 g, 121 mmol) in MeCN (400 mL). The reaction system was stirred at 20°C for 3 h. The mixture was concentrated under vacuum, and the residue was partitioned between H2O (100 mL) and EtOAc (100 mL x 3). The combined organic layers were rinsed with brine (100 mL).Washed with anhydrous sodium sulfate, dried, filtered, and concentrated under reduced pressure to give 5-bromo-4-methoxy-pyridine-2-amine (21.0 g, 85% yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 203.2, 205.2 (M+H).

[0207] Step B. (E)-N'-(5-bromo-4-methoxypyridine-2-yl)-N,N-dimethylformamidinium. DMF-DMA (15.7 mL, 1118 mmol) was added to a solution of 5-bromo-4-methoxy-pyridine-2-amine (20.0 g, 98.5 mmol) in MeOH (200 mL). The reaction system was stirred at 75 °C for 3 h. The mixture was concentrated under reduced pressure to give N'-(5-bromo-4-methoxy-2-pyridyl)-N,N-dimethylformamidin (21.0 g, 83% yield), as a brown oil. LCMS (MM-ES+APCI, positive ion mode): m / z 258.2, 260.2 (M+H).

[0208] Step C. (E)-N'-(5-bromo-4-methoxypyridyl)-N-hydroxyformamidin. Hydroxylamine hydrochloride (11.3 g, 163 mmol) was added to a solution of N'-(5-bromo-4-methoxy-2-pyridyl)-N,N-dimethylformamidin (21.0 g, 81.4 mmol) in MeOH (220 mL). The reaction system was stirred at 70 °C for 1 h. The mixture was filtered and the filter cake was washed with MeOH (20 mL). The filter cake was dried under vacuum to obtain N'-(5-bromo-4-methoxy-2-pyridyl)-N-hydroxy-formamidinium (17.8 g, 88% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 246.2, 248.2 (M+H).

[0209] Step D. 6-bromo-7-methoxy-[1,2,4]triazolo[1,5-a]pyridine. Trifluoroacetic anhydride (12.9 mL, 92.7 mmol) was added to a solution of N'-(5-bromo-4-methoxy-2-pyridyl)-N-hydroxy-formamidinium (17.8 g, 71.3 mmol) in THF (200 mL). The mixture was stirred at 20 °C for 12 h. The reaction was quenched with water (50 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (0% to 65% EtOAc / PET) to give 6-bromo-7-methoxy-[1,2,4]triazolo[1,5-a]pyridine (3.0 g, 18% yield) as a yellow solid. LCMS(MM-ES+APCI, positive ion mode): m / z 228.2, 230.2 (M+H).

[0210] Step E. 7-Methoxy-6-methyl-[1,2,4]triazolo[1,5-a]pyridine. Dioxane (30 mL) and H2O (6 mL) were added to a solution of 6-bromo-7-methoxy-[1,2,4]triazolo[1,5-a]pyridine (3.0 g, 13.2 mmol) in 1,4-dioxane (30 mL) and water (6 mL), followed by the addition of Pd(dppf)Cl2 (0.96 g, 1.32 mmol), K2CO3 (5.45 g, 39.5 mmol) and methylboronic acid (1.57 g, 26.3 mmol). The mixture was purged with N2 and stirred at 110 °C for 2 h. The reaction was quenched with water (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (0% to 65% EtOAc / PET) to give 7-methoxy-6-methyl-[1,2,4]triazolo[1,5-a]pyridine (900 mg, 27% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 164.4 (M+H).

[0211] Step F. 6-methyl-[1,2,4]triazolo[1,5-a]pyridine-7-ol. Pyridine hydrochloride (7.71 g, 66.7 mmol) was added to a solution of 7-methoxy-6-methyl-[1,2,4]triazolo[1,5-a]pyridine (850 mg, 3.33 mmol). The mixture was purged with N2 and heated to 145 °C for 2 h. The reaction mixture was cooled to ambient temperature, quenched with 20 mL of saturated NH4Cl aqueous solution, and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 6-methyl-[1,2,4]triazolo[1,5-a]pyridine-7-ol (380 mg, 77% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 150.4 (M+ H).

[0212] Example 18 (I81) Imidazolo[1,2-b]pyridazine-7-ol Step A. (5-methoxypyridazine-3-yl) tert-butyl carbamate. Two parallel batches each contained 5.0 g of 3-chloro-5-methoxypyridazine (35 g, 100 mL) in 1,4-dioxane (100 mL).10.5 mmol) and tert-butyl carbamate (8.10 g, 69 mmol). Xantphos (2.0 g, 3.5 mmol), Cs₂CO₃ (22.5 g, 69 mmol) and Pd(OAc)₂ (0.78 g, 3.5 mmol) were added, and the mixture was purged with N₂. The reaction mixture was heated at 90 °C for 5 h. The mixture was diluted with water (100 mL) and extracted with EtOAc (150 mL x 3). The combined organic layers were washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude solid was purified by silica gel column chromatography (1% to 50% EtOAc / PET), and the batches were combined to give N-(5-methoxypyridazin-3-yl) tert-butyl carbamate (10.64 g, 68% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 226.1 (M+H).

[0213] Step B. 5-Methoxypyridazine-3-amine. TFA (53.2 mL) was added to a solution of N-(5-methoxypyridazine-3-yl)carbamate tert-butyl ester (10.64 g, 47.2 mmol) in DCM (50 mL). The reaction system was stirred at 25 °C for 4 h. The mixture was concentrated under vacuum and combined with another batch (12.96 g, 57.5 mmol). The mixture was slowly diluted with water (200 mL) and neutralized with a saturated aqueous solution of NaHCO3 (pH = 7 to 8). The aqueous solution was extracted with 25% IPA / DCM (150 mL x 20), and the combined organic layers were washed with brine (1000 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give 5-methoxypyridazine-3-amine (9.34 g, 71% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 126.1 (M+H).

[0214] Step C. 7-Methoxyimidazo[1,2-b]pyridazine. 2-Chloroacetaldehyde (13.7 mL, 212 mmol) was added to a solution of 5-methoxypyridazine-3-amine (3.79 g, 30.3 mmol) in IPA (70 mL). The reaction system was heated to 80 °C and stirred for 20 h. A second batch of 5-methoxypyridazine-3-amine (5.55 g, 44.4 mmol) and 2-chloroacetaldehyde (20 mL, 310 mmol) in IPA (80 mL) was stirred at 80 °C for 16 h. The two batches were combined, and the mixture was concentrated under reduced pressure. The crude residue was purified by grinding in EtOAc (20 mL) at 25 °C for 1 h. The solid product was filtered and dried under vacuum to give 7-methoxyimidazo[1][1,2-b]pyridazine 14 (12.0 g, quantitative yield), a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 150.1 (M+H). Specification 66 / 189 pages 130 CN 121311486 A

[0215] Step D. Imidazolo[1,2-b]pyridazine-7-ol. Two parallel batches containing 7-methoxyimidazo[1,2-b]pyridazine (6.0 g, 40.2 mmol) and DCE (120 mL) were cooled to 0 °C. BBr3 (27.1 mL, 282 mmol) was added dropwise, and the mixture was heated to 80 °C and held for 6 h. The reaction was slowly quenched with ice water (50 mL) and concentrated under vacuum. The residue was diluted with 30% IPA / DCM (120 mL) and stirred for 30 min. The suspension was filtered and washed with 30% IPA / DCM (20 mL). The filtrate was concentrated under reduced pressure and the crude residue was purified by grinding in 30% IPA / DCM (80 mL). The filtrate was filtered to give a solid product. The filtrate was concentrated, water was added, and the mixture was lyophilized to give another solid product. The two batches were combined to give imidazo[1,2-b]pyridazine-7-ol (10.0 g, 92% yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 136.1 (M+H).

[0216] Example 19 (I82) 4-Bromo-2-fluoro-3-(methyl-d3)aniline Step A. 2-fluoro-1-(methyl-d3)-3-nitrobenzene. A solution of 2-(2-fluoro-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxoborane (14.5 g, 54.3 mmol), CsF (28.9 g, 190 mmol), and Pd(Amphos)Cl2 (1.92 g, 2.71 mmol) in DMF (167 mL) and water (102 mL) was purged with N2. CD3I (6.8 mL, 109 mmol) was added, and the reaction mixture was heated to 45 °C and held for 2 h. The mixture was diluted with water (45 mL) and extracted with EtOAc (2 x 75 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to dryness. The crude substance was purified by silica gel column chromatography (10% EtOAc / heptane) to obtain 2-fluoro-1-(methyl-d3)-3-nitrobenzene (6.77 g, 78% yield) as a yellow solid.

[0217] Step B. 2-fluoro-3-(methyl-d3)aniline. Iron powder (7.20 mmol) was added to a solution of 2-fluoro-1-(methyl-d3)-3-nitrobenzene (6.80 g, 43.0 mmol) in EtOH (102 mL) and water (34 mL).The mixture was stirred at 80°C for 2 h and cooled to 30°C. The suspension was filtered and washed with EtOH (35 mL). The filtrate was concentrated under reduced pressure, diluted with water (35 mL), and extracted with EtOAc (2 x 70 mL). The combined organic matter was washed with brine, dried over MgSO4, filtered, and concentrated to give 2-fluoro-3-(methyl-d3)aniline (7.0 g, 88% yield) as a pale yellow oil.

[0218] Step C. 4-Bromo-2-fluoro-3-(methyl-d3)aniline. A solution of 2-fluoro-3-(methyl-d3)aniline (4.56 g, 35.6 mmol) in MeCN (23 mL) was placed under a N2 atmosphere and cooled to -20°C. A solution of NBS (6.33 g, 35.6 mmol) in MeCN (46 mL) was added dropwise. The mixture was stirred at -20 °C for 5 min, quenched with saturated NaHSO3 (23 mL), and extracted with MTBE (9 mL). The organic phase was concentrated to dryness, and the residue was redissolved in MTBE (46 mL). The organic mixture was washed with 10% NaOH (23 mL) and brine (23 mL), dried over MgSO4, and filtered. After concentration, the residue was purified by slurry purification with heptane (14 mL) at -20 °C for 2 h. After filtration and vacuum drying, 4-bromo-2-fluoro-3-(methyl-d3)aniline (3.9 g, 53% yield) was given as a pink solid. LCMS (MM-ES+APCI, positive ion mode): m / z 207.0, 209.0 (M+H).

[0219] Example 20 (I6) 2,3-Dimethyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline Specification 67 / 189 pages 131 CN 121311486 A Step A. 5-(2,3-dimethyl-4-nitrophenoxy)-1-methyl-1H-benzo[d][1,2,3]triazole. Cs2CO3 (1.93 g, 5.91 mmol) and 1-methylbenzotriazol-5-ol (371 mg, 2.36 mmol) were added to a solution of 1-fluoro-2,3-dimethyl-4-nitrobenzene (500 mg, 2.96 mmol) in DMF (10 mL). The mixture was stirred at 50 °C for 2 h, diluted with water (10 mL), and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (5% to 25% EtOAc / PET).The residue yielded 5-(2,3-dimethyl-4-nitro-phenoxy)-1-methyl-benzotriazole (800 mg, quantitative), as a brown oil. LCMS (MM-ES+APCI, positive ion mode): m / z 299.1 (M+H).

[0220] Step B. 2,3-dimethyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline. Fe powder (551 mg, 9.87 mmol) and NH4Cl (528 mg, 9.87 mmol) were added to a solution of 5-(2,3-dimethyl-4-nitro-phenoxy)-1-methyl-benzotriazole (800 mg, 2.47 mmol) in EtOH (10 mL) and water (5 mL). The mixture was stirred at 85 °C for 1 h and cooled to ambient temperature. The suspension was filtered and washed with EtOH (10 mL). The filtrate was concentrated under reduced pressure to give 2,3-dimethyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline (500 mg, 69% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 269.0 (M+H).

[0221] Intermediates I7-I23, I83-I102 in Table 2 were prepared according to steps A to B of Example 20. Step A can be carried out using Cs2CO3 or K2CO3 as a base and DMF or MeCN as a solvent.

[0222] Table 2: List of intermediate compounds I7-I23, I83-I102 Specification 68 / 189 pages 132 CN 121311486 A Specification 69 / 189 pages 133 CN 121311486 A Specification 70 / 189 pages 134 CN 121311486 A

[0223] Example 21 (I24) 3-Methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline Step A. 1-Methyl-5-(2-methyl-4-nitrophenoxy)-1H-benzo[d][1,2,3]triazole. 1-Methyl-1H-benzo[d][1,2,3]triazol-5-ol (14.6 g, 98.3 mmol), 1-fluoro-2-methyl-4-nitrobenzene (15.3 g, 98.3 mmol), and K₂CO₃ (27.2 g, 196.6 mmol) were dissolved in DMF (164 mL, 98.3 mmol) and heated to 90°C under N₂ for 40 minutes. The reaction mixture was cooled to ambient temperature, diluted with 250 mL of water and ice, stirred for 30 minutes, and filtered. The beige...The solid was washed with water and dried under vacuum to give 1-methyl-5-(2-methyl-4-nitrophenoxy)-1H-benzo[d][1,2,3]triazole (27.9 g, 98% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 285.1 (M+H).

[0224] Step B. 3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline. A flask containing 1-methyl-5-(2-methyl-4-nitrophenoxy)-1H-benzo[d][1,2,3]triazole (1.00 g, 3.52 mmol) and Pd / C (749 mg, 0.35 mmol, 5% by weight) was sealed and purged with N2. MeOH (13 mL) and ammonium formate (1.11 g, 17.6 mmol) were added, and the reaction mixture was stirred for 1 h. The mixture was filtered through diatomaceous earth, eluted with MeOH, and the filtrate was concentrated under vacuum to give 3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline (833 mg, 93% yield) as a grayish-white powder. LCMS (MM-ES+APCI, positive ion mode): m / z 255.2 (M+H).

[0225] Example 22 (I25) N-(2-methoxy-5-methyl-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)-6-(methylsulfinyl)pyrimido[5,4-d]pyrimidin-4-amine Step A. 6-(5-methoxy-2-methyl-4-nitrophenoxy)-1-methyl-1H-benzo[d]imidazol. A solution of 1-fluoro-5-methoxy-2-methyl-4-nitrobenzene (0.969 g, 5.23 mmol), 1-methyl-1H-benzo[d]imidazol-6-ol (775 mg, 5.23 mmol), Cs2CO3 (2.05 g, 6.28 mmol) and IPA (10.0 mL) was heated to 85°C and held for 3 h. The mixture was filtered and concentrated under vacuum. The crude material was purified by silica gel chromatography (0% to 100% EtOAc / hexane) to obtain 6-(5-methoxy-2-methyl-4-nitrophenoxy)-1-methyl-1H-benzo[d]imidazole (1.10 g, 66% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 314.1 (M+H).

[0226] Step B. 2-methoxy-5-methyl-4-((1-methyl-1H-benzo[d]imidazole-5-yl)oxy)aniline. 5-(5-methoxy-2-methyl-4-nitrophenoxy)-1-methyl-1H-benzo[d]imidazole (950 mg, 3.03 mmol) and 5% Pd / Al2O3 (645 mg) were added.303 μmol of 2-methoxy-5-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline was suspended in MeOH (15.2 mL) and bubbled with H2 gas for 10 minutes. The reaction system was sealed and stirred at H2 (1 atm) and 25 °C for 16 h. The mixture was filtered to obtain 2-methoxy-5-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline (453 mg, 53% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 284.1 (M+H).

[0227] Example 23 (I26) 2,3,6-trifluoro-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline Step A. 1-methyl-5-(2,3,5-trifluoro-4-nitrophenoxy)-1H-benzo[d][1,2,3]triazole. To a solution of 1,2,3,5-tetrafluoro-4-nitrobenzene (500 mg, 2.56 mmol), 1-methyl-1H-benzo[d][1,2,3]triazole-5-ol (382 mg, 2.56 mmol), and tetrabutylammonium hydrogen sulfate (87 mg, 0.26 mmol) in DCM (12.8 mL), NaOH (2M aqueous solution, 1.3 mL) was added. The reaction mixture was stirred at 23 °C for 16 h. The solution was washed with brine, dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography to give 1-methyl-5-(2,3,5-trifluoro-4-nitrobenoxy)-1H-benzo[d][1,2,3]triazole (143 mg, 17%). LCMS (MM-ES+APCI, positive ion mode): m / z 325.0 (M+H). Instructions for Use, Page 72 / 189, 136 CN 121311486 A

[0228] Step B. 2,3,6-trifluoro-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline. A slurry of 1-methyl-5-(2,3,5-trifluoro-4-nitrophenoxy)-1H-benzo[d][1,2,3]triazole (143 mg, 0.44 mmol) and Pd / C (141 mg, 0.13 mmol, 10 wt%) in MeOH (4.4 mL) was bubbled with H2 for 10 min. The reaction system was sealed and stirred at 23 °C and H2 (1 atm) for 17.5 h. The reaction system was filtered through diatomaceous earth and the pad was washed with MeOH (15 mL). The filtrate was concentrated under vacuum to give 2,3,6-trifluoro-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline (125 mg, 96%), as a grayish-white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 295.1 (M+H).

[0229] Example 24 (I27) 2,6-Difluoro-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline 2,6-Difluoro-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline. Prepared according to steps A to B of Example 23, 2,6-Difluoro-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline (56 mg, 11%), using 1,3,5-trifluoro-2-nitrobenzene instead of 1,2,3,5-tetrafluoro-4-nitrobenzene. LCMS (MM-ES+APCI, positive ion mode): m / z 277.1 (M+H).

[0230] Example 25 (I28) 2-Fluoro-3-methoxy-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline Step A. 1-Bromo-3,5-difluoro-4-methoxy-2-nitrobenzene. A solution of 5-bromo-1,3-difluoro-2-methoxy-benzene (4.0 g, 17.9 mmol) in H2SO4 (30 mL) was cooled to 0°C, and KNO3 (2.18 g, 21.5 mmol) was added in portions. The mixture was stirred at 25°C for 1 h and then slowly poured into H2O (100 mL) at 0°C. The aqueous solution (pH 7) was neutralized with NaHCO3, and the product was extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (150 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give 1-bromo-3,5-difluoro-4-methoxy-2-nitrobenzene (4.2 g, 88% yield) as a yellow oil.

[0231] Step B. 5-(5-bromo-3-fluoro-2-methoxy-4-nitrobenzene)-1-methyl-1H-benzo[d][1,2,3]triazole. K2CO3 (2.06 g, 14.9 mmol) was added to a solution of 1-bromo-3,5-difluoro-4-methoxy-2-nitrobenzene (2.00 g, 7.46 mmol) and 1-methylbenzotriazole-5-ol (0.67 g, 4.48 mmol) in DMF (20 mL). The mixture was stirred at 80 °C for 1 h, diluted with water (50 mL), and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude oil was purified by preparative HPLC to give 5-(5-bromo-3-fluoro-2-methoxy-4-nitro-phenoxy)-1-methylbenzotriazole (450 mg, 1.13 mmol, 25% yield) as a yellow solid. LCMS(MM-ES+APCI, positive ion mode): m / z 397.0, 398.9 (M+H).

[0232] Step C. 2-fluoro-3-methoxy-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline. Add 10% Pd / C (200 mg, 25 µmol) to a solution of 5-(5-bromo-3-fluoro-2-methoxy-4-nitro-phenoxy)-1-methyl-benzotriazole (200 mg, 0.50 mmol) in THF (page 73 / 189, CN 121311486 A) (50 mL). Evacuate the flask and backfill with H2 three times. Stir the mixture at 25 °C and H2 atmosphere (3 atm) for 2 h, elute with MeOH (50 mL), and filter the suspension through a diatomaceous earth pad. The crude material was purified by preparative TLC (10% MeOH / DCM) to give 2-fluoro-3-methoxy-4-(1-methylbenzotriazol-5-yl)oxy-aniline (50 mg, 34% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 289.0 (M+H) Example 26 (I103) 3-Chloro-5-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline Step A. 5-(2-bromo-6-chloro-4-nitrophenoxy)-1-methyl-1H-benzo[d][1,2,3]triazole. Cs₂CO₃ (512 mg, 1.57 mmol) was added to a solution of 1-bromo-3-chloro-2-fluoro-5-nitrobenzene (200 mg, 0.79 mmol) and 1-methylbenzotriazole-5-ol (117 mg, 0.79 mmol) in DMF (2.5 mL). The reaction mixture was stirred at 25 °C for 1.5 h. The mixture was diluted with water, the layers were separated, and the aqueous phase was extracted with EtOAc (8 mL x 3). The combined organic layers were washed with brine (6 mL x 3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give 5-(2-bromo-6-chloro-4-nitro-phenoxy)-1-methylbenzotriazole (290 mg, 94% yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 383.0, 384.9 (M+H).

[0233] Step B. 3-Bromo-5-chloro-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline. 5-(2-bromo-6-chloro-4-nitro-phenoxy)-1-methyl-benzotriazole (290 mg, 0.74 mmol) was added to EtOH (6 mL) and water (2 mL).NH4Cl (238 mg, 4.45 mmol) was added to the solution in mL. The mixture was heated to 60 °C and Fe (207 mg, 3.70 mmol) was added. The reaction mixture was stirred at 80 °C for 1 h, diluted with MeOH (20 mL), and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure. The crude product was diluted with water (20 mL) and extracted with EtOAc (12 mL × 3). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 3-bromo-5-chloro-4-(1-methylbenzotriazol-5-yl)oxy-aniline 4 (255 mg, 93% yield) as a brown oil. LCMS (MM-ES+APCI, positive ion mode): m / z 353.0, 355.0 (M+H).

[0234] Step C. 3-Chloro-5-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline. K2CO3 (191 mg, 1.38 mmol) and Pd(dppf)Cl2 (51 mg, 69 μmol) were added to a solution of 3-bromo-5-chloro-4-(1-methylbenzotriazol-5-yl)oxy-aniline (255 mg, 0.69 mmol) and methylboronic acid (41 mg, 0.69 mmol) in 1,4-dioxane (3 mL) and water (0.3 mL). The reaction system was purged with N2 and stirred at 100 °C for 3 h. The mixture was transferred to a separatory funnel, diluted with water (15 mL), and extracted with EtOAc (8 mL x 3). The combined organic layers were washed with brine (6 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (25% to 50% EtOAc / PET) to give the product 3-chloro-5-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline (115 mg, 55% yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 289.2 (M+H).

[0235] Example 27 (I104) 2-fluoro-6-methoxy-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline Specification 74 / 189 pages 138 CN 121311486 A Step A. 2-bromo-1,3-difluoro-5-methoxy-4-nitrobenzene. Fuming HNO3 (8.99 mL, 199 mmol) was added dropwise to an ice-cold solution of 2-bromo-1,3-difluoro-5-methoxybenzene (8.00 g, 35.9 mmol) in DCM (80 mL) under a N2 atmosphere at 0 °C. The mixture was then heated to ambient temperature and stirred for 2 hours.h. The reaction mixture was diluted with ice water (200 mL) and alkalized with a saturated aqueous solution of NaHCO3 (pH = 8). The product was extracted with DCM (60 mL x 3), and the combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (0% to 4% EtOAc / PET) to give 2-bromo-1,3-difluoro-5-methoxy-4-nitrobenzene (9.0 g, 94% yield) as a white solid.

[0236] Steps B to D. 2-fluoro-6-methoxy-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline. 2-Fluoro-6-methoxy-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline (180 mg, 64% yield) was prepared according to steps A to C of Example 26, replacing 1-bromo-3-chloro-2-fluoro-5-nitrobenzene. The result was a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 302.8 (M+H).

[0237] Example 28 (I105) 2-Fluoro-4-((7-fluoro-1-methyl-1H-benzo[d]imidazol-5-yl)oxy)-6-methoxy-3-methylaniline Steps A to D. 2-Fluoro-4-((7-fluoro-1-methyl-1H-benzo[d]imidazol-5-yl)oxy)-6-methoxy-3-methylaniline was prepared according to steps A to D of Example 27, replacing 1-methylbenzotriazol-5-ol with 7-fluoro-1-methyl-1H-benzo[d]imidazol-5-ol, to obtain 2-fluoro-4-((7-fluoro-1-methyl-1H-benzo[d]imidazol-5-yl)oxy)-6-methoxy-3-methylaniline (225 mg, 45% yield), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 320.0 (M+H).

[0238] Example 29 (I106) 3-Fluoro-5-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline Specification 75 / 189 pages 139 CN 121311486 A Step A. 5-(2-bromo-6-fluoro-4-nitrophenoxy)-1-methyl-1H-benzo[d][1,2,3]triazole. K2CO3 (290 mg, 2.10 mmol) was added to a solution of 1-bromo-2,3-difluoro-5-nitrobenzene (200 mg, 0.84 mmol) and 1-methylbenzotriazol-5-ol (139 mg, 0.84 mmol) in DMF (8 mL). The reaction system was stirred at 80°C for 1 h, andDilute with water (100 mL). Transfer the mixture to a separatory funnel and extract the aqueous layer mixture with EtOAc (100 mL x 2). Wash the combined organic layers with brine (100 mL × 3), dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. Purify the residue by silica gel column chromatography (10% to 50% EtOAc / PET and 2% MeOH / DCM) to give 5-(2-bromo-6-fluoro-4-nitro-phenoxy)-1-methyl-benzotriazole (1.55 g, 70% yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 367.0, 368.9 (M+H).

[0239] Step B. Add Pd(dppf)Cl2 (58 mg, 80 μmol) and K2CO3 (275 mg, 1.99 mmol) to a solution of 5-(2-bromo-6-fluoro-4-nitro-phenoxy)-1-methyl-benzotriazole (300 mg, 0.80 mmol) and methylboronic acid (57 mg, 0.96 mmol) in 1,4-dioxane (5 mL) and H2O (1 mL). Pd(dppf)Cl2 (58 mg, 80 μmol) and K2CO3 (275 mg, 1.99 mmol) are added to the solution. The reaction system is purged with N2, stirred at 90 °C for 2 h, and quenched with H2O (100 mL). The two-phase mixture is separated, and the aqueous layer is extracted with EtOAc (100 mL x 3). The combined organic layers are dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20% to 50% EtOAc / PET) to give 5-(2-fluoro-6-methyl-4-nitro-phenoxy)-1-methyl-benzotriazole (300 mg, 23% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 303.0 (M+H).

[0240] Step C. Fe (157 mg, 2.81 mmol) and NH4Cl (151 mg, 2.82 mmol) were added to a solution of 5-(2-fluoro-6-methyl-4-nitro-phenoxy)-1-methyl-benzotriazole (230 mg, 0.71 mmol) in EtOH (2 mL) and H2O (2 mL). The mixture was stirred at 60 °C for 1 h and eluted with EtOH (20 mL). The suspension was filtered. The filtrate was concentrated under vacuum to obtain 3-fluoro-5-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline (360 mg, quantitative yield), which was a grayish-white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 273.1 (M+H).

[0241] Example 30 (I107) 2,5-difluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)anilineSteps A to C. 2,5-Difluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline. Prepared according to steps A to C of Example 29, replacing 1-bromo-2,3-difluoro-5-nitrobenzene with 3-bromo-1,2,4-trifluoro-5-nitrobenzene, to give 2,5-difluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline, specification page 76 / 189, 140 CN 121311486 A (1.60 g, 77% yield), as a pink solid. LCMS (MM-ES+APCI, positive ion mode): m / z 291.1 (M+H).

[0242] Example 31 (I108) 2-Fluoro-4-((7-fluoro-1-methyl-1H-benzo[d]imidazol-5-yl)oxy)-3-methylaniline Step A. 2-Fluoro-4-((7-fluoro-1-methyl-1H-benzo[d]imidazol-5-yl)oxy)-3-methylaniline. DMSO (15 mL) was added to a flask containing 7-fluoro-1-methyl-benzimidazol-5-ol (772 mg, 4.29 mmol), 2-fluoro-4-iodo-3-methylaniline (1 g, 3.57 mmol), CuI (204 mg, 1.07 mmol), pyridinecarboxylic acid (88 mg, 0.72 mmol), and K3PO4 (1.52 g, 7.14 mmol) at 25 °C. The mixture was purged with N2 and heated to 80 °C for 16 h. The reaction was quenched with H2O (50 mL), and the aqueous mixture was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with water (150 mL) and brine (80 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0% to 75% EtOAc / PET) to give 2-fluoro-4-(7-fluoro-1-methyl-benzimidazol-5-yl)oxy-3-methyl-aniline (500 mg, 45% yield) as a pink solid. LCMS (MM-ES+APCI, positive ion mode): m / z 290.2 (M+H).

[0243] Intermediates I108–I115 in Table 12 were prepared according to step A of Example 31.

[0244] Table 12: List of intermediate compounds I108 to I115

[0245] Example 32 (I116) 3-Ethyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline Specification 77 / 189 pages 141 CN 121311486 A Step A. 5-(2-bromo-4-nitrophenoxy)-1-methyl-1H-benzo[d][1[2,3] Triazole. K₂CO₃ (1.26 g, 9.09 mmol) and 1-methylbenzotriazole-5-ol (0.68 g, 4.55 mmol) were added to a solution of 2-bromo-1-fluoro-4-nitrobenzene (1.00 g, 4.55 mmol) in DMF (10 mL). The mixture was stirred at 25 °C for 2 h. The reaction was quenched with H₂O (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with water (50 mL x 2) and brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (0% to 25% EtOAc / PET) to give 5-(2-bromo-4-nitro-phenoxy)-1-methylbenzotriazole 3 (800 mg, 50% yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 349.0, 351.0 (M+H).

[0246] Step B. 1-Methyl-5-(4-nitro-2-vinylphenoxy)-1H-benzo[d][1,2,3]triazole. Pd(dppf)Cl2 (145 mg, 0.20 mmol), Na2CO3 (425 mg, 4.01 mmol), and potassium vinyltrifluoroborate (322 mg, 2.41 mmol) were added to a solution of 5-(2-bromo-4-nitro-phenoxy)-1-methyl-benzotriazole (700 mg, 2.00 mmol) in 1,4-dioxane (10 mL) and water (2 mL). The reaction system was stirred at 110 °C for 2 h. The mixture was concentrated under vacuum, and the crude residue was purified by silica gel column chromatography (0% to 25% EtOAc / PET) to give 1-methyl-5-(4-nitro-2-vinyl-phenoxy)benzotriazole (500 mg, 79% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 297.2 (M+H).

[0247] Step C. 3-Ethyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline. 10% Pd / C (1 g) was added to a solution of 1-methyl-5-(4-nitro-2-vinyl-phenoxy)benzotriazole (500 mg, 1.57 mmol) in MeOH. The mixture was degassed and purged three times with H2. The reaction system was stirred at 20°C for 30 minutes and eluted with MeOH (30 mL), then filtered through diatomaceous earth. The filtrate was concentrated, and the residue was purified by silica gel column chromatography (1% to 30% EtOAc / PET) to give 3-ethyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline 5 (230)mg, 52% yield, as a colorless oil. LCMS (MM-ES+APCI, positive ion mode): m / z 269.3 (M+H).

[0248] Example 33 (I117) 4-([1,2,4]triazolo[1,5-c]pyrimidine-7-yloxy)-3-methylaniline Step A. 7-(2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-c]pyrimidine. A solution of 2-methyl-4-nitrophenol (5.94 g, 38.8 mmol), 7-chloro-[1,2,4]triazolo[1,5-c]pyrimidine (5.00 g, 32.3 mmol) and K2CO3 (11.2 g, 80.9 mmol) in MeCN (50 mL) was heated at 80 °C for 3 h. The mixture was concentrated under vacuum, diluted with water (50 mL), and extracted with DCM (25 mL). The organic phase was washed with 2M NaOH aqueous solution (25 mL), dried over anhydrous MgSO4, and filtered. The product was concentrated to dryness to give 7-(2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-c]pyrimidine (2.87 g, 31% yield) as a yellow solid.

[0249] Step B. 4-([1,2,4]triazolo[1,5-c]pyrimidine-7-yloxy)-3-methylaniline. Fe (1.24 g, 22.1 mmol) and NH4Cl (1.97 g, 36.9 mmol) were added to a solution of 7-(2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-c]pyrimidine (2.00 g, 7.37 mmol) in EtOH (30 mL) and water (10 mL). The reaction mixture was heated at 60 °C for 3 h and then cooled to ambient temperature. The mixture was filtered through diatomaceous earth, washed with EtOH (10 mL), and volatiles were removed under vacuum. Water (20 mL) was added, the product was extracted with EtOAc (10 mL x 3), and the combined organic matter was concentrated under reduced pressure. The crude substance was purified by silica gel column chromatography (25% to 60% EtOAc / heptane) to give 4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)-3-methylaniline (0.92 g, 51% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 242.3 (M+H).

[0250] Example 34 (I29) N-(4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin-4-amine Step A.N-(4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin-4-amine. DIPEA (250 µL, 1.43 mmol) was added to a solution of 4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methylaniline (130 mg, 0.48 mmol) and 4-chloro-6-methylthioalkyl-pyrimido[5,4-d]pyrimidine (203 mg, 0.96 mmol) in IPA (5 mL). The mixture was stirred at 25 °C for 12 h and concentrated under reduced pressure. The residue was milled together with MeCN (5 mL) at 25 °C for 30 min. Filtration yielded N-[4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-phenyl]-6-methylthioalkyl-pyrimido[5,4-d]pyrimidin-4-amine (190 mg, 84% yield) as a gray solid. LCMS (MM-ES+APCI, positive ion mode): m / z 449.2 (M+H).

[0251] Step B. N-(4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)-6-(methylsulfinyl)pyrimido[5,4-d]pyrimidin-4-amine. Potassium persulfate (242 mg, 1.44 mmol) was added to a solution of N-[4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-phenyl]-6-methylthioalkyl-pyrimido[5,4-d]pyrimidin-4-amine (270 mg, 0.60 mmol) in MeCN (3 mL) and H2O (3 mL). The reaction mixture was stirred at 50 °C for 1.5 h, diluted with saturated NaHCO3 aqueous solution (15 mL), and extracted with DCM (15 mL x 3). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to obtain N-[4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-phenyl]-6-methylsulfinyl-pyrimido[5,4-d]pyrimidin-4-amine (190 mg, 68% yield), as a yellow gel. LCMS (MM-ES+APCI, positive ion mode): m / z 465.1 (M+H).

[0252] Intermediates I29-I46 and I118-I144 in Table 3 were prepared according to steps A to B of Example 34. Step A can be completed using DIPEA, TEA, or Cs2CO3 as a base. Depending on the substrate, sulfoxide or sulfone was isolated. Both oxidation states are suitable for subsequent reactions.

[0253] Table 3: List of intermediate compounds I29-I46, I117-I144Specification 79 / 189 pages 143 CN 121311486 A Specification 80 / 189 pages 144 CN 121311486 A Specification 81 / 189 pages 145 CN 121311486 A Specification 82 / 189 pages 146 CN 121311486 A Specification 83 / 189 pages 147 CN 121311486 A

[0254] Example 35 (I47) N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(methylsulfinyl)pyrimido[5,4-d]pyrimidin-4-amine Step A. N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin-4-amine. TEA (13.8 mL, 99.1 mmol) was added to a solution of 3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline (21.0 g, 82.6 mmol) and 8-chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine (26.3 g, 124 mmol) in DMF (413 mL). The reaction mixture was heated at 45 °C for 2.5 h, cooled to 0 °C, and water (500 mL) was added. After stirring for 15 min, the mixture was filtered, and the solid was washed with water. The solid was collected and dried under vacuum and at 40 °C to give N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin-4-amine (33.6 g, 95% yield). LCMS (MM-ES+ APCI, positive ion mode): m / z 431.2 (M+H).

[0255] Step B. N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(methylsulfinyl)pyrimido[5,4-d]pyrimidin-4-amine. A solution of N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin-4-amine (51.9 g, 121 mmol) in DCM (603 mL) was cooled to 0 °C. After 2 h, mCPBA (29.1 g, 127 mmol, 75 wt%) was slowly added to DCM (300 mL).The solution was prepared in mL. The ice bath was removed, and the reaction mixture was stirred at 25 °C for 30 min. Sodium thiosulfate (1 M, 1 L) was slowly added, and the reaction mixture was stirred for 10 min. MeOH (300 mL) was slowly added to dissolve the solid, and the layers were separated. The organic matter was washed with saturated NaHCO3 aqueous solution and brine, dried over Na2SO4, filtered, and concentrated to give N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(methylsulfinyl)pyrimido[5,4-d]pyrimidin-4-amine (47.8 g, 89% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 447.2 (M+H).

[0256] Example 36 (I48) N-(2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)-6-(methylsulfinyl)pyrimido[5,4-d]pyrimidin-4-amine Step A. N-(2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin-4-amine. TFA (0.21 mL, 2.83 mmol) was added to a solution of 2-fluoro-3-methyl-4-(1-methylbenzimidazol-5-yl)oxy-aniline (250 mg, 0.92 mmol) and 4-chloro-6-methylthioalkyl-pyrimido[5,4-d]pyrimidine (600 mg, 2.82 mmol) in n-BuOH (5 mL). The mixture was stirred at 80 °C for 2 h and concentrated under vacuum. The crude product was purified by preparative silica gel TLC (10% MeOH / DCM) to give N-[2-fluoro-3-methyl-4-(1-methylbenzimidazol-5-yl)oxy-phenyl]-6-methylthioalkyl-pyrimido[5,4-d]pyrimidin-4-amine (210 mg, 51% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 448.1 (M+H).

[0257] Step B. N-(2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)-6-(methylsulfinyl)pyrimido[5,4-d]pyrimidin-4-amine. N-[2-fluoro-3-methyl-4-(1-methylbenzimidazol-5-yl)oxy-phenyl]-6-methylthioalkyl-pyrimido[5,4-d]pyrimidin-4-amine was used instead of N-[4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-phenyl]-6-methylthioalkyl-pyrimido[5,4-d]pyrimidin-4-amine, prepared according to Step B of Example 34.Preparation yielded N-[2-fluoro-3-methyl-4-(1-methylbenzimidazol-5-yl)oxy-phenyl]-6-methylsulfinyl-pyrimido[5,4-d]pyrimidin-4-amine (150 mg, 72% yield), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 464.0 (M+H).

[0258] Intermediates I48-I50 and I145-I148 in Table 4 were prepared according to steps A to B of Example 36.

[0259] Table 4: List of intermediate compounds I48-I50, I144-I147 Specification 85 / 189 pages 149 CN 121311486 A

[0260] Example 37 (I51) 6-chloro-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine 4,6-dichloropyrido[3,2-d]pyrimidinyl (2.36 g, 11.8 mmol) and 3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)aniline (3.00 g, 11.8 mmol) were suspended in IPA (29.5 mL) and heated to 85°C and held for 40 minutes. The reaction system was cooled to ambient temperature, the slurry was filtered under vacuum, and the precipitate was washed with MTBE. The filtrate was concentrated under vacuum, and the solid was washed with MTBE. The two batches of solids were combined to give 6-chloro-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine (5.16 g, quantitative yield), as a fine yellow powder. LCMS (MM-ES+APCI, positive ion mode): m / z 418.1 (M+H).

[0261] Example 38 (I52) 6-Chloro-N-(2-fluoro-4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)pyrido[3,2-d]pyrimidine-4-amine Specification 86 / 189 pages 150 CN 121311486 A Step A. 6-Chloro-N-(2-fluoro-4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)pyrido[3,2-d]pyrimidine-4-amine. Add DIPEA (0.14 mL, 0.83 mmol) to a solution of 4,6-dichloropyrido[3,2-d]pyrimidine (55 mg, 0.28 mmol) and 2-fluoro-4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-aniline (80 mg, 0.28 mmol) in IPA (5 mL).The mixture was stirred at 80 °C for 1 h and concentrated under vacuum. The crude material was purified at 25 °C by passing it through a slurry in EtOAc (5 mL) for 10 min. After filtration, the solid was dried to give 6-chloro-N-[2-fluoro-4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-phenyl]pyrido[3,2-d]pyrimidine-4-amine (135 mg, 79% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 454.3 (M+H).

[0262] Intermediates I52, I149-I164 in Table 13 were prepared according to step A of Example 38.

[0263] Table 13: List of intermediate compounds I52, I149-I164 Specification 87 / 189 pages 151 CN 121311486 A Specification 88 / 189 pages 152 CN 121311486 A

[0264] Example 39 (I53) 6-chloro-N-(2,3-difluoro-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine 6-chloro-N-(2,3-difluoro-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine. TFA (38 µL, 0.51 mmol) was added to a solution of 2,3-difluoro-4-(1-methylbenzotriazol-5-yl)oxy-aniline (140 mg, 0.51 mmol) and 4,6-dichloropyrido[3,2-d]pyrimidine (101 mg, 0.51 mmol) in n-BuOH (5 mL). The mixture was stirred at 100 °C for 1 h and concentrated under vacuum. The residue was diluted with water (5 mL), alkalized with a saturated aqueous solution of NaHCO3 (5 mL), and extracted with EtOAc (20 mL × 2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The crude product was purified by silica gel column chromatography (15% EtOAc / PET) to obtain 6-chloro-N-[2,3-difluoro-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrido[3,2-d]pyrimidine-4-amine (128 mg, 55% yield), as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 440.0 (M+H).

[0265] Intermediates I53, I165-I172 in Table 14 were prepared according to step A of Example 39.

[0266] Table 14: List of intermediate compounds I53, I165-I172 Specification 89 / 189 pages 153 CN 121311486A

[0267] Example 40 (I173) 6-Fluoro-N-(2-Fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine Step A. 6-Fluoro-N-(2-Fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine. KF (93.3 mg, 1.61 mmol) and DIPEA (0.28 mL, 1.61 mmol) were added to a solution of 6-chloro-N-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrido[3,2-d]pyrimidin-4-amine (140 mg, 0.32 mmol) in DMSO (6 mL). The reaction mixture was stirred at 100 °C for 4 h. The mixture was concentrated under reduced pressure to give 6-fluoro-N-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrido[3,2-d]pyrimidin-4-amine 7 (200 mg, quantitative yield) as a pale yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 420.1 (M+H). Instructions for Use, pages 90 / 189, 154, CN 121311486 A

[0268] Example 41 (I54) 4-(4-chloropyrido[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate tert-butyl ester Step A. 4-(6-carbamoyl-5-nitropyridin-2-yl)piperazine-1-carboxylate. DIPEA (2.59 mL, 14.9 mmol) and tert-butyl piperazine-1-carboxylate (1.39 g, 7.44 mmol) were added to a solution of 6-chloro-3-nitropyridin-2-carboxamide (1.00 g, 4.96 mmol) in DMSO (30 mL). The mixture was stirred at 90 °C for 1 h, quenched with H2O (100 mL), and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give 4-(6-carbamoyl-5-nitro-2-pyridyl)piperazine-1-carboxylate tert-butyl ester (2.0 g, quantitative yield), as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 352.0 (M+H).

[0269] Step B. 4-(5-amino-6-carbamoylpyridyl-2-yl)piperazine-1-carboxylate tert-butyl ester. 4-(6-carbamoyl-5-nitro-2-pyridyl)piperazine-1-carboxylate tert-butyl ester (1.8 g, 5.12 mmol) was added to EtOH.Fe powder (1.14 g, 20.5 mmol) and NH4Cl (1.10 g, 20.5 mmol) were added to a solution of (20 mL) and H2O (10 mL). The mixture was stirred at 80 °C for 1 h. The suspension was filtered and the filter cake was washed with MeOH (20 mL). The filtrate was concentrated under vacuum to give 4-(5-amino-6-carbamoyl-2-pyridyl)piperazine-1-carboxylic acid tert-butyl ester 4 (1.8 g, quantitative), as a gray solid. LCMS (MM-ES+APCI, positive ion mode): m / z 322.1 (M+H).

[0270] Step C. 4-(8-hydroxypyrimidino[5,4-d]pyrimidin-2-yl)piperazine-1-carboxylic acid tert-butyl ester. A solution of tert-butyl 4-(5-amino-6-carbamoyl-2-pyridyl)piperazine-1-carboxylate (1.7 g, 5.29 mmol) in CH(OEt)3 (20 mL) was heated to 100 °C and held for 2 h. The reaction was quenched with water (50 mL) and extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (25% to 35% EtOAc / PET) to give tert-butyl 4-(4-hydroxypyridino[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate (1.1 g, 60% yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 332.1 (M+H).

[0271] Step D. 4-(8-chloropyrimidino[5,4-d]pyrimidin-2-yl)piperazine-1-carboxylate tert-butyl ester. A solution of 4-(4-hydroxypyridino[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate tert-butyl ester (527 mg, 1.51 mmol) in toluene (10 mL) was cooled to 0 °C, followed by the addition of POCl3 (0.18 mL, 1.96 mmol) and DIPEA (1.31 mL, 7.54 mmol). The mixture was stirred at 80 °C for 2 h and concentrated under vacuum to give 4-(4-chloropyridino[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate tert-butyl ester (800 mg, quantitative), as a brown oil. LCMS (MM-ES+APCI, positive ion mode): m / z 350.0 (M+H).

[0272] Example 42 (I55) 3-(4-chloropyridino[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester Specification 91 / 189 pages 155 CN 121311486 A 3-(4-chloropyridino[3,2-d]pyrimidin-6-yl)-33,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester. Prepared according to steps A to D of Example 41, using 3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester instead of piperazine-1-carboxylic acid ester, 3-(4-chloropyridino[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester (350 mg, quantitative yield) as a black oil. LCMS (MM-ES+APCI, positive ion mode): m / z 362.0 (M+H).

[0273] Example 43 (I56) 6-(4-chloropyridano[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl 6-(4-chloropyridano[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester was prepared according to steps A to D of Example 41 in place of tert-butyl piperazine-1-carboxylic acid to obtain 6-(4-chloropyridano[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester (420 mg, quantitative yield), as a brown oil. LCMS (MM-ES+APCI, positive ion mode): m / z 362.0 (M+H).

[0274] Example 44 (I57) 4-(4-chloro-5-fluoropyridino[3,4-d]pyrimidin-6-yl)piperazine-1-carboxylate tert-butyl ester Specification 92 / 189 pages 156 CN 121311486 A Step A. 4-(5-bromo-3-fluoropyridino-2-yl)piperazine-1-carboxylate tert-butyl ester. Add K2CO3 (9.26 g, 67.0 mmol) and piperazine-1-carboxylate (9.60 g, 51.6 mmol) to a solution of 5-bromo-2,3-difluoropyridine (10.0 g, 51.6 mmol) in DMF (100 mL). The reaction system was stirred at 100 °C for 2 h, slowly quenched with water (100 mL), and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with water (100 mL x 2) and brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The crude oil was purified by silica gel column chromatography (1% to 30% EtOAc / PET) to give tert-butyl 4-(5-bromo-3-fluoro-2-pyridyl)piperazine-1-carboxylate (11 g, 59% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 304.1 (M+H-tBu).

[0275] Step B.5-Bromo-2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-3-fluoroisonicotinic acid. A solution of tert-butyl 4-(5-bromo-3-fluoro-2-pyridyl)piperazin-1-carboxylate (10.0 g, 27.8 mmol) in THF (30 mL) was cooled to -78 °C. LDA (2M in THF, 20.8 mL, 41.6 mmol) was added dropwise, and the reaction mixture was stirred for 30 min. Solid CO2 (1.22 g, 27.8 mmol) was added, and stirring was continued at -78 °C for 2 h. The mixture was slowly quenched with saturated NH4Cl aqueous solution (50 mL), heated to 25 °C, and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The crude oil was purified by silica gel column chromatography (0% to 90% EtOAc / PET) to give 5-bromo-2-(4-tert-butoxycarbonylpiperazin-1-yl)-3-fluoro-pyridine-4-carboxylic acid (8.0 g, 71% yield), as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 348.0 (M+H-tBu).

[0276] Step C. tert-butyl 4-(5-bromo-3-fluoro-4-(methoxycarbonyl)pyridine-2-yl)piperazin-1-carboxylic acid. To a solution of 5-bromo-2-(4-tert-butoxycarbonylpiperazin-1-yl)-3-fluoro-pyridine-4-carboxylic acid (8.0 g, 19.8 mmol) in DMF (80 mL), K₂CO₃ (5.47 g, 39.6 mmol) and MeI (6.16 mL, 99.0 mmol) were added. The mixture was stirred at 20 °C for 2 h, quenched with water (30 mL), and extracted with EtOAc (40 mL x 3). The combined organic layers were washed with water (100 mL x 2) and brine (100 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude oil was purified by silica gel column chromatography (1% to 20% EtOAc / PET) to give tert-butyl 4-(5-bromo-3-fluoro-4-methoxycarbonyl-2-pyridyl)piperazine-1-carboxylate (6.0 g, 72% yield) as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 364.1 (M+H-tBu).

[0277] Step D. 4-(5-((diphenylmethylene)amino)-3-fluoro-4-(methoxycarbonyl)pyridyl-2-yl)piperazine-1-carboxylate. A solution of tert-butyl 4-(5-bromo-3-fluoro-4-methoxycarbonyl-2-pyridyl)piperazine-1-carboxylate (5.0 g, 12.0 mmol) in 1,4-dioxane (50 mL) was purged with N2. Add Pd2(dba)3(1.09)The mixture was prepared by heating 1.20 g (1.20 mmol), Xantphos (1.04 g, 1.79 mmol), Cs₂CO₃ (9.74 g, 30.0 mmol), and diphenylmethyleneimine (2.41 mL, 14.4 mmol) to 100 °C for 2 h. The reaction was quenched with water (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude solid was purified by silica gel column chromatography (1% to 50% EtOAc / PET) to give tert-butyl 4-[5-(diphenylmethyleneamino)-3-fluoro-4-methoxycarbonyl-2-pyridyl]piperazine-1-carboxylate (5.8 g, 94% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 519.5 (M+H).

[0278] Step E. 4-(5-amino-3-fluoro-4-(methoxycarbonyl)pyridin-2-yl)piperazine-1-carboxylate tert-butyl ester. 2M HCl (11.2 mL, 22.4 mmol) was added to a solution of 4-[5-(diphenylmethyleneamino)-3-fluoro-4-methoxycarbonyl-2-pyridinyl]piperazine-1-carboxylate (5.8 g, 11.2 mmol) in MeOH (20 mL) and water (20 mL). The mixture was stirred at 20 °C for 2 h, neutralized with a saturated aqueous solution of NaHCO3 (200 mL) (pH 7), and extracted with EtOAc (60 mL x 3). The combined organic layers were washed with brine (60 mL), dried over Na2SO4, filtered, and concentrated under vacuum. The crude residue was purified by silica gel column chromatography (1% to 50% EtOAc / PET) to obtain tert-butyl 4-(5-amino-3-fluoro-4-methoxycarbonyl-2-pyridyl)piperazine-1-carboxylate (3.1 g, 78% yield), as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 93 / 189 pages 157 CN 121311486 A 355.2 (M+H).

[0279] Step F. tert-butyl 4-(5-fluoro-4-hydroxypyridino[3,4-d]pyrimidin-6-yl)piperazine-1-carboxylate. To a solution of tert-butyl piperazine-1-carboxylate (3.0 g, 8.47 mmol) in 2-methoxyethanol (30 mL), NaOAc (2.08 g, 25.4 mmol) and formamidin hydrochloride (2.73 g, 33.9 mmol) were added. The mixture was stirred at 110 °C for 2 h, quenched with water (30 mL), and treated with EtOAc (40 mL).x 3) Extraction. The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude oil was purified by silica gel column chromatography (1% to 50% EtOAc / PET) to give tert-butyl 4-(5-fluoro-4-hydroxy-pyridino[3,4-d]pyrimidin-6-yl)piperazine-1-carboxylate (1.9 g, 64% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 294.0 (M+H-tBu).

[0280] Step G. tert-butyl 4-(4-chloro-5-fluoropyridino[3,4-d]pyrimidin-6-yl)piperazine-1-carboxylate. DIPEA (4.5 mL, 25.8 mmol) and POCl3 (0.58 mL, 6.18 mmol) were added to a solution of 4-(5-fluoro-4-hydroxy-pyrido[3,4-d]pyrimidin-6-yl)piperazine-1-carboxylic acid tert-butyl ester (1.8 g, 5.15 mmol) in PhMe (20 mL). The mixture was stirred at 100 °C for 2 h, slowly quenched with a saturated aqueous solution of NaHCO3 (30 mL), and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude solid was purified by silica gel column chromatography (1% to 50% EtOAc / PET) to give tert-butyl 4-(4-chloro-5-fluoro-pyridano[3,4-d]pyrimidin-6-yl)piperazine-1-carboxylate (1.10 g, 58% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 368.2 (M+H).

[0281] Example 45 (I58) 4-(4-chloro-7-methoxypyridano[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate Step A. 2,6-dibromo-3-methoxy-5-nitropyridine. Nitric acid (32.9 mL, 732 mmol) was added dropwise to ice-cold sulfuric acid (30 mL), followed by the addition of 2,6-dibromo-3-methoxy-pyridine (7.50 g, 28.1 mmol) in portions. The mixture was stirred at 0 °C for 20 min, at 10 °C for 10 min, and at 60 °C for 2.5 h. The reaction mixture was slowly poured into ice water (200 mL), and the yellow precipitate was collected, washed with water (800 mL), and dried under vacuum to give 2,6-dibromo-3-methoxy-5-nitro-pyridine (3.32 g, 36% yield) as a pale yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 312.6 (M+H).

[0282] Step B.4-(6-bromo-3-methoxy-5-nitropyridin-2-yl)piperazine-1-carboxylate tert-butyl ester. K₂CO₃ (1.33 g, 9.62 mmol) and piperazine-1-carboxylate tert-butyl ester (597 mg, 3.21 mmol) were added to a solution of 2,6-dibromo-3-methoxy-5-nitropyridinium (1.00 g, 3.21 mmol) in DMF (20 mL). The mixture was stirred at 25 °C for 1 h, diluted with water (50 mL), and extracted with EtOAc (40 mL x 2). The combined organic layers were washed with brine (40 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under vacuum to give 4-(6-bromo-3-methoxy-5-nitro-2-pyridinyl)piperazine-1-carboxylate tert-butyl ester (1.70 g, 88% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 439.0 (M+Na+).

[0283] Step C. 4-(6-cyano-3-methoxy-5-nitropyridin-2-yl)piperazine-1-carboxylate tert-butyl ester. CuCN (438 mg, 4.89 mmol) was added to a solution of 4-(6-bromo-3-methoxy-5-nitro-2-pyridinyl)piperazine-1-carboxylate (1.70 g, 4.07 mmol) in DMF (40 mL). The mixture was stirred at 100 °C for 1 h, diluted with water (60 mL), and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (60 mL × 2), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to give tert-butyl 4-(6-cyano-3-methoxy-5-nitro-2-pyridyl)piperazine-1-carboxylate (1.22 g, 68% yield), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 386.0 (M+Na+).

[0284] Step D. tert-butyl 4-(5-amino-6-carbamoyl-3-methoxypyridyl-2-yl)piperazine-1-carboxylate. Fe powder (937 mg, 16.8 mmol) and NH4Cl (1.80 g, 33.6 mmol) were added to a solution of 4-(6-cyano-3-methoxy-5-nitro-2-pyridyl)piperazine-1-carboxylic acid tert-butyl ester (1.22 g, 3.36 mmol) in EtOH (30 mL) and water (10 mL). The mixture was stirred at 80 °C for 1 h and filtered. The filtrate was concentrated under vacuum, diluted with water (40 mL), and diluted with EtOAc (30 mL x3) Extraction. The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give tert-butyl 4-(5-amino-6-carbamoyl-3-methoxy-2-pyridyl)piperazine-1-carboxylate (1.14 g, 73% yield), as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 352.1 (M+H).

[0285] Step E. 4-(4-hydroxy-7-methoxypyrido[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate. A solution of tert-butyl 4-(5-amino-6-carbamoyl-3-methoxy-2-pyridyl)piperazine-1-carboxylate (1.14 g, 3.24 mmol) in CH(OEt)3 (15 mL) was heated to 100 °C and stirred for 2 h. The mixture was concentrated under vacuum, and the residue was purified by silica gel column chromatography (5% to 10% MeOH / DCM) to give tert-butyl 4-(4-hydroxy-7-methoxy-pyridano[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate (350 mg, 27% yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 362.3 (M+H).

[0286] Step F. tert-butyl 4-(4-chloro-7-methoxy-pyridano[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate hydrochloride. DIPEA (0.28 mL, 1.60 mmol) and POCl3 (0.37 mL, 4.01 mmol) were added to a solution of 4-(4-hydroxy-7-methoxy-pyrido[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate tert-butyl ester (145 mg, 0.40 mmol) in toluene (1 mL). The reaction mixture was stirred at 90 °C for 1 h and concentrated under vacuum to give 4-(4-chloro-7-methoxy-pyrido[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate tert-butyl ester hydrochloride (167 mg, quantitative yield) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 380.3 (M+H-HCl).

[0287] Example 46 (I59) 1-(4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one Step A. 4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-carboxylic acid tert-butyl ester. To N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-carboxylic acid tert-butyl ester.[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(methylsulfinyl)pyrimido[5,4-d]pyrimidin-4-amine (5.10 g, 11.4 mmol) and piperazine-1-carboxylic acid tert-butyl ester (4.26 g, 22.8 mmol) in a solution of 1,4-dioxane (62 mL) (Instructions for use, page 95 / 189, 159 CN 121311486 A) DIPEA (3.98 mL, 22.8 mmol) was added. The reaction mixture was heated to 80 °C and held for 2 h, then concentrated under vacuum. The solid was purified by silica gel column chromatography (0% to 100% EtOAc / DCM) to give tert-butyl 4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazine-1-carboxylate (6.41 g, 99% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 569.3 (M+H).

[0288] Step BN-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(piperazine-1-yl)pyrimido[5,4-d]pyrimidin-4-amine. TFA (65.2 mL, 846 mmol) was added to a solution of 4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazine-1-carboxylic acid tert-butyl ester (48.1 g, 84.6 mmol) in DCM (423 mL). The reaction mixture was stirred at ambient temperature for 15 h and concentrated under vacuum. The mixture was dissolved in 20% MeOH / DCM and neutralized with 1M NaOH (pH 7). The layers were separated, and the organic matter was washed with saturated NaHCO3 aqueous solution (2x), water, and brine. The organic matter was dried over Na2SO4, filtered, and concentrated under vacuum. The crude substance was purified by silica gel column chromatography (0% to 20% MeOH / DCM) to obtain N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(piperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-amine (35.2 g, 89% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 469.3 (M+H).

[0289] Alternative step BN-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(piperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-amine hydrochloride. HCl (4 M, 4 mL, 16 mmol in EtOAc) was added to an ice-cold solution of 4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrimido[5,4-d]pyrimidin-6-yl]piperazin-1-carboxylic acid tert-butyl ester (410 mg, 0.72 mmol) in DCM (10 mL). The mixture was stirred at 0 °C for 1 h and concentrated under vacuum to give N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazin-1-yl-pyrimido[5,4-d]pyrimidin-4-amine hydrochloride (435 mg, quantitative yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 469.1 (M+H).

[0290] Example 47 (I60) (E)-4-(3-fluoroazacyclobutane-1-yl)but-2-enoic acid Step A. (E)-4-(3-fluoroazacyclobutane-1-yl)but-2-enoic acid. DIPEA (3.12 mL, 7.93 mmol) was added dropwise to a solution of 3-fluoroazacyclobutane hydrochloride (500 mg, 4.48 mmol) and (E)-4-bromobut-2-enoic acid (740 mg, 4.48 mmol) in DMF (10 mL) at 25 °C. The mixture was heated to 60 °C, stirred for 1 h and concentrated under vacuum to obtain (E)-4-(3-fluoroazacyclobutane-1-yl)but-2-enoic acid (945 mg, quantitative), as a yellow oil. LCMS (MM-ES+ APCI, negative ion mode): m / z 158.2 (M-H+).

[0291] Example 48 (I61) 1-(4-hydroxypiperidin-1-yl)prop-2-en-1-one Step A. 1-(4-hydroxypiperidin-1-yl)prop-2-en-1-one. TEA (27.5 mL, 198 mmol) and acryloyl chloride (8.1 mL, 98.9 mmol) were added to a solution of piperin-4-ol (10.0 g, 98.9 mmol) in DCM (15 mL) at 0 °C. The reaction system was stirred at 0 °C for 2 h under N2 and then stirred at 25 °C for 12 h. The mixture was concentrated under reduced pressure and the crude substance was purified by preparative HPLC (20% MeCN / 0.05% NH4OH aqueous solution) to obtain 1-(4-hydroxypiperidin-1-yl)prop-2-en-1-one (5.5 g, 32% yield), as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 156.2 (M+H).

[0292] Example 49(I174) 1-(3-hydroxypyrrolidone-1-yl)prop-2-en-1-one Step A. 1-(3-hydroxypyrrolidone-1-yl)prop-2-en-1-one. Prepared according to Example 48 using pyrrolidone-3-ol instead of piperidin-4-ol, 1-(3-hydroxypyrrolidone-1-yl)prop-2-en-1-one (1.02 g, 52% yield) was obtained as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 283.2 (2x M+H).

[0293] Example 50 (I62) 1-(3-(methylamino)azacyclobutane-1-yl)prop-2-en-1-one 2,2,2-trifluoroacetate Step A. (1-acryloylazacyclobutane-3-yl)(methyl)carbamate tert-butyl ester. A solution of N-(azacyclobutan-3-yl)-N-methyl-tert-butyl carbamate hydrochloride (300 mg, 1.35 mmol) in THF (5 mL) was added to a solution of N-(azacyclobutan-3-yl)-N-methyl-tert-butyl carbamate hydrochloride (0.15 mL, 4.04 mmol). After addition, the mixture was cooled to 0 °C and acrylonitrile chloride (0.22 mL, 2.69 mmol) was added dropwise. The reaction mixture was stirred at 20 °C for 0.5 h and slowly quenched with a saturated solution of NaHCO3 (10 mL). The mixture was extracted with DCM (15 mL x 3), and the combined organic layers were washed with brine (15 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give N-methyl-N-(1-propenylazacyclobutan-3-yl)-butyl carbamate (300 mg, 93% yield) as a pale yellow oil.

[0294] Step B. 1-(3-(methylamino)azacyclobutane-1-yl)prop-2-en-1-one 2,2,2-trifluoroacetate. TFA (1.00 mL, 13.5 mmol) was added to a solution of N-methyl-N-(1-propane-2-enoylazacyclobutane-3-yl)carbamate (300 mg, 1.25 mmol) in DCM (3 mL). The mixture was stirred at 20 °C for 0.5 h and concentrated under vacuum to give 1-[3-(methylamino)azacyclobutane-1-yl]prop-2-en-1-one 2,2,2-trifluoroacetate (300 mg, 1.18 mmol, 95% yield), a pale yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 141.0 (M+H-TFA).

[0295] Example 51 (I63) (E)-4-(pyrrolidine-1-yl)but-2-enoic acid Step A. (E)-4-(pyrrolidine-1-yl)but-2-enoic acid. To pyrrolidine (0.33 mL, 3.97 mmol) and (E)-4-bromoprop-2-enoic acid (400DIPEA (1.38 mL, 7.95 mmol) was added to a solution of (E)-4-pyrrolidine-1-ylbut-2-enoic acid (1.4 g, quantitative yield) in DMF (10 mL). The mixture was heated to 60 °C, stirred for 1 h and concentrated under vacuum to give (E)-4-pyrrolidine-1-ylbut-2-enoic acid (1.4 g, quantitative yield) as a yellow oil. LCMS (MM-ES+APCI, negative ion mode): m / z 154.2 (M-H+).

[0296] Example 52 (I64) (E)-4-hydroxybut-2-enoic acid specification 97 / 189 pages 161 CN 121311486 A Step A. (E)-4-hydroxybut-2-enoic acid. (E)-4-bromobut-2-enoic acid (300 mg, 1.82 mmol) was added to a solution of KOH (408 mg, 7.27 mmol) in H2O (4 mL). The mixture was heated to 60°C, stirred for 1 h, and concentrated under vacuum to obtain (E)-4-hydroxybutyrocyanic acid (510 mg, quantitative yield) as a white solid. LCMS (MM-ES+APCI, negative ion mode): m / z 101.1 (M-H+).

[0297] Example 53 (I175) (E)-4-fluorobutyrocyanic acid Step A. Ethyl (E)-4-fluorobutyrocyanate. A solution of ethyl (E)-4-bromobutyrocyanate (0.36 mL, 2.59 mmol) in MeCN (6 mL) was added to a solution of AgF (986 mg, 7.77 mmol) in MeCN (10 mL). The vial was purged with N2, and the reaction system was stirred at 25°C in the dark for 24 h. The mixture was filtered, and the filter cake was washed with DCM (20 mL). The filtrate was concentrated under vacuum to obtain ethyl (E)-4-fluorobutyrocyanate 7 (340 mg, 99% yield), a brown oil.

[0298] Step B. (E)-4-fluorobutyrocyanic acid. LiOH•H2O (286 mg, 6.81 mmol) was added to a solution of ethyl (E)-4-fluorobutyrocyanate 7 (300 mg, 2.27 mmol) in THF (3 mL) and water (3 mL). The reaction system was stirred at 25 °C for 2.5 h. The mixture was acidified to pH = 4 with 1M HCl (15 mL). The aqueous mixture was extracted with DCM (20 mL x 3). The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, and concentrated under vacuum to obtain (E)-4-fluorobutyrocyanic acid 5 (60 mg, 25% yield), a yellow oil. (MM-ES+APCI, negative ion mode): m / z 103.0 (M-H+).

[0299] Example 54(I176) (2S,3S)-2-methyl-3-(methylamino)pyrrolidine-1-carboxylate tert-butyl ester Step A. (2S,3S)-2-methyl-3-((4-nitrophenyl)sulfonylamino)pyrrolidine-1-carboxylate tert-butyl ester. TEA (0.80 mL, 5.75 mmol) and 2-nitrobenzenesulfonyl chloride (550 mg, 2.48 mmol) were added sequentially to a solution of (2S,3S)-3-amino-2-methyl-pyrrolidine-1-carboxylate (430 mg, 2.15 mmol) in THF (5 mL) at 0 °C. The reaction mixture was stirred at 25 °C for 1 h. The mixture was poured into water (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (2S, 3S)-2-methyl-3-[(2-nitrophenyl)sulfonylamino]pyrrolidine-1-carboxylic acid tert-butyl ester (1.20 g, quantitative yield), as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 285.9 (M+H-Boc).

[0300] Step B. (2S, 3S)-2-methyl-3-((N-methyl-4-nitrophenyl)sulfonylamino)pyrrolidine-1-carboxylic acid tert-butyl ester. K₂CO₃ (500 mg, 3.62 mmol) and MeI (0.15 mL, 2.41 mmol) were added to a solution of (2S, 3S)-2-methyl-3-[(2-nitrophenyl)sulfonylamino]pyrrolidine-1-carboxylic acid tert-butyl ester (600 mg, 1.56 mmol) in DMF (6 mL). The reaction mixture was stirred at 25 °C for 1 h. The mixture was then poured into water (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (2S,3S)-2-methyl-3-[methyl-(2-nitrophenyl)sulfonyl-amino]pyrrolidine-1-carboxylate 4 mg (710 Specification 98 / 189 pages 162 CN 121311486 A mg, quantitative yield), as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 299.8 (M+H-Boc).

[0301] Step C. (2S,3S)-2-methyl-3-(methylamino)pyrrolidine-1-carboxylate tert-butyl ester. Add K₂CO₃ (700 mg, 5.06 mmol) to a solution of (2S,3S)-2-methyl-3-[methyl-(2-nitrophenyl)sulfonyl-amino]pyrrolidine-1-carboxylic acid tert-butyl ester (700 mg, 1.75 mmol) in MeCN (5 mL).mmol) and 2-fluorobenzenethiol (0.38 mL, 3.55 mmol). The reaction system was stirred at 20 °C for 2 h. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (1% to 20% MeOH / DCM) to give (2S,3S)-2-methyl-3-(methylamino)pyrrolidine-1-carboxylic acid tert-butyl ester (340 mg, 82% yield) as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 159.1 (M+H-tBu).

[0302] Intermediates I176-I178 in Table 15 were prepared according to steps A to C of Example 54.

[0303] Table 15: List of intermediates I176-I178

[0304] The synthesis of compounds of formula (I), (IA)-(ID), (IA-1), (IA-2), (IB-1) or (IB-2) is described below.

[0305] Example 55 (R)-1-(2-methyl-4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one (compound 1) Step A. (R)-2-methyl-4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-carboxylic acid tert-butyl ester. DIPEA (45 mg, 0.35 mmol) was added to a solution of N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-methylsulfinyl-pyrimido[5,4-d]pyrimidin-4-amine (80 mg, 0.14 mmol) and (R)-2-methylpiperazine-1-carboxylic acid tert-butyl ester (42 mg, 0.21 mmol) in IPA (1.5 mL). The mixture was stirred at 80 °C for 16 h and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (10% to 100% EtOAc / PET) to obtain (R)-2-methyl-4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrimido[5,4-d]pyrimidin-6-yl]piperazine-1-carboxylic acid tert-butyl ester (40 mg, 41% yield), as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 583.3 (M+H).

[0306] Step B. (R)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(3-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-amine hydrochloride. Add HCl (4 M, 1 mL, 4.0 mmol in 1,4-dioxane) to a solution of (R)-2-methyl-4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrimido[5,4-d]pyrimidin-6-yl]piperazin-1-carboxylic acid tert-butyl ester (35 mg, 50 µmol) in DCM (1 mL). The mixture was stirred at 25 °C for 1 h and concentrated under reduced pressure to give (R)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(3-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-amine hydrochloride (40 mg, quantitative yield), as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 483.3 (M+H-HCl).

[0307] Step C. (R)-1-(2-methyl-4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one. TEA (16 µL, 116 µmol) was added to a solution of (R)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(3-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-amine hydrochloride (30 mg, 58 µmol) in DMF (1 mL). The mixture was cooled to 0 °C and acryloyl chloride (4.7 µL, 58 µmol) was added dropwise. The reaction mixture was heated to 25 °C and stirred for 0.5 h, quenched with saturated NaHCO3 aqueous solution (0.2 mL), and filtered. The filtrate was concentrated under vacuum, and the residue was purified by preparative HPLC (30% to 60% MeCN / 0.05% NH4HCO3 aqueous solution). Lyophilization yielded (R)-1-(2-methyl-4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one (10 mg, 25% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 537.1 (M+H).

[0308] Compounds 1-49 and 111-195 in Table 4 were prepared according to steps A to C of Example 55.

[0309] Step A can be performed using IPA, DMF, DMSO, or 1,4-dioxane as a solvent. Boc deprotection (step B) can also be performed well using HCl (4M in 1,4-dioxane or EtOAc) or TFA. Step C can use DMF or DCM as a solvent interchangeably. Purification options include C18 preparative HPLC, silica gel chromatography, and / or preparative TLC.

[0310] Table 4: List of compounds 1-49, 111-195 Specification 100 / 189 pages 164 CN 121311486 A Specification 101 / 189 pages 165 CN 121311486 A Specification 102 / 189 pages 166 CN 121311486 A Specification 103 / 189 pages 167 CN 121311486 A Specification 104 / 189 pages 168 CN 121311486 A Specification 105 / 189 pages 169 CN 121311486 A Specification 106 / 189 pages 170 CN 121311486 A Specification 107 / 189 pages 171 CN 121311486 A Specification 108 / 189 pages 172 CN 121311486 A Specification 109 / 189 Pages 173 CN 121311486 A Specification 110 / 189 Pages 174 CN 121311486 A Specification 111 / 189 Pages 175 CN 121311486 A Specification 112 / 189 Pages 176 CN 121311486 A

[0311] According to steps A to C of Example 55, compounds 196 to 208 in Table 16 below were prepared as racemic mixtures. Enantiomers were separated by chiral supercritical fluid chromatography (SFC).

[0312] Table 16: Compounds 193-205 Specification 113 / 189 pages 177 CN 121311486 A Specification 114 / 189 pages 178 CN 121311486 A

[0313] Example 56 2-fluoro-1-(5-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimidino[5,4-d]pyrimidin-2-yl)-2,5-diazabicyclo[2.2.2]octane-2-yl)prop-2-en-1-one (Compound 50) Step A.5-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimidino[5,4-d]pyrimidin-2-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylic acid tert-butyl ester. 5-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-2,5-diazabicyclo[2.2.2]octane-2-carboxylate tert-butyl ester was prepared according to step A of Example 55 in place of 2,5-diazabicyclo[2.2.2]octane-2-carboxylate (44.8 mg, 80% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 595.3 (M+H).

[0314] Step B. 6-(2,5-diazabicyclo[2.2.2]octane-2-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine. The tert-butyl 2-octane-2-carboxylate was prepared according to step B of Example 55, replacing (R)-2-methyl-4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrimido[5,4-d]pyrimidin-6-yl]piperazine-1-carboxylate, to obtain 6-(2,5-diazabicyclo[2.2.2]octane-2-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-2,5-diazabicyclo[2.2.2]octane-2-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d])-2-yl)-2-( ... [1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine (38.1 mg, quantitative yield). LCMS (MM-ES+APCI, positive ion mode): m / z 495.3 (M+H).

[0315] Step C. 2-fluoro-1-(5-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-2,5-diazabicyclo[2.2.2]octan-2-yl)prop-2-en-1-one. 6-(2,5-diazabicyclo[2.2.2]octane-2-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,[2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine (38.4 mg, 0.078 mmol), 2-fluoroacrylic acid (15.4 mg, 0.171 mmol), DIPEA (0.07 mL, 0.4 mmol), and HATU (65.0 mg, 0.171 mmol) were diluted in DMF (1 mL). The reaction mixture was stirred at room temperature for 1 h, partitioned between 20% MeOH / DCM (20 mL) and brine, and extracted with 20% MeOH / DCM (5 x 10 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over anhydrous MgSO4, and concentrated under vacuum. The crude residue was purified by silica gel chromatography (0% to 20% MeOH / DCM) to give 2-fluoro-1-(5-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-2,5-diazabicyclo[2.2.2]octane-2-yl)prop-2-en-1-one (21.3 mg, 46% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 567.3 (M+H).

[0316] Compounds 50-59 in Table 5 below were prepared according to Example 56. * Racemic mixtures separated by SFC.

[0317] Table 5: List of compounds 50-59 Specification 116 / 189 pages 180 CN 121311486 A Specification 117 / 189 pages 181 CN 121311486 A

[0318] Example 57 1-(3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-yl)prop-2-en-1-one (compound 60) Specification 118 / 189 pages 182 CN 121311486 A Step A. 3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester. To N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(methanesulfonyl)pyrimido[5,4-d]pyrimidin-4-amine (200 mg, 0.43 mmol) and 6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptane (171K₂CO₃ (120 mg, 0.86 mmol) was added to a solution of DMF (2.1 mL). The mixture was stirred at 90 °C for 4 h, diluted with MeOH, and filtered. The filtrate was concentrated under vacuum and purified by preparative HPLC (5% to 95% MeCN / 0.1% TFA aqueous solution). The purified product was neutralized with saturated NaHCO₃ aqueous solution and extracted with 4:1 DCM:IPA to give 3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester (34 mg, 14% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 581.4 (M+H).

[0319] Step B: 6-(3,6-diazabicyclo[3.1.1]heptane-3-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine. Add TFA (1 mL, 13 mmol) to a solution of 3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester (34 mg, 59 µmol) in DCM (1 mL). The mixture was stirred at 25 °C for 2 h and concentrated under reduced pressure. The residue was dissolved in 4:1 DCM:IPA and washed with saturated NaHCO3 aqueous solution (50 ml x 2) and brine (50 ml x 1). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by preparative HPLC (5% to 95% MeCN / 0.1% TFA aqueous solution). The product was neutralized with saturated NaHCO3 aqueous solution and extracted with 4:1 DCM:IPA to give 6-(3,6-diazabicyclo[3.1.1]heptane-3-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine (15 mg, 53%) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 481.2 (M+H).

[0320] Step C. 1-(3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)benzene(3,6-D-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine (15 mg, 31 µmol) in DCM (0.2 mL) was reacted with TEA (8.7 µL, 62 µmol). The mixture was cooled to -78 °C and acryloyl chloride (5.6 µL, 69 µmol) was added dropwise. The reaction system was heated to 25 °C, stirred for 0.5 h, and quenched with saturated NaHCO3 aqueous solution (0.2 mL). The reaction mixture was diluted with a separate saturated aqueous solution of NaHCO3 and extracted with a 4:1 DCM:IPA mixture (50 ml x 2). The combined organic matter was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC (5% to 95% MeCN / 0.1% TFA aqueous solution). The product was neutralized with a saturated aqueous solution of NaHCO3 and extracted with a 4:1 DCM:IPA mixture to give 1-(3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-pyrimidin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-yl)prop-2-en-1-one (6.9 mg, 41%) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 535.3 (M+H).

[0321] Compounds 60-66 in Table 6 below were synthesized according to Example 57. Step A can be completed using K2CO3 or DIPEA as a base and DMF, DMSO or IPA as a solvent.

[0322] Table 6: List of compounds 60-66 Specification 120 / 189 pages 184 CN 121311486 A

[0323] Example 58 N-(2-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-2-azaspiro[3,3]heptane-6-yl)acrylamide (compound 225) Step A. (2-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)tert-butyl N-(2-azaspiro[3,3]heptane-6-yl)carbamate was added to a solution of N-(2-azaspiro[3,3]heptane-6-yl)carbamate (200 mg, 0.94 mmol) and N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-methylsulfinyl-pyrimido[5,4-d]pyrimidin-4-amine (421 mg, 0.94 mmol) in IPA (10 mL). The reaction mixture was heated to 80 °C and maintained for 15 h. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (50% to 100% EtOAc / PET) to give N-[2-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrimidino[5,4-d]pyrimidin-6-yl]-2-azaspiro[3.3]heptane-6-yl]carbamate (328 mg, 59% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 595.6 (M+H).

[0324] Step B. 6-(6-amino-2-azaspiro[3.3]heptane-2-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine. Add TFA (4 mL) to a solution of N-[2-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrimido[5,4-d]pyrimidin-6-yl]-2-azaspiro[3.3]heptane-6-yl]carbamate (318 mg, 0.53 mmol) in DCM (10 mL). Stir the mixture at 20 °C for 20 min and concentrate under vacuum. The residue was dissolved in water (6 mL), and extracted with saturated NaHCO3 aqueous solution (pH = 7) and EtOAc (20 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 6-(6-amino-2-azaspiro[3.3]heptane-2-yl)-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrimido[5,4-d]pyrimidin-4-amine 4 (130 mg, 262.87 μmol, 49.16% yield) as a yellow solid, which was used in the next step without further purification.

[0325] Example 591-(6-(8-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-1,6-diazaspiro[3.3]heptane-1-yl)prop-2-en-1-one (compound 67) Step A. 1-Acryloyl-1,6-diazaspiro[3.3]heptane-6-carboxylic acid tert-butyl ester. TEA (0.12 mL, 0.83 mmol) was added to a solution of 1,6-diazaspiro[3.3]heptane-6-carboxylic acid tert-butyl ester oxalate (80 mg, 0.28 mmol) in DCM (2 mL) at 25 °C. The reaction system was cooled to -40°C, and propionyl chloride (23 µL, 0.28 mmol) was added. The mixture was stirred for 1 h. The reaction was quenched with saturated NaHCO3 aqueous solution (0.1 mL), extracted with DCM (10 mL x 3), and the combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give tert-butyl 1-propionyl-1,6-diazaspiro[3.3]heptane-6-carboxylate (60 mg, 86% yield), a pale yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 253.1 (M+H).

[0326] Step B. 1-(1,6-diazaspiro[3.3]heptane-1-yl)propionyl-2-en-1-one 2,2,2-trifluoroacetate. TFA (18 µL, 0.24 mmol) was added to a solution of 1-propanoyl-1,6-diazaspiro[3.3]heptane-6-carboxylic acid tert-butyl ester (60 mg, 0.24 mmol) in DCM (1 mL). The mixture was stirred at 25 °C for 1 h and concentrated under vacuum to give 1-(1,6-diazaspiro[3.3]heptane-1-yl)propanoyl-2-en-1-one 2,2,2-trifluoroacetate (62 mg, quantitative yield) as a pale yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 153.1 (M+H-TFA).

[0327] Step C. 1-(6-(8-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-1,6-diazaspiro[3,3]heptane-1-yl)prop-2-en-1-one. To N-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-methylsulfinyl-pyrimido[5,4-d]pyrimidin-4-amine (50 mg, 0.11 mmol) and 1-(1,6-diazaspiro[3,3]heptane-1-yl)prop-2-en-1-one 2,2,2-Trifluoroacetate (62 mg, 0.23 mmol) was added to a solution of IPA (3 mL) with DIPEA (42 mg, 0.32 mmol). The mixture was stirred at 80 °C for 2 h and concentrated under vacuum. The crude substance was purified by preparative HPLC (25% to 55% MeCN / 0.08% NH4HCO3 aqueous solution) to give 1-[6-[4-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrimidino[5,4-d]pyrimidin-6-yl]-1,6-diazaspiro[3,3]heptane-1-yl]prop-2-en-1-one (13 mg, 22% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 553.2 (M+H).

[0328] Compounds 67, 68, 226-230 in Table 17 were synthesized according to steps A to C of Example 59. * Racemic mixtures separated by SFC.

[0329] Table 17: List of compounds 67, 68, 226-230 Description 122 / 189 pages 186 CN 121311486 A

[0330] Example 60 (R)-2-fluoro-1-(4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimidino[5,4-d]pyrimidin-2-yl)-2-(trifluoromethyl)piperazin-1-yl)prop-2-en-1-one (compound 231) Step A. (R)-4-(2-fluoroacryloyl)-3-(trifluoromethyl)piperazin-1-carboxylic acid tert-butyl ester. DIPEA (0.21 mL, 1.18 mmol) and 2-fluoropropionic-2-enoyl chloride (43 mg, 0.39 mmol) were added to a solution of (3R)-3-(trifluoromethyl)piperazine-1-carboxylate (100 mg, 0.39 mmol) in DCM (2 mL). The mixture was stirred at 25 °C for 1 h. The reaction was quenched with water (20 mL) and extracted with DCM (20 mL x 3). The combined organic phases were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by preparative TLC (25% EtOAc / PET) to give (3R)-4-(2-fluoropropionic-2-enoyl)-3-(trifluoromethyl)piperazine-1-carboxylate 3 (122 mg, 95% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 271.1 (M+H-tBu). Specification 123 / 189 pages 187 CN 121311486 A

[0331] Step B.(R)-2-fluoro-1-(2-(trifluoromethyl)piperazin-1-yl)prop-2-en-1-one. A solution of (3R)-4-(2-fluoroprop-2-enoyl)-3-(trifluoromethyl)piperazin-1-carboxylate tert-butyl ester (120 mg, 0.37 mmol) in DCM (2 mL) and TFA (1 mL) was stirred at 25 °C for 30 min. The mixture was concentrated under reduced pressure to give 2-fluoro-1-[(2R)-2-(trifluoromethyl)piperazin-1-yl]prop-2-en-1-one trifluoroacetate (100 mg, 79% yield) as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 227.0 (M+H).

[0332] Step C. (R)-2-fluoro-1-(4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimidino[5,4-d]pyrimidin-2-yl)-2-(trifluoromethyl)piperazin-1-yl)prop-2-en-1-one. DIPEA (0.19 mL, 1.07 mmol) and KF (42 mg, 0.72 mmol) were added to a solution of 6-chloro-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrimido[5,4-d]pyrimidin-4-amine (163 mg, 0.36 mmol) and 2-fluoro-1-[(2R)-2-(trifluoromethyl)piperazin-1-yl]propyl-2-en-1-one trifluoroacetate (81 mg, 0.24 mmol) in IPA (5 mL). The reaction mixture was stirred at 80 °C for 12 h. The mixture was concentrated under reduced pressure, diluted with water (20 mL), and extracted with EtOAc (15 mL x 3). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC (38% to 68% MeCN / 0.08% NH4HCO3 aqueous solution) to give 2-fluoro-1-[(2R)-4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxyaniline]pyrimido[5,4-d]pyrimidin-6-yl]-2-(trifluoromethyl)piperazin-1-yl]propyl-2-en-1-one (55.2 mg, 24% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 609.3 (M+H).

[0333] Example 61 1-(3-((8-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)(methyl)amino)azacyclobutane-1-yl)prop-2-en-1-one (Compound 69)Step A. 1-(3-((8-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimidino[5,4-d]pyrimidin-2-yl)(methyl)amino)azacyclobutane-1-yl)prop-2-en-1-one. The 1-[3-[[4-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrimido[5,4-d]pyrimidin-6-yl]methyl-amino]azacyclobutane-1-yl]prop-2-en-1-one (8 mg, 5% yield) was prepared according to step C of Example 59 to obtain 1-[3-[[4-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrimidino[5,4-d]pyrimidin-6-yl]methyl-amino]azacyclobutane-1-yl]prop-2-en-1-one (8 mg, 5% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 541.2 (M+H).

[0334] Example 62 N-methyl-N-(2-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-2-azaspiro[3.3]heptane-6-yl)acrylamide (compound 232) Specification 124 / 189 pages 188 CN 121311486 A Step A. 6-(methylamino)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester. AcOH (7 μL, 0.12 mmol), tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (250 mg, 1.18 mmol), and NaBH3CN (223 mg, 3.55 mmol) were added to a solution of methylamine hydrochloride (160 mg, 2.37 mmol) and TEA (0.49 mL, 3.55 mmol) in MeOH (10 mL). The mixture was stirred at 20 °C for 2 h. The reaction was quenched with water (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give tert-butyl 6-(methylamino)-2-azaspiro[3.3]heptane-2-carboxylate 2 (215 mg, 80% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 227.4 (M+H).

[0335] Steps B to D. N-methyl-N-(2-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triN-methyl-N-(2-(8-((3-methyl-4-(((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimidino[5,4-d]pyrimidin-2-yl)-2-azaspiro[3.3]heptane-6-yl)acrylamide was prepared according to steps A to C of Example 59, replacing tert-butyl 6-((methylamino)-2-azaspiro[3.3]heptane-2-carboxylate with tert-butyl 6-((methylamino)-2-azaspiro[3.3]heptane-6-yl)acrylamide (15 mg, 12% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 563.4 (M+H).

[0336] Example 63 (E)-1-(4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)-4-(1H-pyrazol-1-yl)but-2-en-1-one (compound 233) Step A. (E)-4-bromobut-2-enoyl chloride. Oxaloyl chloride (0.12 mL, 1.33 mmol) was added to a solution of (E)-4-bromobut-2-enoic acid 4 (200 mg, 1.21 mmol) in DCM (4 mL). The mixture was cooled to 0°C and DMF (1 drop) was added. The mixture was heated to 20°C and stirred for 2 h. A solution of (E)-4-bromobut-2-enoyl chloride 2 (222.36 mg, crude) in DCM (4 mL) was obtained and used as is in step B.

[0337] Step B. (E)-4-chloro-1-(4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimidino[5,4-d]pyrimidin-2-yl)piperazin-1-yl)but-2-en-1-one. DIPEA (86 µL, 0.50 mmol) was added to a solution of N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazin-1-yl-pyrimido[5,4-d]pyrimidin-4-amine hydrochloride (100 mg, 0.20 mmol) in DCM (1 mL). The mixture was cooled to 0 °C, and (E)-4-bromobut-2-enoyl chloride (73 mg, 0.40 mmol) was added dropwise. The reaction mixture was heated to ambient temperature, stirred for 2 h, and concentrated under vacuum. The residue was purified by preparative silica gel TLC (5% MeOH / DCM) to obtain (E)-4-chloro-1-[4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrimido[5,4-d]pyrimidin-6-yl]piperazin-1-yl]but-2-en-1-one (22 mg, 19% yield) was a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 571.2 (M+H).

[0338] Step C. A solution of 1H-pyrazole (4.7 mg, 68 μmol) in THF (0.5 mL) was cooled to 0 °C, and NaH (2.7 mg, 68 μmol, 60% w / w) was added. The mixture was heated to ambient temperature and stirred for 30 minutes. Add (E)-4-chloro-1-[4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrimidino[5,4-d]pyrimidin-6-yl]piperazin-1-yl]but-2-en-1-one (20.4 mg, 34 μmol), and stir the mixture for another 30 minutes. Quench the reaction with saturated NH4Cl aqueous solution (0.2 mL), dilute with water, and extract with EtOAc (2 mL x 3). Wash the combined organic layers with brine (2 mL), dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The crude residue was purified twice by preparative HPLC (30% to 60% MeCN / 0.08% NH4HCO3 aqueous solution) and lyophilized to give (E)-1-[4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrimido[5,4-d]pyrimidin-6-yl]piperazin-1-yl]-4-pyrazol-1-yl-but-2-en-1-one (2.7 mg, 12% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 603.4 (M+H).

[0339] Example 64 1-(4-(8-((4-(imidazo[1,2-b]pyridazin-7-yloxy)-3-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one (compound 234) Step A. 6-chloro-N-(4-(imidazo[1,2-b]pyridazin-7-yloxy)-3-methylphenyl)pyrimido[5,4-d]pyrimidin-4-amine. A mixture of 4-imidazo[1,2-b]pyridazin-7-yloxy-3-methylaniline (85 mg, 0.35 mmol) and 4,6-dichloropyrimido[5,4-d]pyrimidine (78 mg, 0.39 mmol) in IPA was stirred at 30°C for 1 h. The reaction system was concentrated under vacuum to obtain 6-chloro-N-(4-imidazo[1,2-b]pyridazine-7-yloxy-3-methyl-phenyl)pyrimido[5,4-d]pyrimidin-4-amine 3 (135mg, 95% yield), is a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 405.2 (M+H).

[0340] Steps B to D. 1-(4-(8-((4-(imidazo[1,2-b]pyridazin-7-yloxy)-3-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one. The product was prepared by replacing N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-methylsulfinyl-pyrimido[5,4-d]pyrimidin-4-amine with 6-chloro-N-(4-(imidazo[1,2-b]pyridazin-7-yloxy)-3-methylphenyl)pyrimido[5,4-d]pyrimidin-4-amine according to steps A to C of Example 55, yielding 1-(4-(8-((4-(imidazo[1,2-b]pyridazin-7-yloxy)-3-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one (24.5 mg, 20% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 509.3 (M+H). Instructions for Use 126 / 189 pages 190 CN 121311486 A

[0341] Compounds 234-237 in Table 18 below were synthesized according to steps A to D of Example 64.

[0342] Table 18: List of Compounds 234-237

[0343] Example 65 (R)-1'-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3-methylene-[1,3'-bipyrrolidine]-2-one (compound 238) Step A. (S)-3-(4-chlorobutyrylamino)pyrrolidine-1-carboxylic acid tert-butyl ester. TEA (2.62 mL, 18.8 mmol) was added to a solution of (3S)-3-aminopyrrolidine-1-carboxylate (3.50 g, 18.8 mmol) in DCM (30 mL). The solution was cooled to 0 °C, and 4-chlorobutyryl chloride (2.10 mL, 18.8 mmol) was added. The mixture was stirred at 25 °C for 3 h. The reaction was quenched with water (120 mL), eluted with EtOAc (60 mL), and filtered through diatomaceous earth. The two-phase mixture was separated, and the aqueous layer was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (1% to 30% EtOAc / PET) to obtain (3S)-3-(4-chlorobutyrylamino)pyrrolidine-1-carboxylic acid tert-butyl ester (4.70 ppm).g, 72% yield), as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 235.3 (M+H-tBu).

[0344] Step B. (S)-2-oxo-[1,3'-bipyrrolidine]-1'-tert-butyl carboxylate. NaH (0.57 g, 14.1 mmol, 60% w / w) was added in portions to a solution of (3S)-3-(4-chlorobutyrylamino)pyrrolidine-1-butyl carboxylate 3 (4.70 g, 13.5 mmol) in THF (80 mL) at 0 °C. The mixture was stirred at 0 °C for 30 min and then at 80 °C for 2 h. The reaction was quenched with saturated NH4Cl aqueous solution (30 mL), diluted with water (60 mL), and extracted with EtOAc (50 mL x 3). The organic layers were combined, washed with water (50 mL x 2) and brine (50 mL), dried over Na2SO4, filtered, and concentrated under vacuum. The crude residue was purified by silica gel column chromatography (1% to 20% EtOAc / PET) to give (3S)-3-(2-oxopyrrolidine-1-yl)pyrrolidine-1-carboxylic acid tert-butyl ester (1.56 g, 46% yield) as a pale yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 199.3 (M+H-tBu).

[0345] Step C. 1'-(tert-butyl)-3-ethyl(3'S)-2-oxo-[1,3'-bipyrrolidine]-1',3-dicarboxylic acid ester. LiHMDS (1 M, 10.9 mL, 10.9 mmol) was added to a solution of (3S)-3-(2-oxopyrrolidone-1-yl)pyrrolidone-1-carboxylate 4 (1.40 g, 5.45 mmol) in THF (24 mL) at -70 °C under a N2 atmosphere. The mixture was stirred at -70 °C for 1 h, and diethyl carbonate (1.32 mL, 10.9 mmol) was added to THF (2.4 mL). The solution was then heated to ambient temperature and held for 2 h. The reaction was quenched with brine (30 mL) and extracted with EtOAc (50 mL x 2). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (1% to 50% EtOAc / PET) to give ethyl 1-[(3S)-1-tert-butoxycarbonylpyrrolidine-3-yl]-2-oxo-pyrrolidine-3-carboxylate (1.25 g, 70% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 271.3 (M+H-tBu).

[0346] Step D.(3'S)-1'-(tert-Butoxycarbonyl)-2-oxo-[1,3'-bipyrrolidine]-3-carboxylic acid. To a solution of ethyl 1-[(3S)-1-tert-Butoxycarbonylpyrrolidine-3-yl]-2-oxo-pyrrolidine-3-carboxylic acid (1.00 g, 3.06 mmol) in MeOH (8 mL) and water (8 mL), NaOH (0.12 g, 3.06 mmol) was added. The mixture was stirred at 25 °C for 3 h. The reaction mixture was diluted with water (50 mL) and eluted with EtOAc. The suspension was filtered through diatomaceous earth. The layers were separated, and the aqueous layer was extracted with EtOAc (30 mL x 3). The combined organic phases were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 1-[(3S)-1-tert-butoxycarbonylpyrrolidine-3-yl]-2-oxo-pyrrolidine-3-carboxylic acid (575 mg, 53% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 243.3 (M+H-tBu).

[0347] Step E. (S)-3-methylene-2-oxo-[1,3'-bipyrrolidine]-1'-carboxylic acid tert-butyl ester. (CHO)n (154 mg, 3.02 mmol) was added to a solution of 1-[(3S)-1-tert-butoxycarbonylpyrrolidine-3-yl]-2-oxo-pyrrolidine-3-carboxylic acid (600 mg, 2.01 mmol) in EtOAc (14 mL). The mixture was cooled to 0 °C and Et₂NH (0.25 mL, 2.41 mmol) was added. The reaction mixture was heated to 50 °C and held for 3 h. The mixture was diluted with water (80 mL) and eluted with EtOAc (50 mL), then filtered through diatomaceous earth. The layers were partitioned, and the aqueous layer was extracted with EtOAc (40 mL x 3). The combined organic phases were washed with brine (80 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (1% to 50% EtOAc / PET) to give (3S)-3-(3-methylene-2-oxo-pyrrolidine-1-yl)pyrrolidine-1-carboxylic acid tert-butyl ester (400 mg, 72% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 211.3 (M+H-tBu).

[0348] Step F. (S)-3-methylene-[1,3'-bipyrrolidine]-2-one trifluoroacetate. TFA (1.93 mL) was added to a solution of (3S)-3-(3-methylene-2-oxo-pyrrolidine-1-yl)pyrrolidine-1-carboxylic acid tert-butyl ester (400 mg, 1.44 mmol) in DCM (6 mL). The reaction system was stirred at 20 °C for 2 hours.h. The mixture was concentrated under vacuum to give 3-methylene-1-[(3S)-pyrrolidine-3-yl]pyrrolidine-2-one trifluoroacetate (400 mg, 99% yield), as a pale yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 167.1 (M+H).

[0349] Step G. (R)-1'-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3-methylene-[1,3'-bipyrrolidine]-2-one. Add DIPEA (0.93 mL, 5.35 mmol) and 6-methylsulfinyl-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]pyrimido[5,4-d]pyrimidin-4-amine (154 mg, 0.34 mmol) to a solution of 3-methylene-1-[(3S)-pyrrolidine-3-yl]pyrrolidine-2-one trifluoroacetate (200 mg, 0.71 mmol) in IPA (10 mL). Heat the reaction mixture to 80 °C and stir for 2 h. Dilute the mixture with water (30 mL) and extract with EtOAc (25 mL x 3). Wash the combined organic layers with brine (30 mL), dry to anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The crude residue was purified by preparative HPLC (25% to 55% MeCN / 0.05% NH4OH aqueous solution) and lyophilized to give 3-methylene-1-[(3R)-1-[4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)anilino]pyrimido[5,4-d]pyrimidin-6-yl]pyrrolidine-3-yl]pyrrolidine-2-one (12 mg, 6% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 535.2 (M+H).

[0350] Compounds 238 to 241 in Table 19 below were synthesized according to steps A to G of Example 65.

[0351] Table 19: List of compounds 238-241

[0352] Example 66 1-(6-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.1.0]hexane-3-yl)prop-2-en-1-one (compound 242) Step A. 6-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)(Amino)pyrimidino[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester. Add DIPEA (75 µL, 0.43 mmol) to a solution of N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-methylsulfonyl-pyrimidino[5,4-d]pyrimidin-4-amine (100 mg, 0.22 mmol) and 3,6-diazabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (39.8 mg, 0.22 mmol) in DMSO (1.5 mL). Stir the mixture at 80 °C for 12 h. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (5 mL x 4). The combined organic layers were washed with brine (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Purification by silica gel column chromatography (0% to 10% MeOH / DCM) yielded 6-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrimido[5,4-d]pyrimidin-6-yl]-3,6-diazabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (89.0 mg, 48% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 567.5 (M+H).

[0353] Step B. 6-(3,6-diazabicyclo[3.1.0]hexane-6-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine. The solution of 6-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrimido[5,4-d]pyrimidin-6-yl]-3,6-diazabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (89.0 mg, 0.10 mmol) and 2,6-dimethylpyridine (72 µL, 0.62 mmol) in DCM was cooled to 0°C. TMSOTf (0.11 mL, 0.59 mmol) was added, and the mixture was stirred at 0 °C for 2 h. The reaction was quenched with water (10 mL) and extracted with 10% MeOH / DCM (4 mL x 3). The combined organic layers were washed with brine (4 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by preparative TLC (10% MeOH / DCM) to give 6-(3,6-diazabicyclo[3.1.0]hexane-6-yl)-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrimidino[5[4-d]pyrimidin-4-amine (40.0 mg, 71% yield), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 467.3 (M+H).

[0354] Step C. 1-(6-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimidino[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.1.0]hexane-3-yl)prop-2-en-1-one. TEA (31 µL, 221 µmol) was added to a solution of 6-(3,6-diazabicyclo[3.1.0]hexane-6-yl)-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrimido[5,4-d]pyrimidin-4-amine (40.0 mg, 74 μmol) in DCM (2 mL). The mixture was cooled to 0 °C, and a solution of acrylonitrile chloride (6.0 µL, 74 μmol) in DCM (0.5 mL) was slowly added. The reaction mixture was stirred at 0 °C for 1 h and concentrated under vacuum. MeOH (1 mL) and DMF (0.5 mL) were added to the crude residue, and the suspension was filtered. The filtrate was purified by preparative HPLC (20% to 40% MeCN / 0.01% NH4OH aqueous solution) and lyophilized to give 1-[6-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrimido[5,4-d]pyrimidin-6-yl]-3,6-diazabicyclo[3.1.0]hexane-3-yl]prop-2-en-1-one (7.1 mg, 18% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 521.3 (M+H).

[0355] Example 67 cis-1-((1r,5s)-3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimidino[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptane-6-yl)prop-2-en-1-one (compound 243) Specification 130 / 189 pages 194 CN 121311486 A Step A. cis-(1r,5s)-3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl) (1r,5s)-3,6-diazabicyclo[3.2.0]heptane-6-carboxylic acid tert-butyl ester. 3,6-diazabicyclo[3.1]heptane-6-carboxylic acid tert-butyl ester is used instead of cis-(1r,5s)-3,6-diazabicyclo[3.2.0]heptane-6-carboxylic acid tert-butyl ester.[0] tert-butyl hexane-3-carboxylate was prepared according to step A of Example 66 to give cis-(1r,5s)-3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptane-6-carboxylate (100 mg, 75% yield), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 581.3 (M+H).

[0356] Step B. Cis-6-((1s,5s)-3,6-diazabicyclo[3.2.0]heptane-3-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine. ZnBr2 (349 mg, 1.55 mmol) was added to a solution of cis-(1r,5s)-3-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrimido[5,4-d]pyrimidin-6-yl]-3,6-diazabicyclo[3.2.0]heptane-6-carboxylic acid tert-butyl ester (90 mg, 0.16 mmol) in DCM. The reaction system was stirred at 25 °C for 12 h. The mixture was added to water (10 mL), the suspension was filtered, and the filter cake was washed with EtOAc (20 mL). The solid was dried under vacuum to give cis-6-((1s,5s)-3,6-diazabicyclo[3.2.0]heptane-3-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine (60.0 mg, 59% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 481.1 (M+H).

[0357] Step C. cis-1-((1r,5s)-3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimidino[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptane-6-yl)prop-2-en-1-one. Replace 6-(3,6-diazabicyclo[3.2.0]heptane-3-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine with cis-6-((1s,5s)-3,6-diazabicyclo[3.1.0]hexane-6-yl)-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]Pyrimido[5,4-d]pyrimidin-4-amine was prepared according to step C of Example 66 to give cis-1-((1r,5s)-3-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptane-6-yl)prop-2-en-1-one (4.2 mg, 21% yield) as a yellow solid.

[0358] Example 68 1-(3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)prop-2-en-1-one (compound 70) Specification 131 / 189 pages 195 CN 121311486 A Step A. 3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octan-8-carboxylic acid tert-butyl ester. A solution of 6-chloro-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine (100 mg, 0.24 mmol), tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (102 mg, 0.48 mmol), and Cs₂CO₃ (234 mg, 3 equivalents, 0.72 mmol) in DMSO (0.80 mL) was stirred at 95 °C for 16 h, followed by stirring at 120 °C for 15 h. The reaction mixture was cooled to 25 °C, diluted with EtOAc, and washed with water and brine. The organic phase was dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was purified by silica gel chromatography (0 to 20% MeOH / DCM) to give 3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (38.6 mg, 27%) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 594.3 (M+H).

[0359] Step B. 6-(3,8-diazabicyclo[3.2.1]octane-3-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[3,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octane-3-yl)-N-(3-methyl-4-((1-methyl-1H-phenyl)[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine. TFA (0.10 mL) was added to a solution of 3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (38.6 mg, 0.65 mmol) in DCM (0.65 mL). The reaction system was stirred for 1 h, quenched with saturated NaHCO3 aqueous solution, and extracted with 4:1 CHCl3:IPA. The organic phase was dried over Na₂SO₄, filtered, and concentrated under vacuum to give 6-(3,8-diazabicyclo[3.2.1]octane-3-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine (31.3 mg, 97%), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 494.3 (M+H).

[0360] Step C. 1-(3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octane-8-yl)prop-2-en-1-one. Acrylyl chloride (5.6 μL, 0.70 mmol) was added to a solution of 6-(3,8-diazabicyclo[3.2.1]octane-3-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine (31 mg, 0.63 mmol) and TEA (18 μL, 0.13 mmol) in DCM (0.80 mL) at -78 °C. The reaction mixture was stirred at this temperature for 20 min, quenched with saturated aqueous NaHCO3 solution, and extracted with DCM (3x). The combined organic phases were dried over Na2SO4, filtered, and concentrated under vacuum. The crude residue was purified by preparative HPLC (5 to 100% MeCN / 0.1% TFA aqueous solution). The product was neutralized with a saturated aqueous solution of NaHCO3 and extracted with 20% MeOH / DCM to give 1-(3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octane-8-yl)prop-2-en-1-one (22.7 mg, 65%), as a yellow solid. LCMS(MM-ES+APCI, positive ion mode): m / z 548.3 (M+H).

[0361] Compounds 70-82 and 244-340 in Table 7 below were synthesized according to Example 68. Step A can be carried out using inorganic bases or tertiary amine bases in DMF or DMSO on pages 132 / 189 of the specification, CN 121311486 A. The reaction time is shortened when microwave heating is used. Boc deprotection (step B) can be completed using HCl (4M in 1,4-dioxane or 2M in EtOAc) or TFA. For step C, DCM and THF are both acceptable solvents.

[0362] Table 7: List of compounds 70-82, 244-340 Specification 133 / 189 pages 197 CN 121311486 A Specification 134 / 189 pages 198 CN 121311486 A Specification 135 / 189 pages 199 CN 121311486 A Specification 136 / 189 pages 200 CN 121311486 A Specification 137 / 189 pages 201 CN 121311486 A Specification 138 / 189 pages 202 CN 121311486 A Specification 139 / 189 pages 203 CN 121311486 A Specification 140 / 189 pages 204 CN 121311486 A Specification 141 / 189 pages 205 CN 121311486 A Specification 142 / 189 pages 206 CN 121311486 A Specification 143 / 189 pages 207 CN 121311486 A

[0363] According to steps A to C of Example 68, compounds 335 to 340 in Table 20 below were prepared as racemic mixtures. Enantiomers were separated by chiral supercritical fluid chromatography (SFC).

[0364] Table 20: 335-340 Specification 144 / 189 pages 208 CN 121311486 A

[0365] Example 69 N-((3R,4R)-1-(4-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-4-methylpiperidin-3-yl)acrylamide (compound 341) Step A. (3R,4R)-3-acryloylamino-4-methylpiperidin-1-carboxylic acid tert-butyl ester. To (3R,4R)-3-amino-4-methylpiperidin-1-carboxylic acid tert-butyl ester (120 mg, 0.56 mmol) and TEA (0.24 mL, 1.72 mmol)Add 90 µL, 1.11 mmol) of acrylonitrile chloride to a solution in DCM (1 mL). Stir the reaction mixture at 25 °C for 1 h. Concentrate the mixture under reduced pressure and purify the crude residue by preparative TLC (50% EtOAc / PET) to give tert-butyl (3R,4R)-4-methyl-3-(acryloylamino)piperidin-1-carboxylate 3 (113 mg, 75% yield) as a pale yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 169.3 (M+H-tBu).

[0366] Step B. N-((3R,4R)-4-methylpiperidin-3-yl)acrylamide trifluoroacetate. A solution of (3R,4R)-4-methyl-3-(propionylamino)piperidin-1-carboxylic acid tert-butyl ester (100 mg, 0.37 mmol) in DCM (2 mL) and TFA (1 mL) was stirred at 25 °C for 30 min. The reaction mixture was concentrated under reduced pressure to give N-[(3R,4R)-4-methyl-3-piperidinyl]propionyl-2-enamide trifluoroacetate (150 mg, quantitative yield) as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 168.9 (M+H). Instruction manual 145 / 189 pages 209 CN 121311486 A

[0367] Step C. N-((3R,4R)-1-(4-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-4-methylpiperidin-3-yl)acrylamide. KF (42 mg, 0.72 mmol) and DIPEA (0.24 mL, 1.37 mmol) were added to a solution of N-[(3R,4R)-4-methyl-3-piperidinyl]prop-2-enamide trifluoroacetate (100 mg, 0.35 mmol) and 6-chloro-N-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrido[3,2-d]pyrimidin-4-amine (150 mg, 0.29 mmol) in DMSO (3 mL). The reaction mixture was heated to 140 °C and maintained for 1 h. The mixture was filtered, and the filtrate was purified by preparative HPLC (37% to 67% MeCN / 0.08% NH4HCO3 aqueous solution) and lyophilized to give N-[(3R, 4R)-1-[4-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrido[3,2-d]pyrimidin-6-yl]-4-methyl-3-piperidinyl]propenamide (81.5%).mg, 40% yield), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 568.3 (M+H).

[0368] Compounds 341-350 in Table 21 below were synthesized according to steps A to C of Example 69. * Racemic mixture separated by SFC.

[0369] Table 21. Compounds 341-350 Specification 146 / 189 pages 210 CN 121311486 A

[0370] Example 70 1-((2R,4S)-2-methyl-4-(methyl(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)amino)pyrrolidine-1-yl)prop-2-en-1-one (compound 351) Specification 147 / 189 pages 211 CN 121311486 A Step A. ((3S,5R)-1-acryloyl-5-methylpyrrolidine-3-yl)carbamate tert-butyl ester. Using ((3S,5R)-5-methylpyrrolidine-3-yl) tert-butyl carbamate instead of (3R,4R)-3-amino-4-methylpiperidine-1-carbamate, tert-butyl carbamate was prepared according to step A of Example 69 to obtain ((3S,5R)-1-acryloyl-5-methylpyrrolidine-3-yl) tert-butyl carbamate (120 mg, 95% yield), as a colorless oil.

[0371] Step B. ((3S,5R)-1-acryloyl-5-methylpyrrolidine-3-yl)(methyl)carbamate tert-butyl. NaH (28 mg, 0.71 mmol, 60% w / w) and methyl iodoformate (59 µL, 0.94 mmol) were added to a solution of N-[(3S, 5R)-5-methyl-1-prop-2-enoyl-pyrrolidine-3-yl]carbamate (120 mg, 0.47 mmol) in THF (5 mL) at 0 °C. The mixture was stirred at 25 °C for 0.5 h. The reaction was quenched with saturated aqueous NH4Cl solution (10 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by preparative TLC (100% EtOAc) to obtain N-methyl-N-[(3S, 5R)-5-methyl-1-prop-2-enoyl-pyrrolidine-3-yl]carbamate tert-butyl ester (110 mg, 87% yield), as a yellow oil.

[0372] Steps C to D. 1-((2R,4S)-2-methyl-4-(methyl(4-((3-methyl-4-((1-methyl-1H-benzo[d]))[1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)amino)pyrrolidine-1-yl)prop-2-en-1-one. Prepared according to steps B to C of Example 69, using ((3S,5R)-1-acryloyl-5-methylpyrrolidine-3-yl)(methyl)carbamate tert-butyl ester instead of (3R,4R)-3-acryloylamino-4-methylpiperidin-1-carbamate tert-butyl ester. LCMS (MM-ES + APCI, positive ion mode): m / z 550.2 (M+H).

[0373] Example 71 1-((2R,5S)-5-((4-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)(methyl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (compound 352) Steps A to D. 1-((2R,5S)-5-((4-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)(methyl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one. 1-((3S,6R)-6-methylpiperidin-3-yl)carbamate tert-butyl ester was prepared according to steps A to D of Example 70, replacing ((3S,5R)-5-methylpyrrole-3-yl)carbamate tert-butyl ester and 6-fluoro-N-(2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine, to obtain 1-((2R, 5S)-5-((4-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)(methyl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (38.8 mg, 14% yield), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 582.4 (M+H).

[0374] Example 72 (S)-2-(1-acryloyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile (compound 83) Step A.(S)-2-(cyanomethyl)-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylic acid tert-butyl ester. A solution of 6-chloro-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine (20 mg, 48 µmol), (S)-2-(cyanomethyl)piperazine-1-carboxylic acid tert-butyl ester (13 mg, 57 μmol), Cs2CO3 (31 mg, 96 μmol), and dichloro[1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) (9 mg, 10 µmol) in 1,4-dioxane (0.24 mL) was heated to 90 °C and held for 16 h. The reaction mixture was concentrated under vacuum and the residue was purified by silica gel chromatography (0 to 10% MeOH / DCM) to give (S)-2-(cyanomethyl)-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylic acid tert-butyl ester (9.0 mg, 31%) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 607.3 (M+H).

[0375] Step B. (S)-2-(4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazine-2-yl)acetonitrile. Tert-butyl piperazine-1-carboxylate was prepared according to step B of Example 68, replacing 3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate. [2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile (11.3 mg, 64%), is a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 507.3 (M+H).

[0376] Step C.(S)-2-(1-Acryloyl-4-(4-((3-Methyl-4-((1-Methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile. The 6-(3,8-diazabicyclo[3.2.1]octane-3-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidine-4-amine was replaced with (S)-2-(4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidine-4-amine according to Example 68 Step C yielded (S)-2-(1-acryloyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile (3.9 mg, 31%), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 561.3 (M+H).

[0377] Compounds 83, 353-357 in Table 22 were synthesized according to steps A to C of Example 72.

[0378] Table 22. Compounds 83, 353-357

[0379] Example 73 (R)-2-(1-acryloyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile (Compound 84) (R)-2-(1-acryloyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile (R)-2-(cyanomethyl)piperazine-1-carboxylate tert-butyl ester was used instead of (S)-2-(cyanomethyl)piperazine-1-carboxylate tert-butyl ester, prepared according to steps A to C of Example 72, to obtain (R)-2-(1-acryloyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazine-2-yl)acetonitrile (11.20 mg, 19%), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode):m / z 561.3 (M+H).

[0380] Example 74 (S)-2-(1-(2-fluoroacryloyl)-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile (compound 85) Step A. (S)-2-(1-(2-fluoroacryloyl)-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile. DIPEA (0.10 mL, 0.59 mmol) was added to a solution of (S)-2-(4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile (60.0 mg, 0.12 mmol), 2-fluoroacrylic acid (24 mg, 0.26 mmol), and HATU (99 mg, 0.26 mmol) in DMF (1.2 mL). The reaction mixture was stirred for 1.5 h, diluted with 25% IPA / CHCl3, and washed with H2O. The organic phase was dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by preparative HPLC (5% to 100% MeCN / 0.1% TFA aqueous solution). The product was neutralized with saturated NaHCO3 aqueous solution and extracted with 25% IPA / CHCl3 to give (S)-2-(1-(2-fluoroacryloyl)-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile (29.43 mg, 43%), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 579.3 (M+H).

[0381] Example 75 (R)-2-(1-(2-fluoroacryloyl)-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile (Compound 86) (R)-2-(1-(2-fluoroacryloyl)-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile. Using (R)-2-(4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile, replacing (S)-2-(4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile, prepared according to step A of Example 74, yielded (R)-2-(1-(2-fluoroacryloyl)-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3] ... Triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-2-yl)acetonitrile (37.7 mg, 47%), is a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 579.3 (M+H).

[0382] Example 76 Specification 151 / 189 pages 215 CN 121311486 A 2-fluoro-1-(3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)prop-2-en-1-one (compound 87) Step A. 3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octan-8-carboxylic acid tert-butyl ester. DIPEA (42 µL, 0.24 mmol) was added to a slurry of 6-chloro-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine (40 mg, 0.01 mmol) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (31 mg, 0.14 mmol) in 1,4-dioxane (1.0 mL). The reaction mixture was heated to 110 °C and stirred for 2 h. DMSO (1 mL) was added, and the reaction mixture was heated to 140 °C and maintained for 14 h. The mixture was diluted with water (10 mL), extracted with 20% MeOH / DCM (10 mL x 6), dried over anhydrous MgSO4, filtered, and concentrated under vacuum. The crude product was purified by silica gel chromatography (0% to 20% MeOH / DCM) to obtain 3-(4-((3-methyl-4-((1-methyl-1H-benzo[d])).[1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1] tert-butyl octane-8-carboxylate (38 mg, 67% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 594.4 (M+ H).

[0383] Step B. 6-(3,8-diazabicyclo[3.2.1]octane-3-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine. 6-(3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester was prepared according to step B of Example 68, replacing 3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester. (3-Methyl-4-((1-Methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine (13.9 mg, 45% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 494.3 (M+H).

[0384] Step C. 2-Fluoro-1-(3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octane-8-yl)prop-2-en-1-one. The 2-fluoro-1-(3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine was prepared according to step C of Example 56, replacing 6-(2,5-diazabicyclo[2.2.2]octan-2-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrimido[5,4-d]pyrimidin-4-amine. Benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclic[3.2.1] Octane-8-yl)prop-2-en-1-one (8.7 mg, 52% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 566.3 (M+H). Specification 152 / 189 pages 216 CN 121311486 A

[0385] Compounds 87, 88, 358-369 in Table 23 below were synthesized according to steps A to C of Example 76.

[0386] Table 23. Compounds 87, 88, 358-369 Specification 153 / 189 Page 217 CN 121311486 A

[0387] Example 77 1-(2,2-dimethyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one (compound 89) Step A. 6-(3,3-dimethylpiperazin-1-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine. A mixture of 6-chloro-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine (100 mg, 0.24 mmol), tert-butyl 2,2-dimethylpiperazine-1-carboxylate (103 mg, 0.48 mmol), and Cs₂CO₃ (234 mg, 0.72 mmol) in DMF (0.8 mL) was heated to 110 °C and maintained for 18 h. The reaction mixture was diluted with EtOAc and washed with H₂O and brine. The organic phase was dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was purified by silica gel chromatography (0% to 20% MeOH / DCM) to give 6-(3,3-dimethylpiperazin-1-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine (8.6 mg, 7%). LCMS (MM-ES+APCI, positive ion mode): m / z 496.3 (M+H).

[0388] Step B. 1-(2,2-dimethyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one. At 0°C, 6-(3,3-dimethylpiperazin-1-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)benzeneAcrylyl chloride (0.2 M, 0.10 mL, 20 μmol) was added to a solution of pyrido[3,2-d]pyrimidin-4-amine (8.6 mg, 17 μmol) and TEA (5 μL, 35 μmol) in DCM (0.17 mL). The reaction mixture was stirred for 10 min, quenched with saturated NaHCO3 aqueous solution, and extracted with DCM. The combined organic phases were dried over Na2SO4, filtered, and concentrated under vacuum. The residues were purified by preparative HPLC (5% to 100% MeCN / 0.1% TFA aqueous solution). The product was extracted with saturated NaHCO3 aqueous solution (page 154 / 189, CN 121311486 A) and then with 20% MeOH in DCM to give 1-(2,2-dimethyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one (5.7 mg, 59%) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 550.3 (M+H).

[0389] Example 78 (S)-1-(3-methyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one 2,2,2-trifluoroacetate (compound 90) Step A. (S)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(2-methylpiperazin-1-yl)pyrido[3,2-d]pyrimidin-4-amine. 6-chloro-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine (50 mg, 0.12 mmol), (S)-3-methylpiperazine-1-carboxylic acid tert-butyl ester (96 mg, 0.48 mmol), and Cs₂CO₃ (39 mg, 0.12 mmol) were dissolved in DMSO (1.1 mL). The reaction mixture was stirred at 115 °C for 2 h and then at 150 °C for 16 h. The mixture was concentrated under vacuum and purified by silica gel chromatography (0% to 20% MeOH / DCM) to give (S)-3-methyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylic acid tert-butyl ester (60mg, 77% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 482.3 (M+H).

[0390] Step B. (S)-1-(3-methyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one 2,2,2-trifluoroacetate. Replace 6-(3,3-dimethylpiperazin-1-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(2-methylpiperazin-1-yl)pyrido[3,2-d]pyrimidin-4-amine (25 mg, 52 µmol) with (S)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin- 4-Amine, prepared according to step B of Example 77, yielded (S)-1-(3-methyl-4-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)propyl-2-en-1-one 2,2,2-trifluoroacetate (8.5 mg, 24% yield). LCMS (MM-ES+APCI, positive ion mode): m / z 536.3 (M+H).

[0391] Example 79 1-(4-(4-((2-fluoro-4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one (compound 91) Specification 155 / 189 pages 219 CN 121311486 A Step A. 4-(4-((2-fluoro-4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-carboxylic acid tert-butyl ester. DIPEA (0.11 mL, 0.63 mmol) was added to a solution of 6-chloro-N-[2-fluoro-4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-phenyl]pyrido[3,2-d]pyrimidin-4-amine (95 mg, 0.21 mmol) and piperazine-1-carboxylic acid tert-butyl ester (39 mg, 0.21 mmol) in DMF (5 mL). The mixture was stirred at 120 °C for 6 h, diluted with water (10 mL), and diluted with EtOAc (15 mL x3) Extraction. The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to give 4-[4-[2-fluoro-4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-aniline]pyrido[3,2-d]pyrimidin-6-yl]piperazine-1-carboxylic acid tert-butyl ester (92 mg, 73% yield), as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 604.4 (M+H).

[0392] Step B. N-(2-fluoro-4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)-6-(piperazine-1-yl)pyrido[3,2-d]pyrimidin-4-amine 2,2,2-trifluoroacetate. Tert-butyl 4-[4-[2-fluoro-4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-aniline]pyrido[3,2-d]pyrimidin-6-yl]piperazine-1-carboxylate was used instead of tert-butyl 3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate, prepared according to step B of Example 68, yielded N-[2-fluoro-4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-phenyl]-6-piperazine-1-yl-pyrido[3,2-d]pyrimidin-4-amine 2,2,2-trifluoroacetate (94) mg, quantitative yield), is a yellow oily substance. LCMS (MM-ES+APCI, positive ion mode): m / z 504.2 (M+H-TFA).

[0393] Step C. 1-(4-(4-((2-fluoro-4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one. 1-[4-[4-[4-[2-fluoro-4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-phenyl]-6-piperazin-1-yl-pyrido[3,2-d]pyrimidin-4-amine 2,2,2-trifluoroacetate (76 mg, 0.12 mmol)]-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine was prepared according to step C of Example 68 to obtain 1-[4-[4-[2-fluoro-4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methyl-aniline]pyrido[3,2-d]pyrimidin-4-amine].[2-d]pyrimidin-6-yl]piperazin-1-yl]propyl-2-en-1-one (4.7 mg, 7% yield) is a grayish-white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 558.3 ​​(M+H).

[0394] Example 80 1-(4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one (compound 92) Step A. 4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-carboxylic acid tert-butyl ester. 3-Methyl-4-(1-methylbenzo[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylic acid tert-butyl ester (310 mg, 0.88 mmol) was added to a solution of 4-(4-chloropyridino[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylic acid tert-butyl ester (310 mg, 0.59 mmol) in IPA (5 mL). The mixture was stirred at 80 °C for 2 h, quenched with H2O (10 mL), and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by preparative HPLC (45% to 75% MeCN / 10 mM NH4HCO3 aqueous solution) to give tert-butyl 4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrido[3,2-d]pyrimidin-6-yl]piperazine-1-carboxylate (150 mg, 43% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 568.1 (M+H).

[0395] Step B. N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(piperazine-1-yl)pyrimido[5,4-d]pyrimidin-4-amine 2,2,2-trifluoroacetate. TFA (2 mL, 27.0 mmol) was added to a solution of 4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrido[3,2-d]pyrimidin-6-yl]piperazine-1-carboxylic acid tert-butyl ester (140 mg, 0.24 mmol) in DCM (2 mL). The mixture was stirred at 25 °C for 1 h and concentrated under vacuum to give N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazine-1-yl-pyrido[3,2-d]pyrimidin-4-amine 2,2,2-trifluoroacetate (140 mg, quantitative yield), as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 468.1 (M+H-TFA).

[0396] Step C. 1-(4-(8-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one. A solution of N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazin-1-yl-pyrido[3,2-d]pyrimidin-4-amine 2,2,2-trifluoroacetate (140 mg, 0.24 mmol) in DCM (3 mL) was purged with N2 and cooled to -40 °C. TEA (101 µL, 0.72 mmol) and acrylonitrile chloride (24 µL, 0.29 mmol) were added dropwise, and the mixture was stirred at -40 °C for 1 h. The reaction was quenched with a saturated aqueous solution of NaHCO3 (5 mL) and extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude substance was purified by preparative HPLC (25% to 55% MeCN / 10 mM NH4HCO3 aqueous solution) to obtain 1-[4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrido[3,2-d]pyrimidin-6-yl]piperazin-1-yl]prop-2-en-1-one (50 mg, 39% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 522.1 (M+H).

[0397] Compounds 92, 370-372 in Table 24 were synthesized according to steps A to C of Example 80.

[0398] Table 24. Compounds 92, 370-372

[0399] Example 81 1-(3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-6-yl)prop-2-en-1-one (Compound 93) 1-(3-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-6-yl)prop-2-en-1-one .1]Heptane-6-yl)prop-2-en-1-one. With 3-(4-chloropyridino[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester in place of 4-(4-chloropyridino[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylic acid tert-butyl ester was prepared according to steps A to C of Example 80 to give 1-[3-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyridino[3,2-d]pyrimidin-6-yl]-3,6-diazabicyclo[3.1.1]heptane-6-yl]prop-2-en-1-one (22 mg, 6% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 534.4 (M+H).

[0400] Example 82 1-(4-(4-((2-fluoro-5-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one (compound 94) Step A. N-(2-fluoro-5-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(piperazin-1-yl)pyrido[3,2-d]pyrimidin-4-amine. N-[2-fluoro-5-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline was prepared according to step A of Example 80, replacing 3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline, as a pale yellow solid (150 mg, 77%). The solid was prepared by replacing 3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazin-1-yl-pyrido[3,2-d]pyrimidine-4-amine. LCMS (MM-ES+APCI, positive ion mode): m / z 486.2 (M+H).

[0401] Step B. 1-(4-(4-((2-fluoro-5-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one. The tert-butyl 1-[4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazin-1-yl-pyrido[3,2-d]pyrimidin-4-amine was used instead of 4-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrido[3,2-d]pyrimidin-6-yl]piperazin-1-carboxylate, prepared according to step C of Example 80, yielded 1-[4-[4-[2-fluoro-5-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrido[3,2-d]pyrimidin-6-yl]piperazin-1-yl]propyl-2-en-1-one (70 mg, 46% yield), which is white.Colored solid. LCMS (MM-ES+APCI, positive ion mode): m / z 540.3 (M+H).

[0402] Example 83 1-(4-(4-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)benzene Specification 158 / 189 pages 222 CN 121311486 A yl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one (compound 95) Step A. 4-(4-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-carboxylic acid tert-butyl ester. DIPEA (0.19 mL, 1.10 mmol) and tert-butyl 4-(4-chloropyrido[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate (193 mg, 0.55 mmol) were added to a solution of 2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline (100 mg, 0.37 mmol) in IPA (6 mL). The reaction was stirred at 90 °C for 2 h, diluted with water (20 mL), and extracted with 10% MeOH / DCM (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude solid was purified by silica gel column chromatography (0% to 75% EtOAc / PET) to give tert-butyl 4-[4-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrido[3,2-d]pyrimidin-6-yl]piperazine-1-carboxylate (100 mg, 35% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 586.3 (M+H).

[0403] Step B. N-(2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(piperazine-1-yl)pyrido[3,2-d]pyrimidin-4-amine hydrochloride. HCl (4 M, 2.5 mL, 10 mmol in 1,4-dioxane) was added to a solution of 4-[4-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrido[3,2-d]pyrimidin-6-yl]piperazine-1-carboxylic acid tert-butyl ester (100 mg, 0.13 mmol) in DCM (2.5 mL). The mixture was stirred at 25 °C for 1 h and concentrated under vacuum to give N-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrido[3,2-d]pyrimidin-6-yl]piperazine-1-carboxylic acid tert-butyl ester (100 mg, 0.13 mmol) in DCM (2.5 mL).[1-(4-(4-((2-fluoro-3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one. DIPEA (0.10 mL, 0.57 mmol) was added to a solution of N-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazin-1-yl-pyrido[3,2-d]pyrimidine-4-amine hydrochloride (100 mg, 0.19 mmol) in DMF (8 mL). The solution was cooled to -50 °C, and then acrylonitrile chloride (16 µL, 0.19 mmol) was added dropwise to DMF (0.5 mL). The mixture was stirred at -50 °C for 1 h and quenched with a saturated aqueous solution of NaHCO3 (0.5 mL). The crude substance was purified by preparative HPLC (24% to 54% MeCN / 0.08% NH4HCO3 aqueous solution) to give 1-[4-[4-[2-fluoro-3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrido[3,2-d]pyrimidin-6-yl]piperazin-1-yl]propyl-2-en-1-one (49 mg, 46% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 540.3 (M+H).

[0405] Example 84 1-(6-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)prop-2-en-1-one (compound 96) Specification 159 / 189 pages 223 CN 121311486 A Step A. 6-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester. 6-(4-chloropyridino[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester (410 mg, 1.13 mmol) was applied to IPA (33-Methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline (288 mg, 1.13 mmol) and DIPEA (0.59 mL, 3.40 mmol) were added to a solution of [mL]. The mixture was stirred at 80 °C for 8 h and concentrated under vacuum. The crude residue was purified by silica gel column chromatography (5% to 10% MeOH / DCM) to give 6-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrido[3,2-d]pyrimidin-6-yl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester (140 mg, 21% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 580.3 (M+ H).

[0406] Step B. 6-(3,6-diazabicyclo[3.1.1]heptane-6-yl)-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine. Add TFA (2 mL, 27 mmol) to a solution of 6-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrido[3,2-d]pyrimidin-6-yl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester (120 mg, 0.21 mmol) in DCM (2 mL). The mixture was stirred at 25 °C for 1 h, slowly quenched with saturated NaHCO3 aqueous solution (10 mL), and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by preparative TLC (10% MeOH / DCM) to give 6-(3,6-diazabicyclo[3.1.1]heptane-6-yl)-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrido[3,2-d]pyrimidin-4-amine (60 mg, 58% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 480.1 (M+H).

[0407] Step C. 1-(6-(4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)prop-2-en-1-one. 6-(3,6-diazabicyclo[3.1.1]heptane-6-yl)-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrido[3,2-d]pyrimidin-4-amine (50 mg, 0.10 g)A solution of 0.30 mmol) in DCM (2 mL) was placed under N2 and cooled to 0 °C. TEA (42 µL, 0.30 mmol) and propylene chloride (9.8 µL, 0.12 mmol) were added dropwise. The mixture was stirred at 0 °C for 1 h, quenched with saturated NaHCO3 aqueous solution (10 mL), and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by preparative HPLC (27% to 57% MeCN / 0.08% NH4HCO3 aqueous solution) to give 1-[6-[4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrido[3,2-d]pyrimidin-6-yl]-3,6-diazabicyclo[3.1.1]heptane-3-yl]prop-2-en-1-one (12 mg, 22% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 534.2 (M+H).

[0408] Example 85 1-(4-(4-((4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylbenzene Specification 160 / 189 pages 224 CN 121311486 A yl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one (compound 97) Step A. 4-chloro-6-(piperazin-1-yl)pyrido[3,2-d]pyrimidinyl. DIPEA (0.13 mL, 0.72 mmol) and POCl3 (0.34 mL, 3.62 mmol) were added to a solution of 120 mg (120 mg, 0.36 mmol) of 4-(4-hydroxypyridano[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylate in toluene (1.2 mL) at ambient temperature. The mixture was heated to 100 °C, stirred for 1 h, and concentrated under reduced pressure to give 4-chloro-6-(piperazine-1-yl)pyridano[3,2-d]pyrimidinyl (90 mg, 20% purity) as a brown solid. LCMS (MM-ES+APCI, positive ion mode): m / z 250.0 (M+H).

[0409] Step B. N-(4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)-6-(piperazin-1-yl)pyrido[3,2-d]pyrimidine-4-amine. Add 4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)-6-(piperazin-1-yl)pyrido[3,2-d]pyrimidine (86 mg, 0.34 mmol) to a solution of 4-chloro-6-(piperazin-1-yl)pyrido[3,2-d]pyrimidine (2.0 mL) in IPA.3] Triazol-5-yl)oxy)-3-methylaniline (56 mg, 0.21 mmol). The reaction mixture was stirred at 80 °C for 1 h and concentrated under vacuum. The residue was diluted with water (50 mL), alkalized with saturated NaHCO3 aqueous solution (pH 8), and extracted with DCM (50 mL x 3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (1% to 40% MeOH / DCM) to give N-(4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)-6-(piperazin-1-yl)pyrido[3,2-d]pyrimidin-4-amine (70 mg, 60% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 486.4 (M+H).

[0410] Step C. 1-(4-(4-((4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one. Add TEA (43 µL, 0.31 mmol) to a solution of N-(4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)-6-(piperazin-1-yl)pyrido[3,2-d]pyrimidin-4-amine (50 mg, 0.10 mmol) in DCM (1.0 mL). Cool the mixture to 0°C and add acrylonitrile chloride (8 µL, 0.10 mmol) dropwise. The reaction system was stirred at 0 °C for 0.5 h and concentrated under vacuum. The crude solid was purified by preparative HPLC (30% to 60% MeCN / 10 mM NH4HCO3 aqueous solution) to give 1-(4-(4-((4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one (12 mg, 19% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 540.3 (M+H).

[0411] Example 86 1-(4-(7-methoxy-4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one (compound 98) Specification 161 / 189 pages 225 CN 121311486 A Step A.7-Methoxy-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(piperazin-1-yl)pyrido[3,2-d]pyrimidin-4-amine. 3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline (58 mg, 0.23 mmol) was added to a solution of tert-butyl piperazine-1-carboxylate hydrochloride (157 mg, 0.38 mmol) in IPA (2 mL). The reaction mixture was stirred at 80 °C for 1 h and neutralized with a saturated aqueous solution of NaHCO3 (pH 7). The mixture was concentrated under vacuum and purified by silica gel column chromatography (20% to 30% MeOH / DCM) to give 7-methoxy-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazin-1-yl-pyrido[3,2-d]pyrimidin-4-amine (125 mg, quantitative yield) as a yellow oil. LCMS (MM-ES+APCI, positive ion mode): m / z 498.3 (M+H).

[0412] Step B. 1-(4-(7-methoxy-4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)propyl-2-en-1-one. TEA (0.10 mL, 0.75 mmol) was added to a solution of 7-methoxy-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazin-1-yl-pyrido[3,2-d]pyrimidin-4-amine (125 mg, 0.25 mmol) in DCM (15 mL). The reaction mixture was cooled to 0 °C and acrylonitrile chloride (41 µL, 0.50 mmol) was added. After stirring at 0 °C for 30 min, the mixture was concentrated under vacuum. The crude residue was purified by preparative HPLC (28% to 58% MeCN / 10 mM NH4HCO3 aqueous solution) to give 1-[4-[7-methoxy-4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline]pyrido[3,2-d]pyrimidin-6-yl]piperazin-1-yl]propyl-2-en-1-one (38.5 mg, 28% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 552.2 (M+H).

[0413] Example 87 1-(4-(4-((2-fluoro-4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methyl1-(4-(4-((2-fluoro-4-((7-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)-3-methylphenyl)amino)-7-methoxypyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one (compound 99) Replacing 3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-3-methylaniline with 2-fluoro-4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methylaniline, 1-[4-[4-[2-fluoro-4-(7-fluoro-1-methyl-benzotriazol-5-yl)oxy-3-methylaniline]-7-methoxy-pyrido[3,2-d]pyrimidin-6-yl]piperazin-1-yl]propyl-2-en-1-one (6.5 mg, 6% yield) was prepared according to steps A to B of Example 86 to obtain a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 588.3 (M+H).

[0414] Example 88 1-(4-(7-fluoro-4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one (compound 373) Specification 162 / 189 pages 226 CN 121311486 A Step A. Methyl 3-amino-5-fluoropyridinecarboxylate. Pd(dppf)Cl2 (0.38 g 0.52 mmol) and TEA (2.91 mL 20.9 mmol) were added to a solution of 2-bromo-5-fluoro-pyridine-3-amine (2.0 g, 10.5 mmol) in MeOH (50 mL). The suspension was degassed under vacuum and purged several times with CO. The mixture was heated to 60°C under CO (50 psi) and held for 48 h. The suspension was eluted with MeOH (50 mL) and filtered through a diatomaceous earth pad. The filtrate was concentrated under reduced pressure and the crude product was purified by preparative HPLC (3% to 33% MeCN / 0.05% NH4HCO3 aqueous solution). Lyophilization gave methyl 3-amino-5-fluoro-pyridine-2-carboxylate (650 mg, 36% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 171.2 (M+H).

[0415] Step B. Methyl 3-amino-6-bromo-5-fluoropyridinecarboxylate. NBS (690 mg, 3.88 mmol) was added to a solution of methyl 3-amino-5-fluoro-pyridine-2-carboxylate (550 mg, 3.23 mmol) in MeCN (10 mL).mmol). The mixture was stirred at 25 °C for 2 h. The reaction system was diluted with water (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (20% to 25% EtOAc / PET) to give methyl 3-amino-6-bromo-5-fluoro-pyridine-2-carboxylate (750 mg, 92% yield) as a white solid. LCMS (MM-ES+APCI, positive ion mode): m / z 249.0, 251.0 (M+H).

[0416] Step C. 3-amino-6-bromo-5-fluoropyridinecarboxylic acid. NaOH (192 mg, 4.80 mmol) was added to a solution of methyl 3-amino-6-bromo-5-fluoro-pyridine-2-carboxylate (300 mg, 1.19 mmol) in THF (2 mL) and water (0.4 mL). The reaction mixture was stirred at 60 °C for 5 h. The mixture was diluted with water (10 mL), acidified with 1 M HCl (pH = 4), and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 3-amino-6-bromo-5-fluoropyridinecarboxylic acid (230 mg, 82% yield) as a gray solid. LCMS (MM-ES+APCI, positive ion mode): m / z 234.9, 236.9 (M+H).

[0417] Step D. 6-Bromo-7-fluoropyridano[3,2-d]pyrimidin-4-ol. Formamidinium acetate (200 mg, 1.92 mmol) was added to a solution of 3-amino-6-bromo-5-fluoropyridinic acid (210 mg, 0.89 mmol) in EtOH (3 mL). The reaction mixture was heated in a microwave at 120 °C for 2 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 6-bromo-7-fluoropyridano[3,2-d]pyrimidin-4-ol (205 mg, 94% yield) as a gray solid. LCMS (MM-ES+APCI, positive ion mode): m / z 244.0, 246.0 (M+H).

[0418] Step E. 6-Bromo-4-chloro-7-fluoropyrido[3,2-d]pyrimidine. POCl3 (0.12 mL, 1.24 mmol) was added to a solution of 6-bromo-7-fluoropyrido[3,2-d]pyrimidine-4-ol (150 mg, 0.61 mmol) in PhMe (3 mL) at 0 °C.mmol) and DIPEA (0.54 mL, 3.09 mmol). The reaction system was heated to 110 °C and held for 2 h. The mixture was concentrated under reduced pressure, and the crude product was dissolved in EtOAc (10 mL) and saturated NaHCO3 aqueous solution (5 mL) was added. The layers were separated, and the aqueous layer was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 6-bromo-4-chloro-7-fluoro-pyrido[3,2-d]pyrimidine (180 mg, quantitative yield) as a yellow solid.

[0419] Step F. 6-Bromo-7-fluoro-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine. 3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-aniline (160 mg, 0.63 mmol) was added to a solution of 6-bromo-4-chloro-7-fluoro-pyrido[3,2-d]pyrimidinium (160 mg, 0.61 mmol) in IPA (4 mL). The reaction mixture was stirred at 80 °C for 2 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (50% to 65% EtOAc / PET) to give 6-bromo-7-fluoro-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrido[3,2-d]pyrimidin-4-amine (170 mg, 40% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 480.0, 482.0 (M+H).

[0420] Step G. 4-(7-fluoro-4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazine-1-carboxylic acid tert-butyl ester. Piperazine-1-carboxylic acid tert-butyl ester (122 mg, 0.66 mmol), 6-bromo-7-fluoro-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]pyrido[3,2-d]pyrimidin-4-amine (150 mg, 0.22 mmol), RuPhos Pd G3 (20 mg, 24 μmol), and Cs2CO3 (210 mg, 0.64 mmol) were reacted in 1,4-dioxane (3The mixture in mL was degassed and purged with N2. The reaction system was heated to 100 °C under N2 and held for 2.5 h. The mixture was diluted with water (5 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (5% MeOH / DCM) to give tert-butyl 4-[7-fluoro-4-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-anilino]pyrido[3,2-d]pyrimidin-6-yl]piperazine-1-carboxylate (64 mg, 33% yield) as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 586.3 (M+H).

[0421] Step H. 7-Fluoro-N-(3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)-6-(piperazin-1-yl)pyrido[3,2-d]pyrimidin-4-amine. TFA (1 mL) was added to a solution of tert-butyl piperazine-1-carboxylate (60 mg, 68 μmol) in DCM (1 mL). The reaction mixture was stirred at 25 °C for 2 h and concentrated under vacuum. The mixture was diluted with saturated NaHCO3 aqueous solution (5 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (10% MeOH / DCM) to obtain 7-fluoro-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazin-1-yl-pyrido[3,2-d]pyrimidin-4-amine (31 mg, 92% yield), as a yellow solid. LCMS (MM-ES+APCI, positive ion mode): m / z 486.2 (M+H).

[0422] Step I. 1-(4-(7-fluoro-4-((3-methyl-4-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)oxy)phenyl)amino)pyrido[3,2-d]pyrimidin-6-yl)piperazin-1-yl)prop-2-en-1-one. A mixture of 7-fluoro-N-[3-methyl-4-(1-methylbenzotriazol-5-yl)oxy-phenyl]-6-piperazin-1-yl-pyrido[3,2-d]pyrimidin-4-amine (28 mg, 57 μmol) and TEA (28 µL, 198 μmol) in DCM (2 mL) was purged with N2 and cooled to 0 °C. Acrylonitrile chloride (5.4 µL, 66 μmol) was added dropwise.μmol), and the reaction system was stirred at 0 °C for ...

Claims

1. A compound having the structure of formula (I): (I) Or a stereoisomer of the compound, a tautomer of the compound, or a pharmaceutically acceptable salt thereof, wherein: X 1 It is CR 1 Or N; X 2 It is CR 2 Or N; Y 1 It is CR 4 Or N; Y 2 It is CR 5a Or N; Y 3 It is C or N; Y 4 It is CR 6 or NR 6 ; Y 5 It is CR 7 , O or NR 7 ; Y 6 It is C or N; R 1 R 2 R 3a R 3b R 3c R 3d R 4 R 5a R 5b and R 7 Each can be independently H, halogenated, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 heteroalkyl; R 6 It is H, C1-C3 alkyl, C1-C3 deuterated alkyl, or C1-C3 haloalkyl; R 8 and R 9 Each is independently an H or C1-C3 alkyl group; Z 1 Yes -NR 9 -, -O-, -S- or direct key; Z 2 Yes -NR 9 -or direct key; L is a C1-C4 alkyl, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, fused heterobicyclic, bridged heterobicyclic, heterospirocyclic, or direct bond; E is an α,β-unsaturated carbonyl group or a C2-C4 alkynyl conjugated carbonyl group; and Each can be a single or double bond independently, provided that the valence allows.

2. The compound of claim 1, wherein the compound has one of the structures of formula (IA)-(ID): (IA) (IB) (IC) 、 (ID) Or a stereoisomer of the compound, a tautomer of the compound, or a pharmaceutically acceptable salt thereof.

3. The compound according to any one of claims 1-2, wherein Y 5 It is N, and Y 3 It's C.

4. The compound according to any one of claims 1-3, wherein the compound has one of the structures of formula (IA-1)-(IB-1): (IA-1) 、 (IB-1) Or a stereoisomer of the compound, a tautomer of the compound, or a pharmaceutically acceptable salt thereof.

5. The compound according to any one of claims 1-2, wherein Y 5 It is CR 7 And Y 3 It is C, and R 7 It is H.

6. The compound of claim 5, wherein the compound has one of the structures of formula (IA-2)-(IB-2): (IA-2) 、 (IB-2) Or a stereoisomer of the compound, a tautomer of the compound, or a pharmaceutically acceptable salt thereof.

7. The compound according to any one of claims 1-6, wherein R 6 It is a C1-C3 haloalkyl group.

8. The compound according to any one of claims 1-7, wherein R 6 It is a C1 haloalkyl group.

9. The compound according to any one of claims 1-8, wherein R 6 It is CHF2 or CF3.

10. The compound according to any one of claims 1-9, wherein Z 1 and Z 2 Each is a direct key.

11. The compound according to any one of claims 1-10, wherein Z 1 Yes -NR 9 -, -O- or -S-, and Z 2 It is a direct key.

12. The compound according to any one of claims 1-11, wherein Z 1 It is a direct key, and Z 2 Yes -NR 9 - 13. The compound according to any one of claims 1-12, wherein Z 1 and Z 2 Each is -NR 9 - 14. The compound according to any one of claims 1-13, wherein R 9 It is H or CH3.

15. The compound according to any one of claims 1-14, wherein R 1 R 2 R 3a R 3b R 3c R 3d R 4 R 5a R 5b and R 7 Each can be independently H, halogenated, C1 alkyl, C1-C2 haloalkyl, or C1-C3 heteroalkyl.

16. The compound according to any one of claims 1-15, wherein R 1 R 2 R 3a R 3b R 3c R 3d R 4 R 5a R 5b and R 7 Each can be independently H, F, Cl, CH3, CH2CF3, CF3, CHF2, CH2OCH3, CD3, OCHF2, OCF3, or OCH3.

17. The compound according to any one of claims 1-16, wherein R 1 and R 2 Each can be independently H, F, CH3 or OCH3.

18. The compound according to any one of claims 1-17, wherein R 3a , R 3b R 3c and R 3d Each can be independently H, CH3, OCH3, CH2OCH3, OCHF2, OCF3, F, or Cl.

19. The compound according to any one of claims 1-18, wherein R 4 It is H, F, CH3, CH2OCH3 or CH2CF3.

20. The compound according to any one of claims 1-19, wherein R 5a and R 5b Each can be independently H, CH3, F, or OCH3.

21. The compound according to any one of claims 1-20, wherein R 7 It is H or CH3.

22. The compound according to any one of claims 1-21, wherein R 8 It is H or CH3.

23. The compound according to any one of claims 1-22, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L have 1-3 nitrogen atoms.

24. The compound according to any one of claims 1-23, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L have 1-2 nitrogen atoms.

25. The compound according to any one of claims 1-24, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L are unsaturated heterocyclic rings.

26. The compound according to any one of claims 1-25, wherein the C3-C8 heterocyclic alkyl group of L is aziridine, pyrrolidine, imidazoline, pyrazolidine, piperidine, 1,2-diazine, 1,3-diazine, 1,4-diazine, aziridine, diaziridine, or aziridine.

27. The compound according to any one of claims 1-26, wherein the fused heterobicyclo of L is 3-azabicyclo[3.1.0]heptane, 2,5-diazabicyclo[4.2.0]octane, octahydropyrrolo[3.4.c]pyrrole, octahydropyrrolo[3.4.b]pyrrole, octahydro-1H-pyrrolo[3.4.c]pyridine, decahydro-2,6-naphthidine, 2,5-diazabicyclo[4.1.0]heptane, 3,6-diazabicyclo[3.2.0]heptane, or 3,6-diazabicyclo[3.1.0]hexane.

28. The compound according to any one of claims 1-27, wherein the bridged heterobicycle of L is 3,8-diazabicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, 8-azabicyclo[3.2.1]octane, 3-azabicyclo[3.2.1]octane, 3,6-diazabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, 3-oxa-9-azabicyclo[3.3.1]nonane, 3-oxa-9-azabicyclo[3.3.1]non-6-ene, 9-azabicyclo[3.3.1]non-2-ene, 8-azabicyclo[3.2.1]oct-2-ene, or 3,6-diazabicyclo[3.1.1]heptane.

29. The compound according to any one of claims 1-28, wherein the heterospirocycle of L is 2,6-diazaspiro[3.3]heptane, 1,6-diazaspiro[3.3]heptane, 2-diazaspiro[3.3]heptane, 1,6-diazaspiro[3.4]octane, 2,6-diazaspiro[3.4]octane, 2,7-diazaspiro[3.5]nonane, 2,8-diazaspiro[4.5]decane, 3,9-diazaspiro[5.5]undecane, 4,8-diazaspiro[2.5]octane, 5,9-diazaspiro[3.5]nonane, 6,10-diazaspiro[4.5]decane, or 1,5-diazaspiro[5.5]undecane.

30. The compound of any one of claims 1-29, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L are further substituted with deuterium, halogenated, C1-C6 alkyl, or C1-C6 heteroalkyl.

31. The compound according to any one of claims 1-30, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L are further substituted with deuterium, halogenated, C1-C3 alkyl, or C1-C3 heteroalkyl.

32. The compound according to any one of claims 1-31, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring are respectively -D, -F, -CH3, -CF3, -CHF2, -CH2F, -CH2CHF2, -CH2CH3, -CH(CH3)2, -CH2OH, -CH2OCH3, Or -CH2CCN can be further replaced.

33. The compound according to any one of claims 1-32, wherein the C3-C8 heterocyclic alkyl group, the fused heterobicyclic ring, the bridged heterobicyclic ring, and the heterospirocyclic ring of L are substituted with mono, di, tri, tetra, penta, or octa.

34. The compound according to any one of claims 1-33, wherein L is a C2-C4 alkyl or a C4-C5 cycloalkyl.

35. The compound according to any one of claims 1-34, wherein the C1-C4 alkyl group of L is –(CH2)2- or -CH2C(CH3)2.

36. The compound according to any one of claims 1-35, wherein the C3-C8 cycloalkyl group of L is , where * indicates that it is related to Z 2 The position of the key.

37. The compound according to any one of claims 1-36, wherein L has one of the following structures: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 , 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 , , , , , , , , , , , , , , , or , Where * indicates that it is related to Z 2 The position of the key.

38. The compound according to any one of claims 1-37, wherein the α,β-unsaturated carbonyl group or C2-C4 alkyne conjugated carbonyl group of E is halogenated, C1-C3 alkylated, C1-C3 alkyl halogenated, C1-C6 heteroalkylated, or -(CH2) n C3-C7 heterocyclic alkyl groups or combinations thereof are further substituted, wherein n is an integer between 1 and 3.

39. The compound according to any one of claims 1-38, wherein the α,β-unsaturated carbonyl group of E has one of the following structures: , , , , , , , , , , , , , , , or .

40. The compound according to any one of claims 1-39, wherein the C2-C4 alkyne conjugated carbonyl group is a C2 alkyne conjugated carbonyl group or a C3 alkyne conjugated carbonyl group.

41. The compound according to any one of claims 1-40, wherein the C2-C4 acetylene conjugated carbonyl group has the following structure: 。 42. The compound according to any one of claims 1-41, wherein E has one of the following structures: , , , , , , , , , , , , , or .

43. The compound of claim 1, wherein the compound has one of the following structures: ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

44. A pharmaceutical composition comprising the compound of claim 1 and an additional therapeutic agent.

45. The compound of any one of claims 1-43 or the pharmaceutical composition of claim 44, for the treatment of diseases associated with mutations in human epidermal growth factor receptor 2 (ErbB2).

46. ​​A method for treating a disease associated with a mutation in ErbB2, comprising: The compound as described in any one of claims 1-43 or the pharmaceutical composition as described in claim 45 may be administered to a subject in need.

47. The method of claim 46, wherein the subject is an animal.

48. The method of any one of claims 46-47, wherein the subject is a human being.

49. The method of any one of claims 46-48, wherein the disease associated with the ErbB2 mutation is cancer.

50. The method of any one of claims 46-49, wherein the cancer is lung cancer, glioma, esophageal cancer, liver cancer, stomach cancer, uterine cancer, cervical cancer, bile duct cancer, skin cancer, head and neck cancer, salivary gland cancer, breast cancer, pancreatic cancer, colorectal cancer, kidney cancer, bladder cancer, or prostate cancer.

51. The method of any one of claims 46-50, wherein the cancer is non-small cell lung cancer.